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Abstract 
A method for developing an optical mapping system to quantify electrical activation 
and repolarisation in murine left atria was created. The spread of activation is 
important in understanding the mechanisms for the rhythm of the heart in healthy 
and diseased states as cardiovascular disease is the leading cause of death 
worldwide.  
The activation spread was recorded using a novel 2nd generation high resolution 
(128x2048 pixels) CMOS camera with the voltage sensitive dye di-4-ANEPPS. 
Algorithms for automatic quantification of action potential duration and conduction 
velocities were implemented in MATLAB. Optical mapping results were validated 
against monophasic action potentials and microelectrode measurements showing 
comparable duration measurements.  
A genetic mouse model of atrial fibrillation was used (Pitx2c+/-) and was found to 
have a shorter action potential duration in the left atrium compared to wild-type mice. 
The results showed a preferential antiarrhythmic effect of the sodium channel 
blocker, flecainide, to the left atrium of Pitx2c+/- mice.  
A second mouse model was used to mimic arrhythmogenic right ventricular 
cardiomyopathy (plako+/-). No significant changes were witnessed in young 
sedentary cohorts at baseline and flecainide slowed conduction in both WT and 
plako+/-. In endurance trained mice, a prolongation of the effective refractory period 
was seen after flecainide treatment. Plako+/- sedentary mice treated with 
dihydrotestosterone showed a prolongation in action potential duration.  
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Project aims and objectives 
The aims of this thesis were to: 
 Develop a high resolution optical mapping system to measure the action 
potential duration (APD) and conduction velocity (CV) of the left atrium (LA) of 
the mouse.  
 Develop novel automated software to analyse the images created by the 
optical mapping system.  
 Investigate the Pitx2c deficient mouse model and its role in atrial fibrillation by 
use of the optical mapping system and measuring APD and CV differences in 
the LA. 
 Test whether flecainide, an antiarrhythmic drug, has a preferential effect on 
the LA of the Pitx2c+/- model compared to wild-type.  
 Investigate atria of a plakoglobin deficient mouse, a model of arrhythmogenic 
right ventricular cardiomyopathy (ARVC), by measuring CV values and APD 
between genotypes.  
 Ascertain whether flecainide has a preferential effect to the plako+/- model.  
 Determine whether endurance training can exacerbate an ARVC phenotype in 
the atria of the plako+/- model.  
 Investigate whether flecainide shows a preferential effect on the endurance 
trained plako+/- model of the LA.   
 Test the effects of anabolic androgen steroid doping by administering 
dihydrotestosterone to the plako+/- model and measuring the APD and CV 
values.  
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 Biological introduction 
This introduction provides a broad overview of the heart and cardiovascular 
disease.  
1.1. The heart  
The heart is a muscular organ which pumps blood around the body of humans 
and other animals via a system of vessels. The blood provides the body with 
oxygen and vital nutrients to sustain life [1]. The heart performs a cycle of 
relaxation and contraction in a single beat and must remain to do so for the 
remainder of one’s life, undergoing an estimated 3 billion beats in a lifetime [2].  
1.1.1. Anatomy and blood flow 
The heart is a single organ but acts as a double pump, one to circulate 
deoxygenated blood to the lungs where it is oxygenated and the other to deliver 
oxygenated blood to the rest of body. In humans and other mammals such as 
mice, the heart is divided into four chambers; left and right atria which sit towards 
the top of the organ and the left and right ventricles at the bottom. Between the 
atria and ventricles are valves which help regulate the direction of blood flow [3]. 
The right atrium (RA) receives deoxygenated blood from the superior and inferior 
venae cavae where it is pumped to the right ventricle (RV) through the tricuspid 
valve (TV) (see Figure 1.1). Subsequently, the RV pumps blood through the 
pulmonary valve (PV) to the pulmonary artery then onto the lungs. The left atrium 
(LA) contracts and circulates oxygenated blood from the lungs to the left ventricle 
(LV) via the mitral valve. Contraction of the LA subsequently pumps blood through 
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the aortic valve to the aorta to the rest of the body [4]. Collectively, these atrial and 
ventricular events form the cardiac cycle. When the heart is in the contracting 
phase of the cardiac cycle, this is known as systole. Diastole is the part of the 
cardiac cycle when the heart is relaxing and refills with blood [3]. 
The ventricles are much thicker and stronger than the atria and the LV is stronger 
than the RV. This corresponds to the greater forces needed by the LV to pump 
blood through the high pressure system of the body. The atrial walls are thinner 
than the ventricular walls, as they only need to pump blood to the ventricles.  
 
Figure 1.1. Anatomy and direction of blood flow through the heart.  
The blue arrows show deoxygenated blood circulating from the superior and inferior 
venae cavae to the right atrium and ventricles, which leaves via the pulmonary artery to 
the lungs. Red arrows show oxygenated blood circulating from the left atrium to the left 
ventricle exiting via the aorta to the rest of the body. The direction of blood flow is 
regulated by four valves; tricuspid valve (TV), pulmonary valve (PV), aortic valve (AoV) 
and the mitral valve (MV). These valves prevent the backflow of blood. Image adapted 
from Davidson’s Principles and Practice of medicine 22nd Edition. Elsevier. 2014. [4].  
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Cardiac output is the volume of blood pumped by the heart per unit time and is 
calculated by the product of the stroke volume and heart rate, usually measured in 
litres/min. The stroke volume is the volume of blood ejected in each cardiac cycle 
and is dependent upon the end-diastolic volume (preload) of the ventricles, 
contractility and systolic aortic pressure (afterload) [1].  
1.1.2. Cardiac muscle  
The heart wall consists of multiple layers: the inner endocardium, the myocardium 
and the outer epicardium. In addition to this, the pericardium is a double-walled 
sac that surrounds the heart. The endocardium is a thin sheet of cells that line the 
internal walls of the heart and valve. The part of the pericardium that forms the 
outer-most border is called the parietal pericardium. The inner layer which is in 
contact with the myocardium is called the epicardium and contains a small amount 
of fluid to lubricate its movements against the pericardium [5]. The myocardium is 
the bulk tissue of the heart, the layer which performs the contractions. The 
myocardial tissue is mainly comprised of cardiomyocytes and a small portion of 
cardiac pacemaker cells and the conduction system of the heart.  
Cardiomyocytes are striated muscle cells which have the ability to contract easily. 
These striations arise from the arrangement of protein filaments (actin and 
myosin). The cardiomyocytes are connected by junctions known as intercalated 
disks which allow for synchronised contraction of the muscle (Figure 1.2A). An 
intercalated disk allows electrical conduction via gap junctions, mechanical 
conduction via fascia adherens (adherent proteins) [4]. Within the cardiomyocytes 
are myofibrils - rod like units made from thick myosin and thin actin filaments 
(Figure 1.2B) [4]. Actin filaments are the major component of the I-band region 
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which is bisected by the Z-lines. Myosin filaments extend throughout the A-band 
region where they are cross linked at the centre by the M-line.  
 
Figure 1.2. Schematic of cardiac muscle fibres and myofibril.  
A) Shows a muscle fibre made from series of cardiomyocytes that are joined through 
intercalated disks. B) Represents the expanded region, which shows a myofibril section. 
Myofibrils are constructed of repeating sarcomeres within cardiomyocytes. Each 
sarcomere is defined as the structures bound between the Z-lines which lie within the I-
band region. The main component of the I-band regions are actin filaments. The A-band 
comprises of thick myosin filaments which are crosslinked at the centre by the M-line. 
Image A) is adapted from Davidson’s Principles and Practice of medicine 22nd Edition. 
Elsevier. 2014. [4]. Image B) was created by the author of this thesis. 
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1.1.3. Electrical conduction system of the heart 
The heart beats in an orderly fashion to circulate blood throughout the body. This 
normal rhythmic activity is called sinus rhythm and consists on average of 65 to 
100 beats per minute (bpm) [1], [4]. The contractions of the atria and ventricles are 
regulated by the transmission of electrical impulses which travel through a network 
of pacemaker cells and the conductions system [6], as shown in Figure 1.3. The 
sinoatrial (SA) node is responsible for the sinus rhythm of the heart. Situated in the 
RA of the heart, it can be thought of as the natural pacemaker. The SA node 
generates the electrical impulse that initiates contraction, which first excites the 
RA then the LA by travelling through Bachmann’s bundle. The impulse travels 
through internodal pathways in the RA to the atrioventricular node. Subsequently, 
the impulse travels through the bundle of His where is divides into the left and right 
bundle branch located in the septum between the ventricles. The left and right 
bundle branches excite the LV and RV, respectively. Both bundle branches 
terminate in Purkinje fibres, where they spread throughout the myocardium in the 
ventricles [7]. The rate at which the impulse travels through the tissue of the heart 
is known as the conduction velocity (CV).  
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Figure 1.3. The cardiac electrical conduction system.  
This illustrates the transmission of the electrical impulses through the heart. The impulse 
is initiated by the sinoatrial node in the right atrium where it travels to the atrioventricular 
node via internodal pathways. In addition to this, a pathway called Bachmann’s bundle 
conducts the impulse to the right atrium from the left atrium. From the atrioventricular 
node, the impulse reaches the Bundle of his whereby it is divided to the left and right 
bundle branches. Finally, the impulse terminates in the Purkinje system where it spreads 
throughout the myocardium in the ventricles. Image extracted from McMaster Physiology 
Review. Retrieved from: 
http://www.pathophys.org/physiology-of-cardiac-conduction-and-contractility/heart-
conduction-colour/ 
 
1.1.4. Ion channels 
Ion channels are proteins that form a pore on the cell membrane, their functions 
include the gating of the flow of ions across the interior and exterior of the cell [8]. 
Governing the flow of ions controls the electrical properties of the cell. The 
transmembrane potential (TMP) is the electrical potential difference between the 
intracellular (ICF) and extracellular (ECF) fluid of the cell. A cardiac ion channel is 
selective; it is only permeable to a single type of ion. Some channels are voltage-
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gated; a specific TMP range is necessary for the channel to be open, outside of 
this range, it becomes impermeable to ions. Different types of voltage-gated ion 
channels have a particular ion selectivity and a particular voltage dependence [9]. 
There is also time dependence for some cardiac ion channels. Time dependent 
channels are configured to close a fraction of a second after opening and cannot 
be re-opened until the TMP returns to resting levels [9]. The different types of 
channels are a result of their protein structure which is encoded by specific genes. 
The key channels in the cardiomyocyte are (Figure 1.4): the potassium (K+) 
channels which mediate the outflow of K+ ions, sodium (Na+) and calcium (Ca2+) 
channels regulating the inflow of Na+ and Ca2+ ions, the Na+/Ca2+ exchanger 
which transports 3 Na+ ions each Ca2+ ion [2].  
 
Figure 1.4. Cardiac ion channels.  
This illustrates the key ion channels on the cardiomyocyte. The region in blue represents 
the cell membrane. Potassium (K+) channels (green) mediate the outward K+ ion current 
across the membrane. The influx of sodium (Na+) and calcium (Ca2+) ions are mediated 
by the Na+ (purple) and Ca2+ (orange) channels, respectively. The Na+/Ca2+ exchanger 
(red) transports 3 Na+ ions for every Ca2+ ion. Image adapted from Cardiac 
channelopathies. Nature. 2002 [2]. 
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1.1.5. The cardiac action potential 
The electromechanical activity of the heart is attributed to the generation of action 
potentials (AP) from cardiomyocytes. An AP is an electrical stimulation as a result 
of a series of ion fluxes which are mediated by channels in the membrane of the 
cardiomyocyte which leads to a contraction. The AP is comprised of five phases 
and is an abrupt reversal of the membrane potential to a positive value. An AP is 
initiated by a pacemaker cell of an adjacent cardiomyocyte. The morphology and 
amplitude of the AP is determined by differences in ion concentration across the 
cell membrane. Ion channels gate the flow of ions between the intracellular and 
the extracellular fluid. Figure 1.5 illustrates the AP and its phases are listed as 
follows [10]: 
 Phase 0 – rapid depolarisation. The potential shifts towards a positive 
voltage range and is governed by the rapid opening of fast sodium (Na+) 
channels causing an influx of Na+ and the TMP rises to be slightly above 
0mV. Fast Na+ channels close as these are time dependent and remain 
open for only a short period. Note that the TMP requires a minimum 
potential in order to initial an AP, this is known as the threshold potential.  
 Phase 1 – rapid repolarisation or peak upstroke. Potassium (K+) channels 
open briefly and an outward flow of K+ returns the TMP to approximately 
0mV.  
 Phase 2 – plateau phase. Maintained by a balance of positive inward and 
outward currents. This is the longest phase of the AP where Calcium (Ca2+) 
ions enter the cell through the long-type Ca2+ channel and is balanced by 
the out flow of K+.  
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 Phase 3 – repolarisation. The plateau phase begins to terminate and late 
repolarisation begins. The Ca2+ channels gradually close but K+ channels 
remain open. The persistent outflow of K+ brings the TMP towards the 
resting potential of -90mV.  
 Phase 4 – resting membrane potential. At this phase the AP is typically held 
at approximately -90mV due to a constant outward leak of K+ and the 
closure of Ca2+ and Na+ channels.  
The action potential duration (APD) is defined as the amount of time in which the 
voltage remains above the resting potential [11]. Looking at the specific times of 
the duration gives insight into the different phases of the AP.  
Once an AP initiates, the cardiomyocyte is unable to initiate a new AP for a brief 
period of time, this is known as the effective refractory period (ERP). The ERP 
occurs due to the fast Na+ channels remaining closed until the cell fully repolarises 
[1]. The ERP can act as a protective mechanism against abnormal heart rhythms 
[12] and allows for adequate time for the chambers of the heart to fill with blood 
before contraction.  
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Figure 1.5. The cardiac action potential.  
An AP is a short lasting event whereby the membrane voltage of a cardiomyocyte rapidly 
rises and falls. The top section illustrates the ionic movements between the extracellular 
(ECF) and the intracellular (ICF) fluid. The stages of an AP are described by five phases 0 
to 4 at the bottom section of the image. At phase 0 the cells rapidly depolarise causing the 
potential to shift towards a positive voltage range caused by an influx of sodium ions 
(Na+). Phase 1 is the rapid repolarisation; the AP upstroke reaches its peak voltage 
caused by an outflow of potassium ions (K+). Phase 2 is the plateau phase, the longest of 
all the phases. The plateau is maintained by a balance of positive inward calcium ions 
(Ca+) and outward K+. Phase 3 is the repolarisation where the plateau begins to terminate 
Ca2+ channels begin to close but K+ channels remain open. Phase 4 is the resting phase, 
whereby the transmembrane potential (TMP) of the AP is typically held at -90mV due to a 
constant outward leak of K+. Image extracted from McMaster Pathophysiology Review. 
Retrieved from:  
http://www.pathophys.org/physiology-of-cardiac-conduction-and-
contractility/actionpotential/ 
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1.1.6. The electrocardiogram 
The electrocardiogram (ECG) is used to assess cardiac rhythm and conduction. 
The basis of an ECG is that the electrical depolarisation of the heart produces a 
small current which reaches the surface of the body [4]. If a series of electrodes 
are placed onto the skin on opposite sides of the heart, the electrical potentials 
can be recorded.  
A normal ECG consists of a P wave, a “QRS complex” and a T wave. There exists 
a U wave and by definition it follows the T wave, however, this wave is 
inconsistent and not always seen [13]. The P wave represents the depolarisation 
of the atria. The QRS complex is caused by currents from the rapid depolarisation 
of the ventricles and is made up of three waves, the Q wave, R wave and the S 
wave. The T wave is caused by currents generated as the ventricles recover from 
the state of depolarisation; this is known as a repolarisation wave. The PR interval 
reflects the time of the electrical impulse to travel from the SA node to the AV 
node. The ST segment represents the period when the ventricle are depolarised. 
The QT segment is the measure of time between the start of the QRS complex to 
the end of the T wave. A lengthened QT interval is a marker for cardiac 
abnormalities, often referred to as long QT syndrome [14]. Between the cycles of 
the ECG waves, the recording returns to baseline, this is known as the isoelectric 
line. Figure 1.6 shows the AP waveforms of the heart from multiple regions 
forming the waves present in an ECG. ECGs are useful in understanding the 
electrical conduction system of the heart; they typically form a predictable pattern 
in a normal heart. Therefore, deviations from the norm can give indication of 
pathological abnormalities [15], hence the importance of ECG interpretation. The 
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placement of ECG electrodes plays an important factor of the waveform of the 
ECG [16]. The depolarisation of the heart towards a positive electrode produces a 
positive deflection, whereas away from the positive electrode creates a negative 
deflection. This differs from the repolarisation. As the heart repolarises, the 
impulse towards the positive electrode produces a negative inflection but away 
from the electrode generates a positive deflection [1]. For example, if the R wave 
of the QRS complex is greater than the S wave, this suggests the depolarisation is 
travelling towards the positive electrode. If the S wave is greater than the R wave, 
this suggests depolarisation away from the positive electrode.  
 
Figure 1.6. Action potential waveforms of the heart.  
This shows the regional waveforms of the electrical activity from different parts of the 
heart forming an electrocardiogram (lower portion of the image). The electrical impulses 
spread from the heart to the surrounding tissue where they can be recorded by 
electrodes. The electrical impulse begins at the Sinoatrial (sinus) node and travels down 
to the atrioventricular (AV) node where it eventually ends in the ventricles. Image 
extracted from Bioelectromagnetism - Principles and Applications of Bioelectric and 
Biomagnetic Fields. Part I. Oxford University Press. 1995 [17].  
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1.2. Cardiovascular disease 
Cardiovascular disease (CVD) is defined as a group of diseases which affect the 
heart or blood vessels and they remain the leading cause of death worldwide [18]. 
It is estimated that 30% of all deaths worldwide were caused by CVD [19]. Within 
the UK, 27% of all deaths were caused by CVD [20]. There are many risk factors 
which contribute to the propensity of CVD. Some of these factors may be 
environmental or lifestyle such as obesity [21] and smoking [22], as well genetic 
predisposition [23].  
The main causes of CVD death are coronary heart disease (CHD) and stroke. The 
heart has its own network of blood vessels on the surface of the heart called 
coronary arteries. CHD is when the blood supply is interrupted, this sometimes 
referred to as ischaemic heart disease. A stroke manifests when the blood flow to 
the brain is disrupted, this can either be ischaemic; due to a lack of blood flow or 
haemorrhagic, due to bleeding [24]. As a result, the function of the brain is 
impaired. In the UK 46% of CVD deaths were due to CHD and 26% were from 
stroke. Overall, CHD was responsible for 16% of all male deaths and 10% for 
women in the UK [19]. 6% of all UK deaths in men and 9% in women were caused 
by stroke [19]. It is clear that CVD presents itself as a significant burden. There is 
also a financial cost of CVD. In England, more than £6.8 billion was spent on 
treating CVD in 2012/2013 from the NHS [20]. In 2014, more than 313 million 
prescriptions were dispensed for CVD in England [20]. 
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1.3. Cardiac arrhythmias 
Cardiac arrhythmias are a group of conditions where the rhythm of the heart is 
irregular or the rate is abnormal. Tachycardia is the term for a fast heart rate, 
usually defined as over 100 bpm. Bradycardia means a slowed heart rate, which is 
defined as less than 60bpm [15]. Arrhythmias can arise when the electrical 
impulses are coming from another part of the heart or there is an impairment of 
the conduction system causing the impulse to take an unusual path [25]. Many 
types of arrhythmia have no symptoms but when they do present, they can range 
from the feeling of skipped beats to chest pains and unconsciousness [26]. Some 
arrhythmias are not serious but others can predispose one to more severe 
conditions such as stroke and heart failure [26]. The most common type of 
arrhythmia is atrial fibrillation (AF) [27], this an uncoordinated and rapid beating of 
the atria, leading to impaired atrial function [25]. More information on AF is 
provided in section 1.4.  
Ectopic beats or extrasystoles are essentially premature extra beats which 
interrupt the normal rhythm of the heart. Extrasystoles can present themselves in 
either the atria, or the ventricle [25]. While the SA node typically regulates the 
sinus rhythm of the heart, an atrial extrasystole occurs when another region of the 
atria depolarises before the SA node triggers, causing a premature beat, this is 
also known as a premature atrial contraction. A similar action occurs in ventricular 
extrasystoles, where the ventricles depolarise before the triggering of the SA node 
[25].  
Afterdepolarisations are abnormal depolarisations in the heart which interrupt the 
repolarisation phase of the AP and can be described as early or delayed. Early 
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afterdepolarisations (EADs) occur during the phase 2 of phase 3 of the AP. 
Delayed afterdepolarisations (DADs) begin during phase 4 of an AP but before 
another AP would normally occur. When an EAD or DAD has amplitude greater 
than the threshold potential, further APs can be initiated, referred to as a triggered 
response [28]. These triggered events can result in extrasystoles and tachycardia 
[28].  
Re-entry is a form of arrhythmia that is caused by the electrical impulse not 
completing the normal circuit, but rather finding an alternative route. Conditions 
that facilitate re-entry include the presence of unidirectional block, where the 
passage of the electrical impulse is inhibited in on direction, and the rate of 
conducting the impulse is slow [29]. A model for re-entry is shown in Figure 1.7. In 
a normal system (Figure 1.7 left), where a conducting bundle forms a branch, the 
electrical impulse will travel down each branch. If these branches are connected 
by a common pathway the impulses will cancel each other. In the case for re-entry 
(Figure 1.7 right), there is a unidirectional block at branch (2). In such a block, the 
impulse can travel retrogradely from branch (3) to (2). As the impulse leaves the 
block, it can re-excite the tissue if it is beyond the ERP and re-enter at (1). An 
electrode at (*) would measure high frequency impulses. If the impulse left the 
block and found the tissue to be within the ERP the tissue would not re-excite. 
Hence, in this instance a longer ERP would be favourable.  
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Figure 1.7. Re-entry model.  
This illustrates the normal and re-entrant models. Conducting bundles branch to (1) and 
(2) and are met by a common pathway at (3). In the case of normal conduction, the 
impulse (blue arrows) divides at the top to branches (1) and (2) and at (3) they meet and 
cancel. If an electrode was placed at (*), it would witness a single AP. For the re-entrant 
model however, there is a unidirectional block (grey box) at branch (2). The impulse only 
travels down branch (1) and conducts to (3). Subsequently, the impulse travels to branch 
(2) (red arrow) and through the block. If the tissue after the block is within its refractory 
period the impulse ends. However, if it is outside of its refraction, the impulse continues, 
and can re-enter at branch (1). The electrode at (*) would measure a series of frequent 
impulses. Image was created by the author of this thesis. 
 
1.3.1. Antiarrhythmic drugs 
Antiarrhythmic drugs (AADs) or agents are a group of pharmaceuticals used to 
supress cardiac arrhythmias. AADs can either be used to control rate or rhythm. 
They can be classified according to whether they interfere with ion channels 
located on the cardiomyocyte or by whether they block receptors [30]. Here we 
shall discuss the class of AADs which act by blocking the Na+ channel, often 
referred to as class I agents. Class I drugs can be further subcategorised into 
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three groups (Ia, Ib and Ic) [30]. Class Ia are drugs which prolong the AP by 
reducing the rate of the upstroke (phase 0). Class Ib agents do not reduce the rate 
of the upstroke but shorten the APD. Class Ic drugs reduce the upstroke rate, slow 
the CV and can prolong the ERP [30]. Na+ channel blockers can convert regions 
of unidirectional block to bidirectional block, abolishing re-entry [31]. Class I 
agents depress the excitability of the cardiomyocytes [31]. These properties can 
be both pro- and antiarrhythmic [32]. 
Flecainide acetate or simply flecainide is a class Ic antiarrhythmic. It is used in a 
variety of arrhythmias such AF [33]. Flecainide was first synthesised in 1972 and 
successfully tested in humans in 1975, soon after in 1982 is was approved for use 
in Europe [34], [35]. Flecainide binds to the open Na+ channel and causes a 
blockade. The main effect of the channel blockade is the slowing of CV and 
prolongation of the ERP. Flecainide is also known to a lesser extent inhibit the K+ 
channels [36]. The effect of flecainide on the Na+ channels increase as the heart 
rate increases, this is known as use-dependence [37], [38].  
1.4. DNA and genetics 
The propensity of CVD may be due to environmental factors but also genetic ones 
[23]. Therefore, this section is a brief highlight of some of the basic principles of 
genetics and deoxyribonucleic acid, commonly referred to as DNA. All living things 
are composed of cells. The heart is mainly composed of cells called 
cardiomyocytes. Within cells the nucleus can be found, where its genetic 
information is stored; information that specifies the form and function of all cells 
within an organism [39]. This information is stored in the form of DNA, strands of 
long molecules coiled to form a double helix (Figure 1.8). DNA is formed of 
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polymer chains of molecules called nucleotides. Each nucleotide is composed of a 
nitrogen containing nucleobase: adenine, thymine, cysteine and guanine (A, T, C 
and G, respectively) [39]. These nucleobases are classified into two types, purines 
(A and G) and pyrimidines (C and T). Two strands of DNA run in opposite 
directions, pairing the nucleobases forming a double helix. During assembly of the 
helical structure, a purine can pair only with a pyrimidine (A-T and G-C), and a 
pyrimidine with a purine (C-G and T-A). This pairing is known as a base pair [26]. 
The sequence of these base pairs specifies the form and function of a cell. Figure 
1.8 illustrates the process of how DNA encodes the biological information of a cell 
as a protein product. Within cells, DNA is organised into coils called 
chromosomes. A gene is a sequence of DNA located on a region of the 
chromosome known as a locus. Introns and exons are nucleotide sequences 
within a gene. Exons are parts of the gene which codes for protein, introns 
however, do not [39]. A gene directly produces a single strand of mRNA 
(messenger ribonucleic acid), this is an identical sequence of one of the two 
strands of DNA – the DNA has been transcripted. Ribosomes are biological 
components which facilitate the synthesis of proteins specified by mRNA. Genes 
can exist in alternative forms, which are located at the same locus on the 
chromosome. These forms are known as alleles. Some alleles can result in 
different observable traits, known as phenotypes, such as hair and eye colour. 
Mammals such as humans and mice have two pairs of chromosomes; one of each 
pair is inherited from each parent [39]. This is also true for genes, one of the two 
copies of each gene from each parent. The genotype can be described as 
homozygous if two identical pairs of alleles at a particular locus are present, 
heterozygous if the two alleles are non-identical. In this thesis, the nomenclature 
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for a genotype that is heterozygous is denoted by a superscripted +/-, e.g. 
“genotype+/-”, i.e. it is deficient in a gene. Homozygous genotypes with two non-
functioning alleles are denoted as “genotype-/-”. Homozygous genotypes with two 
functioning pairs of alleles are stated as wild type (WT) as these are considered 
the “normal” allele at that locus.  
 
Figure 1.8. The flow of information from DNA to protein.  
This depicts the storage of genetic information in the chromosomes (top left) and how 
protein is synthesised. Genes are regions of DNA on the chromosome that encode 
biological information. A gene directly produces a strand of mRNA. Ribosomes serve as a 
site for protein synthesis. The ribosome decodes the mRNA and produces a chain of 
amino acids (polypeptide). The polypeptide later becomes an active protein and performs 
functions in the cell. Image extracted from Braunwald’s Heart Disease. A Textbook of 
Cardiovascular Medicine. Elsevier. 2011 [26]. 
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1.4.1. Single nucleotide polymorphism (SNP) 
A single nucleotide polymorphism (SNPs) is a variation at a single position in a 
DNA sequence. Recall that DNA is a sequence of nucleotides (A, T, C and G). 
Differences in nucleotide sequences (Figure 1.9) that lead to structural change in 
the encoded protein are called mutations. A mutation is defined as occurring in 
less than 1% of a given populations. Hence, if more than 1% of a population does 
not carry the same nucleotide at a specific location in the DNA sequence, this is 
considered a SNP. Some SNP sequences are associated with diseases, whilst 
others are harmless or protective [26].  
 
 
Figure 1.9. A single nucleotide polymorphism. 
This shows a representation of the nucleotide sequence from two people. The base pairs 
highlighted in red shows the location of the polymorphism. If person B shares the same 
nucleotide base at that location with more than 1% of a given population and person A 
does not, Person A is considered to have the SNP. Image was created by the author of 
this thesis. 
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1.5. Atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained arrhythmia in man and a 
common cause of stroke and cardiac deaths, AF is more prevalent in the aging 
population [40] and affects up to 2% of the general population [27]. It is described 
by rapid and disorganised atrial activation [27]. Under sinus rhythm, the hearts 
beats at approximately 65 to 100 bpm and can rise to as much as 200 bpm during 
intense exercise [1]. During AF, atrial cells can depolarise at rates close to 400-
600 times a minute [41]. Fortunately, each of these beats does not lead to a 
ventricular contraction as this would quickly result in loss of consciousness caused 
by a fall in blood pressure. The occurrence of AF is dependent on multiple factors 
such as re-entry. Re-entry can occur due to reduced refractoriness and slow 
conduction [29]. AF can be initiated by ectopy in the form of extrasystoles or 
afterdepolarisations [42]. Current management of AF include rate or rhythm 
control. Rate control methods target the ventricular rate by reducing rate of 
conduction of the atrioventricular (AV) node. The AV node is the key conduction 
bundle that link the electrical signals from the atria to the ventricles (Figure 1.3) 
[43]. Rhythm control attempts to convert the heart to sinus rhythm, e.g. by use of 
antiarrhythmic drugs such as flecainide. Flecainide works by blocking the Na+ 
channels in the heart. The effect of flecainide on the Na+ channels has been 
shown to increase as heart rate increases [27], [37], [44]. There have been many 
studies and good progress has been made in the characterisation of factors that 
cause AF, such as hypertension, diabetes and heart failure [29], [45], [46]. 
However, there is still a need for better therapies to prevent incident and recurrent 
AF [45], [47].  
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1.5.1. Role of Pitx2 
Genome-wide association studies have found common gene variants or single 
nucleotide polymorphisms (SNP) associated with AF on chromosomes 4q25 [48], 
[49]. This region is in close proximity to the paired-like homeodomain transcription 
factor 2 (Pitx2) homeobox gene [50]. Pitx2 is a homeobox gene responsible for the 
left right asymmetry formation of the body [51].  
Four isoforms (a, b, c and d) exist for Pitx2. The c-isoform mRNA has been shown 
to be expressed 100 fold higher in the LA compared to the other chambers of the 
heart and is crucial to the development of the sinoatrial node [52]. These variants 
are associated with altered mRNA expression of the transcription factor Pitx2 and 
show an increased risk of AF [49]. A severe insufficiency of the Pitx2 has been 
shown to lead to structural and electrical remodelling in the atria [53]. Other 
research groups found mouse models of homozygous deletion (Pitx2-/-) leads to 
cardiac abnormalities [51]. A heterozygous (Pitx2c+/) mouse model showed 
increased risk of AF inducibility [53]–[55]. 
1.6. Arrhythmogenic right ventricular cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic 
form of cardiomyopathy, a disease of the heart muscle. It is an inherited disease 
which contributes significantly to the sudden death of young athletes [56], thereby 
suggesting that endurance training facilitates disease progression. ARVC has 
prevalence in the general population of approximately 1:2000 to 1:5000 [57] 
whereby men are more affected by women with the approximate ratio of 3:1 [58]. 
ARVC primarily affects the right ventricle and is characterised by arrhythmia and 
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fibrosis, a thickening and scarring of connective tissue, but ARVC may involve the 
left ventricle [59]. The right ventricle dilates at later stages leading to reduced 
contractility and ejection fraction of the heart [60], [61]. Pre-stages of the fibro-fatty 
infiltration and remodelling are often detected by ECG changes in ARVC patients, 
which can be used as a diagnostic marker [62], [63]. The tissue of the myocardium 
is replaced with fatty and fibrotic tissue. Alterations in the QRS complex of an ECG 
indicate that ARVC sufferers are susceptible to increased arrhythmias [64], [65].  
ARVC is considered a disease of the desmosome. Desmosomes are intercellular 
junctions that connect intermediate filaments to the cell surface and provide strong 
adhesion between cells [66], see Figure 1.10. Mutations in the protein junctions in 
the desmosome of the intercalated disk result in an ARVC phenotype [67], [68]. 
These mutations lead to a change in morphological structure and which can result 
in cell death [59]. Conditions of mechanical stress can weaken the adhesiveness 
of the cells which leads to the hypothesis that environmental factors such as 
endurance training can exacerbate the phenotype and accelerate the 
development of ARVC [64].  
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Figure 1.10. The desmosome.  
This is a simplified model of the desmosome, which highlight the main protein-protein 
interactions. Desmosomes mediate cell-cell contact via a number of proteins: plakoglobin, 
plakophilin, desmoplakin, desmoglein and desmocollin. The keratin filaments are 
anchored to the desmosomal proteins which mediate through the cell wall (grey line). 
Image was created by the author of this thesis.  
 
1.6.1. Role of plakoglobin 
Previous studies have shown that the gene variants that code for plakoglobin is 
located on chromosome 17q21 [69]–[71]. Plakoglobin is a key constituent for the 
adherent junctions and is responsible for the tight adhesion between 
cardiomyocytes (see Figure 1.10) [69], [71]. It is involved in the area composita of 
adhering junctions. This area is thought to be the main component of the 
intercalated disk between cardiomyocytes and consists of adherent fascia proteins 
and desmosomal proteins [67], [68]. Transgenic mouse models have verified the 
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roles of junctional protein dysfunction in ARVC. Mice with homozygous deletion of 
plakoglobin (plako-/-) do not survive gestation [72]. However, heterozygous 
(plako+/-) mice develop the ARVC phenotype with age or endurance training which 
consists of enlarged right ventricle and inducible ventricular tachycardia [64]. 
1.7. Genetically altered murine models 
Genetically altered murine models are becoming increasingly popular for the 
investigation of human cardiac arrhythmias [73]. Albeit some differences such as 
their small size and faster heart rates, they often provide a second best compared 
to the patient themselves. These models allow for control of multiple factors such 
as age, sex and diet reducing genetic and environmental variability [74]. Mice 
have a short gestation period, rapid maturation and their ease of genetic 
manipulation making them very attractive models. Mice and humans also have 
many homologous cardiac developmental pathways but also have considerable 
differences. One example of this is the faster resting heart rates of 600 
beats/minute which is 10x faster than that of a human. Mice have also been 
shown to have a much shorter APD with no plateau phase [75]. The APD of a 
mouse is reported to be 10x less than their human counterpart; this is mainly due 
to the differences in relative abundance of repolarisation currents. One of the 
obvious differences is the lack of a plateau phase in the mouse AP compared to 
humans. The lack of a plateau is attributed to the predominance of activating 
outward potassium channels causing relatively short APDs at around 50% to 
repolarisation compared to the human AP [76]. The currents which play a large 
role in the repolarisation of the human heart are the rectifying potassium currents 
both rapid (IKr) and slow (IKs) [77]. The current IKr is mediated by the hERG (human 
 26 
 
ether-a-go-go-related gene) channel and IKs by the KVLQT1 channel. Both hERG 
and KVLQT1 are proteins which form the channels to moderate the flow of outward 
potassium current [78]. These currents give rise to the long lasting plateau phase 
of the AP in a human but are not present in mice. The prominent currents in mice 
which are responsible for the repolarisation are three distinct potassium currents - 
slowly inactivating potassium current (IK,slow1 and IKslow2) and the non-inactivating 
steady state current (ISS) [73]. Studies have revealed that IK,slow1 is mediated by the 
KV1.5 channel protein and IK,slow2 by KV2.1 [79], [80]. The identity of the protein 
mediating the ISS current remains to be found [73]. The differences in channel 
expression between mice and men give rise to the different currents which 
repolarise the cells causing their morphological differences in AP. Figure 1.11 
shows the differences in ionic current and how they contribute to the morphology 
of a human and mouse AP.  
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Figure 1.11. The human and mouse action potential. 
This shows the morphological differences between a typical human (left) and mouse 
(right) AP. The currents can be seen below each of the APs. The inward currents such as 
the long type (L-type) calcium (ICa,L) and sodium (INa) are shown to appear below the line 
and outward currents are above. The main difference between the human and mouse AP 
is the plateau seen at phase 2. Inward potassium currents, IKr (rapid) and IKs (slow) are 
prominent in the human AP whereas this is true for the slowly inactivating potassium 
currents (IK,slow1&2) and the non-inactivating steady state current (ISS) in mice. Image 
extracted from Studying Cardiac Arrhythmias in the Mouse - A Reasonable Model for 
Probing Mechanisms? Trends in cardiovascular medicine. 2004  [73].  
 
1.8. Action potential measurement techniques  
To measure the millivolt changes in cardiac tissue, there have been numerous 
techniques developed. Some of these techniques involve direct contact but can 
also be non-contact. Monophasic action potential (MAP) electrodes are often used 
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in measurement of cardiac AP. The first MAP was developed over 30 years ago 
[81] and recorded signals by applying a point load to the myocardium. In simplest 
terms, the point of contact measures the voltage with respect to a reference 
electrode but the genesis of the MAP signal is still not understood [82].  
MAP electrodes have often been used in conjunction with a Langendorff 
apparatus, a method of sustaining a whole isolated heart for a prolonged period of 
time [83], as shown in Figure 1.12. The Langendorff apparatus works by reverse 
perfusion. Blood normally leaves the heart by the aorta but here, buffer solution 
used to sustain the heart is flowed into the aorta. During reverse perfusion, the 
aortic valves close and the solution passes through the coronary ostia where it 
passes through the vascular bed. Subsequently, the solution reaches the coronary 
sinus and the atria. The MAP electrodes have the advantage over suction 
electrodes which were developed much earlier on, which caused damage to the 
tissues [81], [84]. The MAP electrode measures the potential from an aggregate of 
surrounding cells and can be difficult to use especially for small organs such as 
murine atria. The gold standard for measuring the cardiac AP is the 
microelectrode, which measures the voltage directly from a single cell. The 
microelectrode technique has been widely used in cardiac research [85]–[87] but 
has one main drawback; it only measures from a single point from a cell. Much 
information can be gathered from measurements of a single AP series such as its 
activation time, duration, effective refractory period (ERP). Despite this, it is often 
necessary to study the effects from multiple regions of the heart. Electrode arrays 
[88] and optical mapping [89], [90] techniques have been developed to overcome 
this drawback by taking measurements from multiple points simultaneously.  
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Figure 1.12. Scheme of a Langendorff apparatus.  
This shows a simplified scheme of the Langendorff system. The heart is cannulated at the 
aorta, and is retrogradely perfused with buffer solution. The solution is directed from the 
reservoir to the heat exchanger coil by the peristaltic pump and the temperature is kept at 
approximately 37ºC. The solution subsequently reaches the bubble trap, where there is 
also a bolus port where drugs can be administered. For murine hearts, the pump is 
usually set to deliver 4ml per minute. This image was adapted from Retrograde heart 
perfusion: the Langendorff technique of isolated heart perfusion. Journal of Molecular and 
cellular cardiology. 2011  [83].  
 
1.9. The need for optical mapping 
Optical mapping is an important tool in cardiac electrophysiology as understanding 
the spread of electrical activity allowed for better knowledge of the mechanisms 
responsible for cardiac arrhythmias. Microelectrode and monophasic action 
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potential (MAP) electrodes are useful tools for studying arrhythmias; however, 
they lack spatial resolution. Optical mapping has provided important insights into 
mechanisms of atrial arrhythmias in murine models [91], [92]. The ability to resolve 
spatially is important as cardiomyocytes depolarise, the AP propagates to other 
regions of the tissue. Measuring a single cell or an aggregate of neighbouring cells 
only provides information regarding that specific region. The depolarisation pattern 
is the basis for sinus rhythm and arrhythmias. Optical mapping can yield 
information such as conduction velocities by mapping the location of multiple APs. 
As such, investigations on re-entrant arrhythmias [93], [94] atrial [55] and 
ventricular fibrillation [95] and many other cardiac arrhythmias have benefited 
greatly from optical mapping.  
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 Introduction to optical mapping  
2.1. General principles 
Optical mapping is an established imaging technique used for the measurement of 
electrical excitability in cardiac tissue [96]–[98] which was first demonstrated in 
1976 [99], and is a valuable tool for aiding our understanding of arrhythmias [92]. 
This is a fluorescence imaging method based on voltage sensitive dyes that bind 
onto the lipid membranes on a cell. During an optical mapping experiment, a 
sample of cardiac tissue is perfused ex vivo and stained using the dye. The 
membrane bound dye is excited by a light source and emits at a longer 
wavelength similar to standard fluorescence techniques but the main difference 
lies in the dyes ability to sense local changes in electric fields [100]. The theory of 
how an excited fluorophore can emit a photon of lower energy is shown in Figure 
2.1. These molecules react by changing their optical spectra which is recorded 
using appropriate filters and cameras. The result of this shift in spectra allowed us 
to visualise cardiac action potentials (APs) as relative changes in fluorescence. 
The motivation for the development of these dyes arises when high spatial and 
temporal resolution measurements are required, which contact methods such as 
microelectrodes do not provide. One of the main aims of an optical mapping 
system is to provide measurements with high signal to noise ratios (SNR) and high 
spatial and temporal resolution. 
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Figure 2.1. Jablonski diagram of fluorescence.  
The fluorophore is excited by an incoming photon. The electron attached to the 
fluorophore’s energy level reaches an excited state as indicated by the green upward 
arrow. As the electron returns to the ground state it emits a photon of lower energy 
compared to the excitation photon as indicated by the red downward arrow.  
 
2.2. Voltage sensitive dyes 
Voltage sensitive dyes are molecular probes that strongly bind onto the cell lipid 
bilayers. Whilst bound, the dye fluoresces with an intensity that is proportional to 
the membrane potential [101]. An ideal dye should have the following properties: 
I. High sensitivity, large shifts in the fractional change in fluorescence in 
response to millivolt changes in potential, denoted by ΔF/F where F is the 
fluorescence.  
II. Minimal photobleaching to maintain a high signal to noise ratio.  
III. Minimal toxicity leading to reduced cellular damage.  
IV. No physiological effects on the cardiac tissue which can skew results.  
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V. Fast responding to changes in potential across membranes.  
Several useful families of compounds have found widespread use in cardiac 
electrophysiology [96], [100]. Styryl dyes are the most used group [96], such as 
the RH (Rina Hildesheim) and ANEP (Amino-Naphthyl-Ethenyl-Pyridinium) dyes. 
Di-4-ANEPPS (di-4-amino-naphthyl-ethylene-pyridinium-propyl-sulfonate) remains 
one of the most used dyes due to its relatively low cost [100]; its chemical 
structure can be seen on Figure 2.2. However, there have been studies to show 
that there is a significant slowing of conduction velocity with the use of di-4-
ANEPPS [102]. The peak excitation and emission wavelength for di-4-ANEPPS is 
at 465nm and 635nm, respectively.  
 
Figure 2.2. Chemical structure of di-4-ANEPPS. 
This shows the chemical structure of di-4-amino-naphthyl-ethylene-pyridinium-propyl-
sulfonate (di-4-ANEPPS), a voltage sensitive dye which responds to changes in 
membrane potential. The excitation wavelength is 465nm and its peak emission is 635nm. 
In the ground state the pyridinium site is slightly positively charged and the negative 
electron cloud resides on the N[(CH2)3CH3]2 amine site. The amine group is the site which 
binds onto the cell membrane. Image adapted from ThermoFisher Scientific. Retrieved 
from: https://www.thermofisher.com/order/catalog/product/D1199 
 
2.2.1. Mode of action 
Di-4-ANEPPS works by the principle of electrochromism (sometimes referred to as 
the Stark Effect). Upon excitation the charge density distribution of the dye shifts 
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from one end of the dye to another, this can be seen in Figure 2.3. Whilst at the 
ground state the pyridinium site is more positively charged (N+) and negative 
electron cloud resides towards the amine group, thus being the electron acceptor 
and donor, respectively. During excitation this charge distribution reverses and the 
amine group becomes the electron acceptor [103]. As the cells polarise (-Vm) with 
an electric field E, it perturbs the spectrum of the dye by changing the energy 
difference between the ground and excited states. As a result, the emission 
spectra shift in wavelength or redshifts as seen in Figure 2.4. It can be seen that in 
order to gain the best fractional change in fluorescence (i.e. largest ΔF/F), the 
peak of the spectra should be avoided and the ideal selections are towards the 
tails of the spectrum. 
 
 
Figure 2.3. Di-4-ANEPPS ground and excited states 
This shows the different charge distributions for di-4-ANEPPS during its ground and 
excited states. Upon excitation, the negative charge density shifts from the amine side to 
the pyridinium side of the molecule. This shift can be seen from the N region on the 
ground state which becomes N+ when excited. The energy difference between the two 
states is shown as hν; where h is Planck’s constant and v the frequency of the photon. 
Image adapted from Design and Use of Organic Voltage Sensitive Dyes. Membrane 
Potential Imaging in the Nervous System: Methods and Application. Springer. 2011  [104]. 
 35 
 
Depending on whether measurements are made on either side of the peak 
emission wavelength, fluorescence changes will either increase or decrease as a 
result, this is seen in Figure 2.4B. Figure 2.5 shows how a long pass filter (red 
line) can result in a negative ΔF/F as cells depolarise from -90mV to 0mV, the red 
shaded regions represent the amount of photons that pass the filter for 
measurement. A long pass filter will allow for a large number of photons to pass 
through provided it is greater than that stated wavelength. In the case in Figure 
2.5, light with a wavelength greater than 630nm will be passed and photons below 
this value were blocked. Long pass filters differ from band pass filters which only 
allow a small portion of photons to be transmitted depending on the window size.  
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Figure 2.4. The shift in emission spectra in di-4-ANEPPS due to cell depolarisation 
(+Vm).  
A) Shows the dye represented as the white rectangles bound onto the cell membrane 
(shown in grey). The dye goes from the excited state (ES) to the ground state (GS), but is 
perturbed by the electric field (E) in the membrane. This perturbation causes the emission 
wavelength to change from λD to λP (depolarised to polarised) which is proportional E. B) 
Represents the emission spectra for the dye at polarised (solid red) and depolarised 
phases (black dashed). The relative changes in fluorescence are indicated by the change 
in percentages for various choices of detection wavelength (λ). It can be seen that the 
choice in wavelength can have a significant effect on the sensitivity of the dye, for 
example, towards the peak of the dyes show almost 0% difference. This image was 
generated by plotting two skewed normal distributions in MATLAB and calculating their 
relative differences. C) The Jablonski diagram shows the excitation and emission of the 
dye. The electric field of the dye differentially stabilises the energy of the ground state 
hence a differing emission wavelength (dashed red line) during depolarisation. Images A) 
and B) were adapted from Design and Use of Organic Voltage Sensitive Dyes. Membrane 
Potential Imaging in the Nervous System: Methods and Application. Springer. 2011 [104].  
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Figure 2.5. Principle of how voltage sensitive dyes generate an inverted action 
potential as a cardiac tissue depolarises.  
This graphic shows as the cardiomyocytes depolarise they reach a more positive voltage, 
in this case from -90mV towards 0mV. The result of this change in voltage shifts the 
emission spectra of the dye. The 630nm long pass (LP) filter indicated by the red line 
allows for only photons with a wavelength of 630nm and above to pass. The red shaded 
regions represent the amount of photons that pass the filter for measurement. As the cells 
depolarise the quantity of light collected reduces (red regions become smaller) and 
created the inverted AP as seen on the right. Image was created by the author of this 
thesis.  
 
Di-4-ANEPPS is frequently chosen due to its large fractional fluorescence 
changes (~8-10% per 100mV) and low toxicity and photobleaching [105], [106]. 
One problem with di-4-ANEPPS is that it can be internalised by the cell causing 
the fluorescence response to drop. This internalisation has prompted a redesign of 
the molecule to contain 2 octyl chains, di-8-ANEPPS, with a longer hydrocarbon 
tail. Increasing the length of the dye reduces the likelihood of it penetrating across 
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the bilayer and internalising, but also reduces its water solubility [100], something 
that needs to be taken under consideration.  
ANEP dyes are also popular due to their linear response to changes in voltage. 
The measured light intensity increases corresponds proportionally to the 
membrane voltage. This linearity occurs at both tails of the emission spectra. For 
example if measurements were made above and below the emission peak, the 
ΔF/F would either increase or decrease by the same amount, this can be seen in 
Figure 2.6 for di-8-ANEPPS. The graph in Figure 2.6 was extracted from a study 
performed on simultaneous voltage and optical recording from cultured mouse 
hippocampal neurons [107]. The study showed that at wavelengths measured 
below 570 nm, depolarisation results in an increase in fluorescence and the 
opposite is seen at above 570 nm [107].  
Optical mapping allows us to measure APs; but does not generally provide 
information on absolute voltage changes in the membrane. This is generally not 
considered a problem for looking at the propagation of excitation through cardiac 
tissue.  
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Figure 2.6. Linear response to membrane potential and fluorescent changes for di-
8-ANEPPS.  
The fractional change in fluorescence, ΔF/F in ANEP dyes had been shown to correspond 
linearly with membrane voltage. The above graph shows the response of di-8-ANEPPS 
from the membrane potential of cultured mouse hippocampal cells. Measurements made 
above and below the peak emission wavelength at 570nm show either an increase or 
decrease in ΔF/F but both show linearity in their responses. This graph was adapted from 
High-speed, random-access fluorescence microscopy: II. Fast quantitative measurements 
with voltage-sensitive dyes. Biophysical Journal. 1999. [107] 
 
2.3. Optics  
The type of optical objectives or lenses required is determined by the type and 
size of the tissue samples investigated. The purpose of these optical lenses are to 
focus the excitation light onto a sample and to collect its fluorescence onto a 
detector. The numerical aperture (NA) of a lens characterises the angular range in 
which it can image over, this is arguably the most important factor of a lens. The 
number of photons that can be collected from a lens is proportional to the square 
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of the NA. For very small samples, microscope objectives are the best choice for 
light detection with magnifications above 5x (NA = 0.25-1.3). For imaging the 
whole heart or larger preparations, much smaller magnifications are required and 
this is known as macroscopic imaging. Photographic lenses are much better 
suited for this as their magnifications are much lower (<10x) and yield greater light 
collection efficiency with numerical apertures of 0.36-0.58. Due to the macroscale 
of imaging, each optical AP is derived from multiple cells, which can be in the 
range of hundreds of cardiomyocytes. Therefore, each signal can be considered 
an average from multiple neighbouring cells.  
2.3.1. Light Sources 
Light sources are required to excite the voltage sensitive dyes and there are 
multiple types which are commonly used in optical mapping. These include: 
Tungsten-Halogen (TH) lamps, arc lamps, lasers and light emitting diode (LED) 
lamps. The choice of light source should be selected according to the preparation 
type, light intensity depending on the signal to noise ratio, imaging area and the 
cost.  
2.3.2. Tungsten-Halogen (TH) Lamps 
TH lamps are one of the most common sources, with a power of 100 or 250 W. 
They yield a moderate light intensity and a smooth spectrum over the visible range 
which is desirable for choosing excitation wavelengths [108]. The TH bulbs 
themselves have a long life-time and low cost. TH lamps provide moderate light 
intensity. For situations where this is insufficient, arc lamps can be considered. 
The most common arc lamps are xenon (Xe) and mercury (Hg).  
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2.3.3. Arc Lamps 
Figure 2.7 shows that like the TH lamps, the Xe spectra are relatively flat over the 
visible range. Arc lamps produce a higher photon flux density per watt as the 
source itself is much smaller [109]. As a result of this higher photon flux, Xe lamps 
have been reported to yield two to three times more light than a TH lamp with 
similar Wattage [110]. Hg and Metal-Halide lamps exhibit multiple large peaks 
which can be seen in Figure 2.7 which makes this an ideal candidate for exciting 
the RH-237 dyes [108].  
 
Figure 2.7. Spectral characteristics of commonly used light sources in optical 
imaging.  
The spectral profiles for multiple excitation sources are shown here. These sources are 
ones commonly found in optical imaging. The distinct peaks are present in the halide and 
mercury lamps making them a good choice for specific dyes. The tungsten-halogen lamp 
shows good output intensity at the infrared region but little output in the ultraviolet. The 
xenon spectrum has strong peaks towards the 800nm region but low output in the visible 
range. However, the profile of the xenon is much more continuous compared to the other 
light sources. Image adapted from Nikon Microscopy. Retrieved from: 
http://www.microscopyu.com/articles/livecellimaging/automaticmicroscope.html 
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2.3.4. Lasers 
Lasers produce monochromatic light, the photons emitted are of a single 
wavelength with high intensity which is very desirable. This light can be easily 
focused onto a small area. However, they come with multiple disadvantages, such 
as their high purchase and running costs and they consume large amounts of 
power [93]. The high intensity also comes at another cost of causing dyes to 
photobleach. To reduce this effect, the illumination times need to be minimised.  
2.3.5. Light Emitting Diodes (LEDs) 
LEDs provide an attractive alternative to lamps and laser sources due to their low 
power consumption, optical stability, and large choice in emission wavelengths. 
Whilst lasers provide photons of a specific wavelength, LEDs can yield light of 
narrow wavelengths, reducing the need for optical filtering and poses a long 
lifetime [111]. The bulbs themselves can be easily changed for other wavelengths. 
Some systems have optical feedback mechanisms to provide image stability and 
the ability for millisecond pulsing. Synchronising image acquisitions with LEDs 
illumination times can reduce the levels of photobleaching.  
2.4. Detectors 
In order to convert the fluorescence from optical mapping experiments to images, 
the emitted photons need to be transduced into electrical charges. Many options 
exist based on two dimensional arrays of silicon elements. Factors to consider for 
a detector are the quantum efficiency, spatial and temporal resolution. When 
imaging hearts of small animals such as mice, the heart rates are an order of 
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magnitude greater than that of humans hence the need for fast readout rates. To 
follow the course of a mouse AP, one should use an acquisition rate of at least 
1000 frames/sec [112]. 
2.4.1. Photodiode arrays (PDA) 
Photodiode arrays will convert incident photons to a proportional current. Each 
diode is connected individually to a current-voltage (I/V) converter, which limits the 
number of elements which are possible to be spaced onto a single chip. The 
advantage of PDAs is that it they have high quantum efficiency ~90% but are 
extremely limited by pixel size. The most popular choice for a PDA is a 16 x 16 
element array by Hamamatsu Photonics Corp (Japan) [112]. Another advantage is 
that as the signals from the diodes are analogue, there is constant generation of 
current which leads to fast sampling rates.  
2.4.2. Charged coupled devices (CCD) 
CCDs provide a significant advantage over PDAs due to their higher spatial 
resolution. Each element in the CCD stores a photogenerated charge which is 
integrated over a period of time, after which it is transmitted to a read out amplifier. 
For each device only one amplifier is required, this allows for the manufacture of 
arrays with a large number of elements. The quantum efficiency of CCD chips can 
be above 80% which makes them comparable to PDAs, but the rates of data 
acquisition are much lower. This can be increased by binning pixels together, but 
this reduces the spatial resolution, defeating its main advantage. One of the most 
advanced CCD devices used in optical mapping have an 80 x 80 pixel array with a 
frame rate of 2000/sec from RedShirt Imaging (Fairfield, CT). For increase rates 
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and quantum efficiency, a 3 x 3 binning mode is possible bringing the number of 
elements to 23 x 23 at 5000 frames/sec [112].  
2.4.3. Complementary metal-oxide semiconductor 
(CMOS) 
CMOS detectors are a form of image sensor with each pixel housing a 
photodetector and an active amplifier. CMOS sensors typically have a faster 
readout than CCDs. Recent developments have shown that CMOS cameras have 
efficiencies close to CCD detectors whilst retaining its high speed acquisition [97]. 
Disadvantages of CMOS detectors are that each sensor typically reads row by row 
which can bring about rolling shutter effects skewing images. Despite this, the 
latest devices from Hamamatsu Photonics allow for reduction of the vertical 
imaging area to increase readout speed whilst maintaining its horizontal pixel 
count [90]. One of their most used devices, the ORCA flash 4.0, enables readout 
speeds of 1603 frames/sec at 128 x 2048 pixels. Figure 2.8 shows the spectral 
response with a maximal QE of over 70% at 600nm. The wide horizontal pixel 
range can allow for dual imaging without the need of a secondary camera by using 
an image splitter to divide the incoming light onto the sensor. Each of the images 
can be filtered at different wavelengths and for different dyes. The advantage of 
dual imaging is that multiple parameters can be measured such as membrane 
voltage and calcium without the need for a secondary camera [94], [113].  
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Figure 2.8. Spectral response of the Hamamatsu ORCA Flash 4.0 CMOS detector.  
This graph shows the quantum efficiency in relation to the wavelength of the incident 
photons on the CMOS detector. The efficiency reaches a peak close to 600nm and at a 
wavelength of 465nm it has a good efficiency of over 50%, making it suitable for the 
fluorescence of di-4-ANEPPS which has an emission peak of 465nm. Image adapted 
from the Hamamatsu technical notes for the ORCA Flash 4.0 September 2015. Retrieved 
from: http://www.hamamatsu.com/resources/pdf/sys/SCAS0080E_C11440-22CU_tec.pdf  
2.4.4. Contact maps 
There exist other methods for imaging the depolarisation of cardiac tissue without 
the use of optics. This involves placing physical electrodes on the surface of the 
samples to form a contact map. Each electrode measures the depolarisation from 
a single cell or an aggregate of cells. Coupling multiple electrodes together can 
yield similar results to that of photodetectors as each electrode effectively 
represents a pixel in the image. The downside of contact mapping is the low 
resolution which is determined by the physical size of each electrode [88]. This 
method has limitations for measuring APDs in smaller samples such as the mouse 
atrium.   
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 Materials and methods 
3.1. Animals 
All surgical procedures were performed according to the Animals (Scientific 
Procedures) Act, 1986 and were approved by the Home office and the local 
authorities.  
3.2. Genetically altered models 
Experiments were performed on heterozygous Plakoglobin deficient mice (plako+/-) 
[64], [114] and Pitx2c+/- heterozygous mice [51], [55], [115].  
3.3. Buffer solutions 
For all experiments a standard bicarbonate buffered Krebs-Henseleit (KHB) 
solution was used containing in mM: NaCl 118; NaHCO3 24.88; KH2PO4 1.18; 
Glucose 5.55; Na-Pyruvate 5; MgSO4 0.83; CaCl2 1.8; KCl 3.52, equilibrated with 
95% O2 and 5% CO2 and heated to 35-37°C. Under these conditions the pH was 
maintained at 7.4. All Chemicals used in buffer solutions were purchased from 
Sigma-Aldrich Corporation unless otherwise stated.  
3.4. Data analysis 
Values were expressed as mean ± standard error of the mean unless otherwise 
stated. Statistical analysis was performed using one way Analysis of Variance 
(ANOVA) with Bonferroni post hoc analysis where appropriate (GraphPad Prism 
5.01). Significance was deemed as p<0.05 or considered very significant at 
p<0.01.  
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3.5. Surgical procedures  
3.5.1. Murine anaesthesia 
I initially weighed the mice and administered 50µl of heparin (LEO Laboratories 
Ltd, UK) by intraperitoneal injection. Heparin is an anticoagulant which prevents 
blood clots. A second intraperitoneal injection was administered by myself with 
200mg/kg of pentobarbital sodium (Euthatal, Merial, UK) causing deep terminal 
anaesthesia. The pedal reflex was then checked to assure the mouse was under 
deep anaesthesia.  
3.5.2. Heart isolation 
Once the mouse exhibited no pedal reflex ensuring deep anaesthesia, it was then 
placed in the supine position on a polystyrene block with the limbs pinned down. 
Forceps were used to draw the skin from below the sternum and scissors were 
used to perform a bilateral dissection. The scissors were used to cut through the 
rib cage and to reveal the diaphragm. Perforating the diaphragm revealed the 
heart and the chest plate was pulled back. Curved forceps were used to scoop 
under the heart and fine scissors were used to sever the vessels releasing the 
whole heart which was then placed in a petri dish with cold KHB solution. The 
KHB solution was stored at 4ºC causing temporary cessation of cardiac activity 
known as cardioplegia. Cardioplegia temporarily stopped the heart from 
contracting which allowed for ease of cannulation. Lung and adipose tissue were 
often removed with the heart as a by-product of this procedure; these excess 
tissues were then discarded leaving behind the whole heart only. Subsequently, 
the hearts were transferred to a new petri dish with cold KHB on a custom stand 
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which housed a 2ml syringe and a cannula (outer diameter 1mm), as seen in 
Figure 3.1. The cannula was in such a position that it protruded into the dish below 
the solution. The aorta was identified and using forceps it was carefully stretched 
over the cannula ensuring the aortic valve was not blocked. Silk sutures held the 
aorta in place. Once on the cannula, 2ml of KHB was retrogradely perfused to 
remove the heart of any excess blood as seen in Figure 3.1. Time from first 
incision to coronary perfusion was kept below 5 minutes. On average samples 
were excised in approximately 2.5 minutes from the first incision of the 
thoracotomy limiting any tissue damage, coinciding with other studies [114], [116].  
 
Figure 3.1. Cannulation of the ascending aorta.  
This shows the heart cannulated at the aorta as indicated above. The cannula is 
connected secured by fine sutures, which can be seen as a fine black string across the 
image. The end of the cannula is connected to a 2ml syringe and held securely with black 
silicone, as indicated above. The heart is submerged in cold buffer solution to cause a 
temporary cessation of contractions of the heart. The syringe was filled with cold buffer 
(before cannulation) and depressed to expel the blood from the heart, as seen as the 
large red regions either side of the heart. 
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3.5.3. Langendorff perfusion and dye loading 
The heart and cannula was transferred and mounted on a vertical Langendorff 
apparatus (Hugo Sachs, Germany) and perfused with KHB. The buffer was kept at 
36-37°C, at constant perfusion pressure (100 ± 5mmHg) and coronary flow (4 ± 
0.5ml/min). A small cannula made from a needle was inserted through the left 
ventricular wall to allow for any excess solution to drain as seen in Figure 3.2. Di-
4-ANEPPS was chosen as it was one of the most currently used voltage dyes with 
a good fractional fluorescent change [93], [102], [104]. The di-4-ANEPPS (50 µM; 
Biotium, California, USA) was stored in 25µl aliquots of 5mg/ml. For each 
experiment an aliquot was mixed with 1ml of Krebs solution and injected through a 
bolus port in the Langendorff system over a period of 5 minutes.  
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Figure 3.2. Langendorff preparation of the heart.  
The heart is shown connected to the aortic cannula by its aorta with sutures. Warm 
perfusate (37ºC), was pumped to the heart passing a bubble trap at the top. Dye was 
added via a bolus port at the back of the bubble trap. The bolus port was connected to a 
piece of tubing as indicated above. The tubing allowed for easy infusion of the dye. A 
small cannula with an outer diameter of 1mm was inserted at the left ventricular wall near 
the apex to allow for excess fluid to drain, at the location indicated above.  
 
3.6. Optical mapping  
After 5 minute dye infusion on the Langendorff apparatus, the left atrium (LA) was 
carefully dissected away from the ventricles using fine forceps and scissors. The 
LA was subsequently transferred to a custom made superfusion chamber, where 
 51 
 
the surface was covered in back silicone (Figure 3.3). The silicone aided in 
removing any background fluorescence. Two fine entomology pins were used to 
hold the LA in place. The pins were placed on the very edges of the tissue to 
ensure they did not obstruct the view of the camera. A space was left where the 
LA were attached to the septal wall to allow space for the stimulus electrodes. 
Preparations were continuously superfused with oxygenated KHB and the 
excitation-contraction uncoupler blebbistatin (5 µM; Cayman Chemical, Michigan, 
USA). The use of blebbistatin was important to inhibit the motion artefacts from 
contractions [55], [117], [118]. The solution was maintained at 35-37ºC by use of a 
heating element and a feedback thermometer created by Martyn Preston of 
Oxford University. The heating element was placed before the inflow of the 
solution with a bubble trap (Labtech, UK). Bubble traps were put in place so that 
these would not cause any ripples in the solution. The solution was transported 
using a peristaltic pump (Minipuls 3, Gilson, UK) providing a rate of 10ml/min. The 
excess solution was removed using a separate peristaltic pump (R323, Watson 
Marlow, UK) and returned to its original container for recirculation.  
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Figure 3.3. The left atrium pinned to the optical imaging chamber.  
This shows the LA secured to the imaging chamber by several fine pins. The LA was 
pinned to a layer of black silicone. Warm buffer solution at 37ºC was pumped into the 
chamber by the inflow port, as shown above. The outflow was placed towards the 
opposite side of the inflow and above the solution. 
 
The LA were paced at twice the diastolic threshold and kept stimulated at a rate of 
200bpm or a beat every 300ms known as a cycle length (CL) of 300ms for at least 
15 minutes to allow for the blebbistatin to inhibit contractions. The LA were then 
paced using the ramp protocol (300ms to 80ms CL) via platinum electrodes placed 
in the tissue bath at twice the diastolic voltage threshold at 2ms pulse width. 
Stimuli were generated using an isolated constant voltage stimulator (Digitimer, 
Hertfordshire, UK) driven by an analogue to digital converter with spike2 software 
(Cambridge Electronic Design, UK). The LA was field illuminated by two twin LEDs 
at 530nm (Cairn Research, Kent, UK). Wide field macroscopic images of emitted 
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fluorescence (630nm) were captured at a sampling frequency of 1 or 2 kHz using 
a novel, high speed, high resolution (128 by 2048 pixels, single pixel area: 6.5µm 
by 6.5µm) camera (ORCA flash 4.0; Hamamatsu, Japan). A schematic of the 
optical mapping system can be seen in Figure 3.4. 
 
Figure 3.4. Schematic of the optical mapping system.  
The LA sample was placed in the superfusion bath and imaged using the custom 
designed optical mapping system. Blue arrows indicate the inflow and outflow of the 
buffer solution which was kept at 35-37ºC. The electrodes stimulate the sample at set 
rates and the LEDs illuminate at 530nm. Images were captured by the CMOS camera 
above the 630nm filter and lens at 1-2 kHz frame rates. Images were exported for offline 
analysis using automated algorithms.  
 
3.6.1. Stimulation protocol 
The stimulus electrodes were carefully placed on the edge of the LA in close 
proximity to the septal region. The LA was then stimulated at twice the diastolic 
threshold at a holding frequency of 300ms CL. To determine the diastolic 
threshold the stimuli were set to 0V and voltage was increased until beats were 
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seen on the time course window. The voltage was then set to double the minimum 
required to induce an action potential (AP). The samples were continuously 
superfused with blebbistatin to reduce the tissue contraction. After 15 minutes of 
blebbistatin infusion, the images were checked to determine whether there were 
any contraction artefacts. When the tissue had suitably stopped contractions the 
ramp protocol was initiated. The ramp consisted of stimulus cycles with 
decreasing length and as described as follows: 
 Holding stimulus rate 300ms CL – 200bpm  
 300 beats at 120ms CL – 500bpm 
 50 beats at 100ms CL – 600bpm 
 50 beats at 80ms CL – 750bpm 
After the ramp was executed, the stimulus rate returned to the holding frequency. 
Figure 3.5 illustrates the APs recorded during a typical protocol. The tissue was 
constantly stimulated at 300ms CL until the ramp was initiated at 10 seconds after 
the start of recording. After the 50 stimulations at 80ms CL the LA returned to a 
stimulated rate of 300ms.  
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Figure 3.5. Action potentials recorded over ramp protocol for a period of 60 
seconds.  
A) Shows the optical APs recorded over 60 seconds during the ramp protocol. An initial 
holding rate of 300ms was used, after which the ramp protocol was selected. The ramp 
was started after 10 seconds of recording. 200 stimuli were recorded at 120ms CL taking 
36 seconds, 50 stimuli at 100ms taking 5 seconds. Finally, the last part of the ramp takes 
50 stimulations at 80ms CL taking 4 seconds. After the ramp, the protocol returns to the 
holding frequency which is shown above at 55 seconds onwards. The red bar highlights 
the zoomed in area for B). 
 
3.6.2. Image recordings 
Images were extracted and collated using WinFluor V3.4.9 (Dr John Dempster, 
University of Strathclyde, UK) so that the fluorescence intensity from a specific 
region of interest (ROI) of 4 x 4 pixels was viewed as a single continuous 
waveform. This permitted the identification and monitoring of a greater number of 
 56 
 
optical action potentials (OAPs) across the entire surface of the mouse LA at high 
spatial resolution. Isochrones are lines which connect points of equal activation 
time. Isochronal or activation maps are commonly used to depict the activation 
pattern from a cardiac tissue sample [119]. The image recordings gathered here 
were exported as uncompressed Tagged Image File Format (TIFF) and were used 
to generate isochronal activation maps.  
3.6.3. Flecainide infusion  
For experiments with flecainide, 1 µM of the drug (Flecainide acetate, Tambocor, 
Meda Pharmaceuticals, Bishop’s Stortford, UK) was added to the KHB and 
superfused for 15 minutes before repeating the stimulus protocol [92]. The time 
course trace was observed to ensure that there was no loss of capture at any of 
the CL. If any beats appeared to be missing, the LA was left to be stimulated at 
the holding frequency for at least a minute before repeating the ramp protocol. If 
there was a significant loss of capture which was more common at the shorter 
CLs, the stimulation threshold voltage was determined at the shorter CL. Doubling 
the threshold voltage, the ramp was repeated. After each experiment it was 
important to flush the optical mapping system with KHB to remove any remaining 
flecainide. 
3.7. Monophasic action potentials (MAPs) 
MAP recordings were obtained in the intact, perfused heart immediately prior to 
dissecting the LA for optical mapping. Whole hearts were cannulated and 
mounted on a vertical Langendorff apparatus (Hugo Sachs, Germany) and the 
aorta was retrogradely perfused with standard bicarbonate KHB solution at 36-
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37°C, at constant perfusion pressure (100 ± 5mmHg) and coronary flow (4 ± 
0.5ml/min). A 2.0 French octapolar mouse electrophysiological catheter with 
electrodes sized 0.5mm and spaced at 0.5mm (CIB’ER MOUSE, NuMED, LLC., 
Hopkinton, N.Y., USA) was inserted into the right atrium (RA) for pacing (120ms to 
80ms, 2ms pulse width), see Figure 3.6A and B. Stable LA MAP recordings were 
obtained using a miniaturised MAP catheter mounted on spring-loaded electrode 
holders. Figure 3.6A shows how MAP electrodes were placed on the heart for 
measurements from other chambers such as the right atrium and the left ventricle 
(LV) as well. This also served to stabilise the heart during contractions for better 
contact between the LA and the electrode. Figure 3.6B shows the schematic of 
the heart, octapolar catheter and the location of the MAP recording electrode. 
Figure 3.6C displays the schematic of the MAP electrode. Voltage signals were 
amplified, digitised and viewed on a PC loaded with iox2 software (EMKA, 
France). Measurements of APD and inter-atrial activation times were acquired 
using algorithms generated in iox2. MAP experiments were performed by Dr 
Fahima Syeda from the University of Birmingham, UK and not by the author of this 
thesis.  
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Figure 3.6. Whole heart stimulation and MAP recordings on the Langendorff 
apparatus.  
A) Image taken from a typical Langendorff experiment. The aorta is cannulated and MAP 
electrodes were placed onto the chambers of the heart. The catheter is inserted to the 
right atrium (RA) as indicated. MAP electrodes were held in pace by spring loaded 
holders. B) Illustrates the heart, octapolar catheter and the recording electrode. An 
octapolar catheter as shown by the black and white rod was inserted through the RA to 
the right ventricle (RV) for stimulation. The blue square represents the MAP electrode 
placed onto the left atrium (LA) for measurement. The left ventricle of the heart is 
chamber labelled LV. C) Schematic of the MAP electrode placed onto the LA. The surface 
of the tissue is represented by the black vertical block. Figure has been adapted and 
edited from unpublished work created Dr Fahima Syeda from the University of 
Birmingham, UK and not by the author of this thesis.  
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3.8. Transmembrane action potentials (TAPs) 
Transmembrane murine atrial action potentials (TAP) were recorded as published 
[85] immediately before or after the optical mapping procedure. TAPs were 
recorded from isolated superfused LA samples prepared using the same 
procedure as optical mapping with borosilicate glass microelectrodes (tip 
resistance 15-30 MΩ), filled with 3M KCl. Figure 3.7 illustrates how TAPs were 
recorded, the location of the stimulus site on the LA is located nearest to the 
septal wall. Voltage signals were amplified (Axoclamp 2B; Molecular Devices, 
USA), digitised and displayed using spike2 software (Cambridge Electronic 
Design, UK). The sampling frequency was 20 kHz. Preparations were paced 
successively using the ramp protocol (300ms to 80ms) with platinum electrodes at 
twice the diastolic voltage threshold, with a minimum of 50 APs recorded at each 
CL using an isolated constant voltage stimulator (Digitimer, UK) driven by an 
analogue to digital converter with Spike2 software (Cambridge Electronic Design, 
UK). Measurements of APD and intra-atrial activation times were obtained using 
custom–made spike2 algorithms. Microelectrode recordings were performed by Dr 
Andrew Holmes from the University of Birmingham, UK and not by the author of 
this thesis.  
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Figure 3.7. Microelectrode recordings from the left atrium.  
Atrial samples were continuously superfused with KHB solution at 35-37ºC and pinned to 
a recording chamber as seen in the photograph portion above. Glass microelectrodes 
with a tip resistance of 15-30MΩ were used for recoding voltage signals. Signals were 
amplified and recorded using Spike2 at a sampling rate of 20 kHz. Microelectrode 
recordings were performed by Dr Andrew Holmes from the University of Birmingham, UK 
and not by the author of this thesis. Figure has been adapted and edited from 
unpublished work created Dr Andrew Holmes from the University of Birmingham, UK and 
not by the author of this thesis.  
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 Optical mapping design and development 
4.1. Overall design 
The main hardware components to the optical mapping system consisted of the 
imaging chamber or superfusion chamber, illumination light emitting diodes 
(LEDs), filters and camera which can be seen in Figure 4.1. Each component is 
described below but also along with the necessary methods for imaging 
acquisition. Finally, after data collection, the methods used to analyse optical 
mapping images are described in detail as these were custom made algorithms in 
MATLAB.  
 
Figure 4.1. Schematic of the optical mapping system. 
The left atrial sample was placed in the superfusion bath and imaged using the custom 
designed optical mapping system. Blue arrows indicate the inflow and outflow of the 
buffer solution which was kept at 35-37ºC. The electrodes stimulate the sample at set 
rates and the LEDs illuminate at 530nm. Images were captured by the CMOS camera 
above the 630nm filter and lens at 1-2 kHz frame rates. Images were exported for offline 
analysis using automated algorithms.  
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4.2. Superfusion system 
During experimentation, the left atrium (LA) was continuously superfused with 
oxygenated KHB. The LA was pinned down to black silicone (Silcoset 158, ACC 
Silicones Limited, UK) on a custom made superfusion chamber. 10mm 
neodymium magnets (Rapid Electronics Ltd, UK) were used to hold the chamber 
onto an optical bench. The solution was maintained at a temperature of 35-37ºC 
using a heater module and feedback thermometer which was managed by a 
control module which indicated the thermometer temperature and the heater 
temperature. The heating element inside the module consisted of an Aluminium 
clad wire wound resistor with an embedded thermocouple for temperature control 
and 4 stainless steel pipes fitted into the housing to transfer heat to the bath 
solution. The heating module and control unit was constructed by Martyn Preston 
(Department of Pharmacology, Oxford University, UK). The position of the 
thermometer was placed between the inflow and the tissue which ensured 
accurate measurements. Typically, setting the heater to 44ºC allowed the 
perfusate to cool to the desired temperature by the time it took to reach the 
chamber through 17cm of tubing. A bubble trap (Labtech Ltd, UK) was placed 
between the heater and the superfusion chamber to remove any bubbles that 
would enter the inflow and disrupt the imaging. Figure 4.2 shows how the KHB is 
heated and bubbles removed before it reaches the chamber for imaging. Black 
silicone rubber was placed at the centre of the superfusion chamber as this 
allowed for the pins to be inserted with tissue. Black also limits the amount of 
reflected light during imaging. The superfusate was transferred to the chamber 
using a peristaltic pump (Minipuls 3, Gilson, UK) and removed by use of another 
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peristaltic pump (R323, Watson Marlow, UK). The KHB was returned to its original 
container for recirculation.  
 
 
Figure 4.2. Optical mapping superfusion system.  
The KHB solution was pumped through the tubing as shown above. The solution was 
then heated using a custom made heater set to 44ºC. As the buffer travels through to a 
bubble trap as indicated above. The buffer solution cools from 44ºC to 35-37ºC as it 
moves through the 17cm of tubing to the superfusion chamber. Black silicone rubber was 
placed in the centre of the chamber as shown above to allow for tissues to be pinned onto 
the surface. The black silicone limits the amount of reflected light. A thermometer was 
placed close to the entrance of the superfusate to regulate the solution temperature.  
 
 
 64 
 
4.3. Optics 
Tissues stained with di-4-ANEPPS were excited by a set of 2 dual LED lamps 
(OptoLED, Cairn Research, UK). The excitation wavelength for di-4-ANEPPS is 
465nm and its peak emission is at 635nm. The power source was set to feedback 
which allowed for continuous stable luminosity. The LED heads were placed in 
close proximity surrounding the superfusion chamber and were filtered using 
530/40nm filters (Chroma, USA), see Figure 4.3. The emission photons were 
focused through a C-mounted lens (Schneider-Kreuznach, Germany). This lens 
has an f-number (N) of 0.95 which equates to a numerical aperture of 0.52 using 
Equation 1. The outflow nozzle was kept out of the line of sight from the tissue to 
the lens as shown in Figure 4.3B. The nozzle was placed over the top of the 
solution to allow for the level of fluid to be maintained at the desired amount. 
𝑁 ≈
1
2𝑁𝐴
 
Equation 1. F-number.  
Equation to determine the relation between f-number (N) and numerical aperture (NA) of a 
lens.  
 
The lens was mounted onto an image splitter (Optosplit II, Cairn Research, UK) 
which housed a filter cube with a dichroic mirror (Cairn Research, UK) with 50% 
transmittance at 546nm. The incoming light was split into two paths where one 
was filtered using a 630nm long pass filter (Chroma, USA) and the other was 
blocked though the auxiliary component mount. For future use the secondary 
mount would be used for other filter ranges and dyes. After filtering the light 
passed onto the CMOS detector (ORCA Flash 4.0, Hamamatsu, Japan).  
(1) 
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Figure 4.3. Optical mapping set up.  
A) Shows the imaging rig which was built on an optical bench. The LA was placed in the 
superfusion chamber were it was illuminated by the LEDs at 530nm. The emitted light 
passes through the splitter to the camera at the top. B) Shows a close up of the 
superfusion area, the outflow tube was placed over the top of the solution on the opposite 
end of the inflow. Placing the nozzle over the top allowed for the solution to be maintained 
at a constant level. The stimulus electrodes were placed at an angle to allow for easy 
reach to the tissue. The LEDs were also placed at an angle and to provide an even 
illumination.  
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4.4. Image Acquisition 
All imaging data was collected using WinFluor Version 3.4.9, developed by Dr 
John Dempster of Strathclyde University, UK and not by the author of this thesis. 
This software was designed for electrophysiology fluorescence imaging. The Flash 
4.0 camera has 2048x2048 pixels; this allowed a maximum readout of 100 
frames/sec. In order to increase the time resolution, the vertical number of pixels 
was reduced as the camera utilised a rolling shutter, reading line by line from the 
centre. To achieve a minimum readout of 1000 frames/sec, a maximum number of 
2048 x 204 pixels were used. Relation between frame rate (fr) and number of 
vertical pixels (Vn) is given by Equation 2. The number of horizontal pixels has no 
effect on the camera readout time. To achieve the fastest frame rates, the imaging 
area was taken from the centre of the sensor. The Y-pixel range was selected 
from 922-1026, this represents 1024 ± 102 pixels from the centre to obtain a 
vertical pixel length of 204 lines. As the horizontal length did not change the 
readout time, the X range was chosen anywhere between 0-2048.  
𝑓𝑟 =
1
(
𝑉𝑛
2 ) × 9.74µ𝑠
 
Equation 2. Frame rate calculation.  
Equation to determine the frame rate of the camera from the number of vertical pixels 
used. Where fr is the frame rate and Vn is the number of vertical lines.  
 
At 1000 frames/sec the maximum exposure time was set to approximately 1ms. 
For high speed recordings such as described here, large volumes of data were 
generated. In order to decrease the data sizes, the number of horizontal pixels 
(2) 
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was reduced so that only the LA was visible in the window. The camera converts 
photons that reach the sensor to 16 bit data values; therefore the fluorescence 
has 65,535 shades of grey. A region of interest (ROI) of 4 x 4 pixels was selected 
from the centre of the LA image; this provided a time course of the fluorescence. 
To maximise the fractional fluorescent change of the dye, the fluorescent intensity 
was kept as high as possible by increasing the LED power source during image 
acquisition. For example, a fluorescent signal of 60,000 units with a 10% ΔF/F 
would give a 6,000 unit change. A signal at 30,000 with the same ΔF/F yields a 
3,000 unit change, showing a lower signal to noise ratio. The LED lamps were 
switched off during recordings as this reduced the risk of photobleaching. To 
record the entire stimulus protocol, a 60 second time lapse mode was set.  
4.5. Pixel binning and improvement of temporal 
resolution 
To gain a stronger signal to noise ratio of the changes in fluorescence, pixels were 
binned together using a 4 x 4 region posteriorly. Figure 4.4A shows the effect of 
varying region size, the trace was exported from the same area. The trace from 
the 4 x 4 ROI shows 10 optical action potentials (OAPs) over a period of 1 second, 
whereas the single pixel trace contains large amounts of noise. It was possible to 
visualise the 10 OAPs from the single pixel trace but analysis proved impossible 
using the algorithms stated. To gain a higher temporal resolution, the camera 
acquisition speed was increased to 2000 frames/sec by halving the vertical 
window size and decreasing the exposure time to 0.5ms. Figure 4.4, demonstrates 
how the AP shape and length remains largely unchanged as a result of increasing 
the acquisition speed as seen in the overlaid trace. This limited the size of the 
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tissues which were recorded but testing the differences in APs showed no 
changes in morphology. Hence, it was decided to use a frame rate of 1000 per 
second as this allowed us for greater resolution isochronal maps.  
 
Figure 4.4. Raw data traces from different region sizes and acquisition rates.  
A) Represents an optical trace over a period of one second stimulated at 100ms CL. The 
signal from a 4 x 4 ROI on the right show 10 distinct peaks with the repolarisation clearly 
visible. The trace displayed on the left was taken at the same region but from a single 
ROI. The peaks were visible from the single pixel region but contain high levels of noise 
and the repolarisation cannot be clearly seen and analysed. B) Shows a comparison of an 
AP signal stimulated at 100ms CL at different recording rates. The signal in black is 
recorded at 1000 frames/sec and the red trace at 2000 frames/sec. The overlay trace 
shows that at different recording rates the AP morphology remains the same. It should be 
noted that the example AP signals shown here were taken at the same region from the 
same sample.  
 69 
 
4.6. Pixel calibration 
The size of each pixel on the CMOS detector was listed as 6.5µm. To convert the 
pixels to physical space, a known length was measured against its image length in 
pixels. A ruler was placed under the lens of the rig and a single image was taken, 
the image was then converted to TIFF and analysed in ImageJ (National Institutes 
of Health, USA). To measure the distance between two known lines on the ruler, 
the straight line tool was used to draw between the two points. The ‘measure’ 
function outputted the line information; from here the distance in pixels was given. 
To obtain the resolution of the system the physical distance was divided by the 
length of the drawn line. The distance between 10mm was 140 pixels which 
results in a resolution of 71.4µm per pixel.  
4.7. Data processing 
4.7.1. Exporting data 
The WinFluor software generated image files in .IDR format, from here the data 
was either exported to an image series in tagged image file format (TIFF) or a 
region of interest (ROI) time course as a text file.  
In order to generate isochronal or activation maps, an image stack of an individual 
beat was selected at each of the paced cycle lengths (CL). The last beat of the 
300ms section of the protocol was selected. The frames before and after the AP 
was selected and exported to TIFF format. As each set of data contained all the 
CL information, the exported files were renamed to add ‘300ms’ in the filename. 
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This was repeated for the CL at 120ms, 100ms and 80ms and the exported files 
were renamed as appropriately.  
To calculate action potential duration (APD) values, a 4 x 4 pixel (ROI) on the 
image was selected and exported as plain text. The last 25 beats of each of the 
stimulus CL were exported. The exported text file was renamed to add the CL in 
the filename. The text file contains two columns of information, the first column 
indicates the time in seconds and the second column the fluorescence values. 
Nine regions were also exported for investigating the LA heterogeneity. The 
WinFluor software exported all selected regions into a single text file. The first 
column of data in this text file indicates the time and columns 2-10 represents the 
fluorescent data for region one onwards. A MATLAB script was used to separate 
these columns into a separate file containing only one region of data. Firstly, a 
new text file was created and the time column of data from the original data file 
was copied to the new file. Subsequently the second column for region one was 
copied to the new text file. This was repeated so that column one of every new file 
indicated the time and the second column was the fluorescent data for each 
subsequent region.  
To investigate the heterogeneity of the LA further, APD maps were also 
generated. This was done by selecting the last 10 beats from the data set at each 
CL and exporting this as an image series in TIFF format.  
4.7.2. Calculating APD values 
The algorithms used to calculate the APD values from the fluorescence data were 
performed using MATLAB version 7.12.0.635 (R2011a) on a 64-bit Intel® Core™ 
i7-3820 desktop machine running Windows 7 Enterprise (Stone Group, UK).  
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4.7.2.1. Baseline wander correction 
Firstly, the fluorescence data which were exported to text files were loaded into 
the MATLAB space. The optical APs presented here showed a decrease in 
fluorescence as the cardiac cells depolarise. In order to convert these signals to 
traditional APs whereby the voltage increases as cells depolarise, the traces were 
inverted by using the ‘imcomplement’ MATLAB function. The obtained traces often 
exhibit shifts in baseline which was attributed to changes in the surface of the bath 
solution causing ripples which introduces refraction to the illumination. 
Photobleaching also causes a decline in fluorescence intensity which can be 
modelled by an inverse exponential decay [1]. As these recordings were taken 
over a short period of a few seconds, this contributed minutely to the shift in 
signal.  
The shifting baseline may display linear or non-linear behaviour. Several methods 
were investigated to correct this artefact so that APD values can be calculated 
correctly. However, creating a constant baseline becomes difficult when the drift 
pattern varies per experiment or pixel within the same tissue. The first method 
tested was using a polynomial fitting algorithm to characterise a signal trace with 
moderate drift and repeated with a slightly more complex drift.  
Figure 4.5 Illustrates the resulting polynomial fitting on a set of two different drift 
patterns taken at 100ms CL over 3 seconds. It can be seen that the 4th order 
polynomial in Figure 4.5A show a reasonable fit and Figure 4.5B shows the 
flattened signal. However, on a slightly complex pattern the 4th fitting breaks down 
as shown in C and D. To compensate for this, higher order polynomials were used 
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to test the fit. As a result, the 11th order showed a good sign of flattening of the 
signal as seen in Figure 4.5E and F. From Figure 4.5F the signal shows signs of 
tailing off at the end. Whilst this shows a good method for baseline drift correction, 
changing the polynomial parameters per trace was inefficient.  
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Figure 4.5. Baseline drift removal by polynomial fitting.  
Examples taken from a 3 second time course from the LA stimulated at 100ms CL with a 
varying baseline. A) Shows the fitting for a 4th order polynomial on the red dashed line. B) 
Shows the corresponding trace with the drift removed by subtracting the polynomial fit 
from the signal. C) Shows the 4th order polynomial fitting in red on a more complex drift 
pattern. D) Represents the results from the fitting on the signal, showing that the baseline 
remained uneven. E) Demonstrates an 11th order polynomial to fit the complex drift 
pattern showing a good fit. F) Displays the resulting baseline corrected trace but it should 
be noted that the end of the signal shows an elevated tail.  
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As the baseline drifts do not appear to follow a predetermined pattern, a method 
was required which was robust for many signal morphologies. Another method 
tested was to apply a linear top hat transform to filter the signal. This removes the 
difference of the signal and its opening by a given structuring element. The 
MATLAB function ‘imopen’ performs an opening function to an image but applying 
this to a 1D signal provides a basis for the top hat filter. The structuring element 
used was linear with a length of 100 points over an angle of 90 degrees. The 
angle was specified by the desired orientation of the line measured counter 
clockwise from the horizontal axis. The length is the approximate distance 
between the centres of the structuring element members at opposite ends of the 
line. 100 was found to be sufficient for the purpose of correcting baseline drift at all 
CLs. Small changes in the length yielded little difference in APD value. Figure 4.6 
illustrates the efficacy of the top hat filter. It shows the top hat filter applied to the 
same signals in Figure 4.5. Figure 4.6A shows a signal stimulated at 100ms CL 
which has a simple drift. Figure 4.6B shows that the baseline has been corrected. 
Figure 4.6C and D display a complex drift pattern which has been corrected with 
the same parameter as the previous signal. The lack of changing of the input 
parameters provides a distinct advantage of the polynomial fitting method that 
allowed for this process to be automated. Other methods to solve this problem 
exist, such as retrospective shading methods for images [120]. Further information 
can be found in the discussion section of this chapter.  
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Figure 4.6. Baseline drift removal using a linear top hat filter.  
Example signals taken from a 3 second time course from the LA stimulated at 100ms CL 
with a varying baseline. A top hat function was applied to these signals with a structuring 
element of 100 points in length with an angle of 90 degrees. The baseline is indicated in 
red. A) Demonstrates the top hat filter applied to a simple drift which is corrected in B. C) 
Shows the top hat filter applied to a complex drift pattern with the same parameters as A 
to yield a flattened baseline signal shown in D.  
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4.7.2.2. Signal averaging 
It is common practice to smooth the signals by using a temporal filter and taking 
measurements from several APs to provide an average. Extending this idea of 
smoothing and measuring multiple APs, repeat measurements of consecutive APs 
were recorded and combined to produce an average AP. This allowed for the SNR 
to be increased.  
The first step was to identify each individual AP in the data set. The ‘findpeaks’ 
function was used to locate the maxima within the trace. The criteria for defining a 
peak were given by any values which were over half the height of the maximum 
value. As the shortest CL in the protocol was 80ms, the minimum peak distance 
from one to the next was defined as 50ms to ensure that the software did not 
confuse smaller maxima as APs. Subsequently, after locating the peak of each 
AP, the whole of the AP was defined as 20 frames before and 60 frames after the 
peak. Ignoring the first and last peak, the APs were then stored in a 3D matrix 
(frame x fluorescence value x AP). The fluorescence value for each frame for 
every AP was averaged which generated an overall mean AP as seen in Figure 
4.7. The first and last peaks were neglected as a way to prevent errors as the 
algorithm was required to look 20 frames before and 60 frames after a peak, this 
often resulted in exceeding matrix dimensions.  
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Figure 4.7. Signal averaging.  
An optical trace where 10 APs stimulated at 100ms CL from the LA was used to 
demonstrate how they were averaged to obtain a mean AP. Each peak of the signal was 
obtained using the ‘findpeaks’ function in MATLAB. From the peak, 20 points before and 
60 points after was deemed as the whole length of the AP. The criteria for determining the 
peak was set to locate points over half the maximum value in the signal and a minimum 
distance of 50 points between peaks. A) Shows an overlay of the 10 optical APs which 
was stored in a separate matrix. B) Shows the result of taking the mean of the selected 
APs. With this mean signal, it was used to calculate the APD of the LA.  
 
4.7.2.3. APD Calculation 
With an averaged signal the APD values were calculated. In order to perform this 
calculation several parameters were required:  
 Baseline value/resting potential or phase 4 of the AP 
 Relative AP amplitude 
 Activation time 
Firstly, to calculate the baseline, the initial values from the first 10 frames were 
averaged. Secondly, the amplitude was given by the maximum value minus the 
baseline. The averaged signal was then differentiated with respect to time where 
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the maximum point corresponded to the activation time. This method is known as 
the fastest upstroke velocity. The repolarisation at 30%, 50% and 70% were 
subsequently calculated (APD30, APD50 and APD70, respectively). To determine 
APD30, the two closest points to 30% of the repolarisation tail was determined as 
shown in Figure 4.8. The APD value typically falls between two points of data 
which is illustrated in the magnified section of Figure 4.8. Using a linear 
interpolation (Equation 3) between these two points allowed for the time value 
where the 30% repolarisation intersection to be found. This was repeated for 
APD50 and APD70. A summary of how the AP signals were processed for APD 
calculation can be seen in Figure 4.9. As this process was all automated it was 
possible to create a folder containing hundreds of text files from multiple 
recordings. A script was generated to automatically read through all the text files 
to calculate the APD values for each mouse at different pacing CL and multiple 
regions.  
𝑦 = 𝑚𝑥 + 𝑐 
Equation 3. Linear Interpolation.  
Equation of a straight line where m is the gradient, c is the y intercept and x is the time 
value. 
 
 
(3) 
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Figure 4.8. APD calculation.  
The signal averaged APs were used to calculate the APD. The baseline was determined 
by taking the mean value of the first 10 points of the signal. The signal was then 
differentiated with respect to time, where the peak yielded the activation time. With the 
baseline and the height of the peak, the amplitude of the signal was found. The values of 
30%, 50%, and 70% repolarisation from the peak height and baseline were determined. 
The corresponding times at 30%, 50% and 70% repolarisation represented APD3, APD50 
and APD70 respectively. The magnified area shows the duration value at 30% 
repolarisation falling between two data points. Interpolating between the two points 
yielded an accurate value; this value was then subtracted from the activation time and 
provided the APD30 value.  
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Figure 4.9. Summary algorithms calculating APD values from fluorescence data. 
Shown above are the steps in the algorithms used to calculate the APD from the optical 
mapping data of the LA. 1) The fluorescence information was imported to MATLAB in text 
format. 2) The APs from the imported data appear upside down compared to traditional 
signals hence they were inverted. 3) The baseline drift of the signal was removed by 
using a linear top hat filter with length 100 points and angle 90 degrees. 4) Individual APs 
were detected using the ‘findpeaks’ algorithm in MATLAB. The criteria for locating a peak 
were given by values which were over half the height of the maximum value in the signal 
and a minimum distance of 50 points between peaks. 5) After each peak was found, they 
were averaged to yield a mean AP. 6) The mean signal was then differentiated, and the 
peak of this was found. 7) The peak of the differentiated signal was used to define the 
activation start time as this was the steepest point in the upstroke. 8) The baseline of the 
signal was calculated from the mean of the first 10 points in the averaged signal. With the 
baseline the amplitude of the signal was found. 9) APDs at 30%, 50% and 70% of the 
repolarisation were found by determining the time where the descending tail of the signal 
reached 30%, 50% and 70% of the signal amplitude. The values were then subtracted 
from the activation start time.  
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4.7.3. Data masking 
Each frame within a data set comprised of the tissue and the background. In order 
to analyse these images accurately, background pixels needed to be distinguished 
from pixels of the LA as the background contains noise. The noise can interfere 
with algorithms and produce inaccurate maps. Segmenting the pixels of the LA 
from the background was performed using an image mask. The mask is 
essentially a binary image where the 1’s represent the LA pixels and 0’s for the 
background. Multiplying the mask with each frame preserves the pixels from the 
tissue and forces the background pixels to become 0’s. To create an image mask, 
there are automatic and manual methods. Manually defining a mask involves a 
user to draw the segment they wish to highlight. Manual segmentation is time 
consuming and can be inconsistent between users but is considered a gold 
standard. The automated methods investigated were edge detection algorithms 
and thresholding. Figure 4.10 illustrates the two methods. Edge detection was 
used to locate pixels where the image brightness changed sharply or had 
discontinuities. Figure 4.10A is a greyscale fluorescence image of a LA sample. 
The Canny edge detection algorithm in MATLAB was used resulting in Figure 
4.10B. The white lines show the pixels where an edge was considered. The 
general outline of the shape was similar to the original image. In order to create 
the mask the lines needed to be connected and any holes filled. The outcome of 
using the canny edge detection algorithm was dependent on each image and as a 
result; the process of connecting lines and filling holes varied by each image. 
Figure 4.10C is the image histogram for the LA. Many of the pixels were within the 
dark region hence a high pixel count towards the zero value in the histogram. 
Figure 4.10D is the result of thresholding above a value of 3000 and performing 
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an image erosion of a two pixel structuring element. This value was chosen as 
many images were investigated and 3000 fluorescence units proved to be suitable 
for a range of intensities. Experiments where the LA had many pixels around the 
3000 fluorescence value were deemed too low for analysis as this would indicate 
that the dye had been poorly perfused. Each segmentation technique has 
limitations, Figure 4.10C shows that there were outlying pixels at the top of the 
image and around the edge of the atria where the pins were used to hold the LA in 
place. To test the efficacy of image segmentation, manual selection is considered 
the gold standard. Ideally, one should perform manual segmentation on a series of 
images with a range of different users and compare the segmentation methods. 
 
Figure 4.10. Data masking for image segmentation.  
A) Shows a raw fluorescence image taken from the optical mapping system of the LA. B) 
One of the edge detection methods used was the Canny edge detector. Some of the 
edges were located but it also highlighted some areas within the sample C) An image 
histogram was used to look at the distribution of 64 bit pixel values. The background 
pixels were predominantly blacks hence the higher pixel count towards the zero value. D) 
Shows the mask from thresholding the LA image. A value set above 3000 and values 
below this were rejected.  
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4.7.4. Action potential duration maps 
To test the heterogeneity of the LA, maps of the APD distribution were generated. 
Each pixel from these maps represented an APD.  
Figure 4.11A illustrates the time course fluorescence from a pixel at the central 
region as indicated by an asterisk and a region towards the outer edge of the LA 
indicated by a cross. The corresponding traces show a large proportion of the 
signal is noise. The trace from the edge region shows a repolarisation passing 
below the initial baseline value which is not typical shape of a cardiac AP. In order 
to increase the signal to noise ratio, an image stack of 10 beats were exported to 
TIFF format. The images were imported to MATLAB where they were averaged to 
create a smaller image stack with a mean beat. The images were initially cropped 
to only display the LA and were Gaussian filtered using a 3 x 3 kernel. The 
average pixel intensity per frame was determined to generate a time course of 
fluorescence data analogous to the optical traces used to calculate APD values. 
The difference here was that each value represented the average fluorescence 
intensity for the entire image rather than just for a small ROI. The signal averaging 
algorithm was performed on this trace but instead of averaging fluorescent value, 
the frame from the image stack was averaged. Image thresholding was used to 
generate a mask to remove the background values. An intensity of 3000 was used 
for the thresholding. The red dots from Figure 4.11A indicate areas where the 
tissue was held onto the silicone rubber in the chamber by small pins. The number 
of pins varied depending on the tissue.  
Figure 4.11B Shows an LA fluorescence image that has been averaged from 10 
beats. It can be seen that the time course traces for the central and edge pixels 
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were improved. The smoother signal allowed for the algorithms to determine the 
repolarisation values as there SNR was increased.  
The APD values for every pixel were calculated using the same algorithms as 
described in the Optical mapping design and development chapter, section 
4.7.2.3. In order to generate a map from these values, each APD value for 30%, 
50% and 70% repolarisation was stored in a corresponding array which was 
displayed as an image. As a result three images were generated for APD30, 
APD50 and APD70 as seen in Figure 4.11C. The areas highlighted in red show 
that there were outliers or areas where the algorithms to determine APD had not 
accurately calculated the values. The highlighted regions were in close proximity 
to the location of the pins, it was assumed that the pins may have caused some 
localised damage which in turn generated poor quality signals with low SNR.  
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Figure 4.11. Action potential duration maps.  
The images depicted above show an example of APs recorded from all pixels to generate 
a map of the APD distribution. The example used was from a LA preparation stimulated at 
100ms CL. A) Shows the original unprocessed LA image with asterisk indicating the 
central region and the cross indicating the outer edge. The corresponding single pixel 
traces are shown on the middle and right of the row and display large amounts of noise 
rendering it unanalysable. The red dots indicate a location of a pin used to hold the LA to 
the silicone rubber mounted on the chamber. The number of pins varied between tissues. 
B) Shows the LA image which was generated from averaging 10 consecutive beats. The 
corresponding single pixel traces from the centre and edge showed a smoother AP hence 
the APD measurements were easier to perform compared no on averaged images. C) 
Illustrates the APD measurements for 30, 50 and 70% repolarisation for each pixel 
represented as a heat map. This shows the heterogeneity of the APD across the whole 
LA. It should be noted that the areas highlighted in red in C) showed outliers, these were 
typically regions where a pin was located. These areas were not easily analysed by the 
algorithms to calculate APD possibly due to weak signals caused by physiological 
damage from the pins.  
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4.7.5. Isochronal maps 
Isochronal maps are image plots which display the activation times for each pixel 
within the image by mapping data values to a colour scheme. In the field of 
cardiac electrophysiology they can also be referred to as activation maps and are 
a common way to depicting an activation pattern on cardiac tissue [119]. The 
isochronal maps were generated allowing for quick visualisation of the activation 
times of the LA. After an image series of a singular beat was imported to MATLAB, 
it was cropped to show only the LA. In addition to this an image mask was created 
by thresholding a value of 3000 to remove the background pixels. Subsequently, 
the images were smoothed spatially using a mean filter with a kernel of 3 x 3. 
Following this, the activation point was determined for every pixel. In order to 
perform this step, a moving average filter was applied temporally to each pixel. 
The filter used was a Savitzky-Golay filter [121] with an 11th order polynomial and 
a frame size of 3. This reduced the noise amplification during differentiation. The 
time signal at each pixel was differentiated and the peak was used to find the 
fastest upstroke; corresponding to the activation time. These steps were repeated 
for every pixel and each of these values was then stored in a corresponding array 
which generated an activation image. The repolarisation tail of the signal was 
ignored by the algorithms as calculating the activation only requires the 
depolarisation. The depolarisation time was recorded and stored in a matrix where 
it was represented as an isochronal image. The image was then median filtered to 
remove outlying pixels using a 3 x 3 kernel.  
The start of activation (t=0) occurred at an arbitrary frame within an image series. 
In order to analyse these automatically, the initial point was calculated. This was 
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done by determining the sequence of consecutive activation times and subtracting 
from the first value of the sequence. As the process of determining the activation 
time was not greatly affected by noise, a single AP was used to generate these 
isochronal maps. This was useful for looking at arrhythmias where multiple APs 
cannot be measured to gain an average value and beat to beat changes can be 
investigated. Figure 4.12 illustrates the steps required to create an activation map 
from the fluorescent TIFF images. As the parameters were predetermined, the 
map generation process was automated.  
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Figure 4.12. Isochronal map generation.  
The isochronal maps depict the activation times and pattern from the data generated from 
the optical mapping system. Shown above are the steps that analyse the raw images to 
generate the maps. 1) Fluorescence images were imported into the MATLAB space the 
format of a TIFF image stack. 2) The image was then cropped manually to highlight the 
desired region. 3) The background of the image was removed by thresholding values 
above 3000 to create an image mask. 4) A median filter was applied to smooth the image 
for analysis. 5) The fluorescence intensity was extracted from a single pixel through the 
time domain. Only pixels from the LA yielded an AP signal. Pixels from the background 
provided no information as they were removed in the earlier steps. 6) The activation time 
of the signal was defined as the steepest point on the upstroke of the AP. This was 
calculated by differentiating the signal with respect to time and using the peak of the 
differential as the point of activation. 7) The previous steps of (5) and (6) were repeated 
for all pixels in the image. 8) The activation time for each pixel was stored in a matrix 
which was used to create the map. Background pixels were also stored as zeros and 
appeared as white pixels in the activation maps. It shows that the scale was set from 0ms 
to 50ms but the majority of pixels were in the 30ms to 40ms range. 9) The time in which 
the LA is activated was determined and used as an offset for the start time of the 
isochronal map. This now shows the pixels to range from 0ms to 20ms.  
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4.7.6. Conduction velocity measurements of the LA 
The conduction velocity (CV) describes the speed and direction of activity. Several 
methods were investigated for measuring CV across the LA. The simplest method 
investigated was to measure the distance between two points. The isochronal map 
was generated using MATLAB and two points were selected from the image. The 
distance between the points and the activation was known and as a result the 
velocity was calculated. There were limitations to this method; the measurements 
had to be taken from two points which were perpendicular to the wavefront. With 
complex activation patterns finding a suitable line between two points proved 
difficult. If the line was not perpendicular the result would be skewed. Figure 4.13A 
and B show the importance of measuring points perpendicular to the wavefront. 
Figure 4.13A the points used is perpendicular to the wavefront, dividing the 
distance between the time difference gives a good estimate of velocity. Figure 
4.13B the points used when not perpendicular to the wavefront. To gain a more 
accurate result, a longer distance which traversed several time zones or contour 
lines was used to gain an average reading. The slight increase in distance yields a 
slower estimate of CV. The isochronal maps generated had many regions with the 
same activation time which posed another problem of where to select the points of 
measurements. From Figure 4.13C, the two points selected were very close to 
each other. The difference was that the second point had been selected a single 
pixel over a different activation time that resulted in a relatively large change in 
velocity. 
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Figure 4.13. Conduction velocity measurements using point to point method. 
A) Shows the CV measurements from two activation time points (t2,t3) which were taken 
perpendicularly to the wavefront or in line with the direction of propagation. The distance 
between the activation points is Δx. The CV was calculated from the distance and time 
between the two points. B) Shows the CV measurement when made from two points 
which intersect the wavefront at an angle. The distance between the two activation points 
was given as Δx’. As the time values for the points have not changed, yet the distance 
between them had increased, the CV value was higher compared to the measurement 
taken perpendicular to the wavefront. C) Illustrates the difference in CV value when the 
points selected were from two pixels in close proximity but differ in activation time. This 
shows the CV measured from two points on the LA stimulated at 100ms CL. The red line 
indicates the distance between the two points which were selected manually. The 
magnified sections show the difference between CV values before (28.5cm/sec) and after 
(31.2cm/sec) the contour line which separate the different activation times. The difference 
of 2.7cm/sec is a relatively large change in value indicating that measuring between two 
points proved to be unreliable. 
 91 
 
Another method tested to calculate the CV was quantifying the spatial 
inhomogeneity in CV using a phase method. Here the phase was defined as the 
maximal difference between neighbouring activation sites [122]. This method also 
allowed for its homogeneity to be measured using a phase map and provided a 
CV value from its median from the distribution of local CV phases. To calculate the 
phase, the isochronal map was loaded into MATLAB whereby the difference from 
each neighbouring pixel was calculated. The maximal value between the 
neighbours was determined and defined as the phase. Figure 4.14A shows an 
example isochronal map stimulated at 100ms CL from the LA. The phase was 
calculated to generate a map B). It can be seen that there were many white gaps 
between the blue phase points; this is a result of many neighbouring pixels 
containing the same value. Each activation point is limited to the value of the 
exposure time; as a result a phase difference was only detected when a 
neighbouring pixel changed value. The phase method proved problematic as the 
maps generated had many pixels of the same value and hence the phase values 
were always the same number which can be seen in Figure 4.14B as the majority 
of pixels were the same colour.  
The final method investigated was to use an algorithm to fit a small localised 
surface to a set of activation points. This surface had a gradient and magnitude 
which was translated into a local CV. As each point on the isochronal map 
represents an activation time, each of these points were defined as a wavefront 
which propagated. The velocity vector for each pixel and its neighbours were 
determined by looking at a window of 4 pixels in each x-y direction within a 
maximum time of 16ms. From this window a polynomial surface was fitted using a 
least-squares algorithm. The x-y window needed to contain enough varying values 
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to yield solutions to the polynomial coefficients. Each polynomial surface 
represented a local isochrone or activation contour, from here the gradient vector 
was found. The gradient vector is always orthogonal to the surface of the local 
isochrone and hence defined the direction of propagation for this window. 
Repeating this over each point yielded a set of CVs for x and y directions. With 
these velocities the magnitude and mean value was calculated. This represented 
the overall CV for a sample. Figure 4.14C shows the activation points in three 
dimensions (x, y, time). It was from these active points that a polynomial surface 
was fitted. As each surface had its own magnitude, this was represented as a set 
of quiver arrows which was superimposed onto the original isochronal image as 
seen in Figure 4.14D. The process of generating the isochronal maps and the 
mathematical operations to calculate CV were performed automatically. A script 
was written to save the CV values for each mouse in a text data file. The result of 
this advanced method allowed for complex conduction patterns to be studied. 
Figure 4.14E shows an isochronal map of the LA stimulated at 100ms CL and the 
corresponding map with a 1µM infusion of flecainide which has induced a CV 
slowing to the point the activation becomes re-entrant which is shown in Figure 
4.14F. The path of conduction is indicated by the curved black arrow.  
The CV measurement method and theory used for calculating CV was developed 
at Washington University lead by Professor Philip Bayly [123], not by the author of 
this thesis. This technique was originally designed for measurements from 
unipolar electrode arrays for epicardial mapping data.  
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Figure 4.14. Conduction velocity measurements from three isochronal maps.  
A) Shows an example of a LA activation map stimulated at 100ms CL. B) Shows the 
corresponding phase map of A). It was calculated by taking the maximal difference 
between each of its neighbouring pixels. The maximal difference between neighbouring 
pixels (i.e. phase difference) was calculated. The median of the distribution of the local 
conduction phases provided its velocity value. This method was first described by 
Lammers et al [122] but proved to be insufficient for calculating CV for maps which have 
many neighbouring pixels with the same activation times. This can be seen in the white 
regions in the image which represent zero values. C) Displays the activation times in 3D 
(x,y,time) – space for an LA sample stimulated at 100ms CL. Surface polynomials were 
fitted onto the points of the activation sites to yield a local gradient vector. D) Shows the 
LA with velocity vector arrows for each polynomial surface superimposed onto the 
isochronal map. Each vector arrow was calculated by fitting a local surface with a 4 x 4 
window in each x-y direction with a maximum time of 16ms. Each window was fitted using 
a least squares algorithm. E) Shows an LA activation map stimulated at 100ms CL. F) 
Illustrates the corresponding LA sample infused with a sodium channel blocker (1µM 
Flecainide) resulting in a complex activation pattern. Using the polynomial fitting method 
the CV was calculated. The black line which separates the blue and red regions 
represents the direction of block. The arrow indicates the path of activation propagation.  
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4.8. Validation of optical mapping  
To investigate the reliability of the optical mapping system, AP recordings were 
compared against other known methods such as monophasic action potentials 
(MAP) and transmembrane action potentials (TAP) which both use direct contact. 
Measurement of APD using MAP electrodes were performed on a Langendorff 
apparatus and TAP using glass microelectrodes were performed using isolated LA 
superfused samples. These techniques are described in the materials and method 
section. CV measurements were not directly compared but the activation times 
were recorded from the contact methods. Activation times from MAP and TAP give 
a rough estimate of the time taken for the tissue to depolarise from the time of the 
stimulus. The stimulation point can be seen as an artefact from the MAP and TAP 
methods. The stimulus artefact arises when the measurement electrodes receives 
a signal caused by the stimulator pulse and not from the tissue. Another method 
used to validate the optical mapping CV was to add noise to the images and 
investigate the resulting CV values.  
4.8.1. Comparisons between optical action potentials 
with MAP and TAP recordings 
To test the accuracy of the APD measurements made from optical mapping, 
signals were measured against the MAP and TAP methods. Figure 4.15A shows 
example traces from the optical mapping system at 300ms and 100ms CL over a 
period of 0.5 seconds from a 4 x 4 region. Figure 4.15B illustrates TAP measured 
with glass microelectrodes at 300ms and 100ms CL and Figure 4.15C from MAP 
electrodes at 100ms CL only. APs measured using this novel method exhibited 
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similar morphology and duration characteristics when compared with those 
recorded using more standard electrophysiology techniques.  
At 300ms CL OAPs at APD50 were 10.9 ± 0.9ms and APD70 14.7 ± 1.2ms and 
showed no difference from TAPs at 300ms CLs (10 cells, 5 atria). In another set of 
experiments, MAPs were recorded from the intact, beating heart just prior to 
dissection of LA tissue for OAP measurement. The MAP data was gathered on a 
Langendorff apparatus which did not include 300ms CL pacing as this rate was 
slower than the inherent natural rate of the whole heart. A significant difference 
was not detected in APD50 or APD70 between OAPs (9.6 ± 0.9ms and 14.3 ± 
1.4ms, respectively), TAPs and MAPs at a more physiological paced CL of 100ms 
(n = 14). However, there was a trend in shorter OAPs compared to TAPs and 
MAPs. This degree of uniformity therefore suggests that OAPs obtained using this 
technique can be used to make accurate and reliable assessments of APDs in the 
mouse atria.  
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Figure 4.15. Comparison of action potentials obtained using the high resolution 
optical system with other standard electrophysiological techniques.  
This shows the characteristic traces of APs from the LA from different techniques. A) 
Show the optical action potentials (OAPs) acquired at 1 kHz for 300ms and 100mc CL. B) 
Show the transmembrane action potentials (TAPs) at 300ms and 100ms CL. C) Show the 
monophasic action potentials (MAPs) recorded at 100ms CL only. The MAPs were 
recorded from a whole isolated heart on a Langendorff apparatus, the inherent heart rate 
of the samples were faster than 300ms CL hence only rates at 100ms were recorded. D) 
Comparisons between the OAPs and TAPs at 300ms CL were made at APDs at 50% and 
70% repolarisation (APD50 and APD70, respectively) which showed no significant 
difference between the two methods. E) Compared the LA samples at 100ms for all three 
techniques for APD50 and APD70 showing no significant difference between the 
techniques. It should be noted that despite no statistical significance optical signals 
showed a slightly lower value. Error bars indicate SEM. Data presented is from 8 regions 
of interest (ROI) from 8 LAs (OAPs), 10 cells from 5 LAs (TAPs) and 14 recordings from 
14 LAs (MAPs).  
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4.8.2. Conduction velocity measurements 
An increase in activation time indicates a decrease in CV. From an isochronal 
map, regions with a larger proportion of pixels towards the red end of the spectrum 
indicate an increase in time across the tissue. The LA showed an increase in 
activation spread with decreasing stimulation CL as shown in Figure 4.16A, this is 
indicated by the increase in red pixels. The activation times from TAP and MAP 
recordings also confirm this. Figure 4.16B and C show that the time from the 
stimulus artefact to the activation time measured by the fastest upstroke had 
increased with shorter CL, indicated by the red double arrows. Figure 4.16D 
provides a mean CV decrease with decreasing CL. The velocity ranged from 
31.32 ± 1.27cm/sec to 25.05 ± 1.10cm/sec from 300ms to 80ms, respectively. F) 
Illustrates the parallel increase in activation times measured by the contact 
methods. MAP recordings were much higher due to the fact that the whole heart 
was stimulated from the RA taking more time to conduct to the left. This differs 
from the isolated LA as this is stimulated directly. Measurements at 300ms CL 
were not performed on using MAP electrodes as the intrinsic rate of the intact 
heart which includes the RA and sinus node was much higher than stimulation 
rate.  
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Figure 4.16. Comparison of conduction velocity measurements with activation 
times at different stimulus cycle lengths.  
A) Examples of the activation spread across the same LA at different CLs as recorded by 
the new optical mapping system at 1000 frames/sec. At shorter CL, the activation times 
across the whole atrium increased. B) TAP and C) MAP recordings indicated a longer 
activation time from the stimulus artefact to the point of activation. Mean CV at different 
CLs, n=13 LA. Error bars indicate ± SEM. F) TAP and MAP activation times at decreasing 
CL. Data presented is from 10 cells from 5 LAs (TAPs) and 31 recordings from 31 LAs 
(MAPs). Error bars indicate ± SEM, * denotes P<0.05 compared with activation time at 
300ms CL; one way ANOVA with Dunnett's post hoc analysis.  
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To test the robustness of the CV calculations, measurements were repeated with 
Gaussian white noise added to each frame of the image series. Bearing in mind 
the signal to noise ratio is a logarithmic measurement, small changes in SNR is 
typically a large change in signal quality. An image of high SNR was measured at 
50dB with 5dB decrements to 30dB. Table 1 shows the results of increasing the 
image noise. As shown, the velocity measurements remain relatively unchanged. 
Sample 2 has the largest variance and standard deviation of 0.71 and 0.84, 
respectively. Sample 1 has the lowest variance of 0.14 and standard deviation of 
0.37.  
SNR (dB) sample 1 sample 2 sample 3 sample 4 sample 5 
50 18.44 21.42 35.17 26.17 22.76 
45 18.35 21.99 34.88 25.82 22.97 
40 18.17 20.72 35.99 24.9 22.86 
35 17.87 20.67 34.21 25.79 23.24 
30 17.53 19.77 34.42 24.37 21.34 
            
Mean 18.07 20.91 34.93 25.41 22.63 
Variance 0.14 0.71 0.49 0.56 0.56 
Standard Deviation 0.37 0.84 0.70 0.75 0.75 
 
Table 1. Left atrial conduction velocity measurements stimulated at 100ms cycle 
length with decreasing signal to noise ratios.  
Five sample data measurements were taken from the LA stimulated at 100ms CL to test 
the effect of noise on CV measurements. Images were distorted by adding Gaussian 
white noise to each frame in the data stack thus reducing the signal to noise ratio (SNR). 
Images of high SNR were measured at 50dB with 5dB decrements to 30dB. As noise was 
increased the CV values remain relatively unchanged as the variance and standard 
deviation have relatively low values. Values given are in cm/sec unless otherwise stated.  
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4.9. Video animation 
Software was also created to visualise the fluorescent activity in the LA and record 
them to .AVI video format. Two versions of the video animation software were 
designed: one version for visualising the isochrones, looking at the times of 
activation of the LA. The isochrones were overlaid onto the greyscale image to 
allow for better understanding of the conduction pathway; the second to display 
the relative fluorescence intensity of the LA whilst stimulated. The difference 
between the two is that the activation videos show a discretised set of isochrones, 
whilst the other displays a continuous set of fluorescence (ΔF/F).  
4.10. Concluding remarks 
This chapter has presented a new optical mapping system capable of imaging 
isolated murine LA, whereby the APD values were compared against 
microelectrode and monophasic action potential electrodes. In contrast, the 
present work mainly focuses on improving the automation of processing the image 
data by further reducing bias and speeding up analysis. The use of the TIFF 
image format allowed for more open access for others to develop an imaging 
system compared to those which often uses proprietary file types. The algorithms 
used have shown to perform APD calculations autonomously from fluorescence 
data, increasing signal quality by use of averaging.  
The baseline correction was shown to allow for signal averaging to generate 
higher SNR signals. Other methods such as polynomial fitting have limited use 
with signals that fluctuate greatly [124]. The isochronal activation maps were 
generated automatically; the only input was the user cropping the image to 
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highlight the ROI. However, other methods exist for the removal of uneven 
baselines. In biomedical imaging, the problem of inhomogeneities that distort the 
background of an image is commonly known as shading  [125]. Applying a 
solution to shading can be an alternative way to correct the variation in baseline. 
One solution by Reyes-Aldasoro utilises a method of generating an estimated 
signal envelop from the input image [120]. This method can be understood as 
stretching a surface over or under a series of objects. The flexibility in this method 
was that it made no assumptions whether the foreground signal was greater or 
lower in intensity than the background. The outcome was that it could develop a 
shading surface which was not easily described by a polynomial function [120].  
The segmentation method of thresholding was shown to be sufficient in removing 
the background from the fluorescence images. However, to improve upon this, 
other segmentation methods exist. There are many thresholding techniques for 
image segmentation which can be subcategorised into methods which use 
histogram shape, entropy and clustering etc. [126]. One popular thresholding 
technique, known as Otsu’s method is common within image processing [126]. 
The algorithm assumes the image contains two pixels classes, background and 
foreground. Otsu’s method performs clustering based thresholding by minimising 
the variance between the background and foreground pixels in an attempt to find 
the optimal threshold [127]. Each method of thresholding will have its own 
advantages and limitations. One should ideally compare manual segmentation on 
a series of images with a range of different users to determine the best method for 
the specified types of images.  
In Figure 4.12, the algorithms used to determine t=0, the activation start point, 
were automated which saved time and in turn allowed for faster analysis. This 
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differs from most current methods where manual selection was required, which 
can introduce subjectivity to results. Whilst it was possible to determine the CV 
without correcting for the start of the propagating AP, having the offset provided 
easy comparison between different tissue samples or the same sample with 
varying CV as seen in Figure 4.16A. This gave a rapid indication of samples which 
had a faster or slower CV.  
CV calculations were automatically performed, which allowed for reproducible 
results and the elimination of user bias. Methods calculating the distance between 
two activation points and their time difference proved to yield varying results that 
were greatly dependent on where the activation points were chosen. Calculating 
CVs was especially difficult from images that had irregular conduction paths as 
described in the results with flecainide. These isochronal maps have many 
neighbouring pixels which show a depolarisation at the same time. This caused 
problems when measuring the activation between two points as this yielded an 
unreliable velocity value. It has also been shown that tissues may have many 
localised CV vectors, the magnitude of these values were dependent on the 
orientation [128].The advantage of using the gradient method as described here 
was that it measured multiple polynomial surfaces that were fitted to the entire 
tissue and yielded an overall CV value. This accounted for the vector components 
in the x and y directions and takes its magnitude into account. The robustness of 
the CV algorithms were also tested by increasing the noise of the images, it is 
shown in Table 1 that there is little variance in the CV with decreasing SNR. As 
SNR is measured on the decibel scale, decrements of 5dB, indicates relatively 
large increases in noise. This is particularly true from 50dB to 30dB, thus 
indicating that the algorithms handle distortions in the image quality very well.  
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It should be noted that one of the limiting factors of signal averaging arises from 
measurements of the APD values. Each of these values must be in a steady state 
as multiple signals were combined. This limited the measurement of arrhythmias 
such as alternans and extra early beats. Measurements from the isochronal maps 
required a single signal as only the depolarisation was necessary. The 
depolarisation and the entirety of the repolarisation were needed to calculate the 
APD, hence signal averaging provided a way to increase the SNR. 
The main achievements for this system was that the APDs measured coincide 
largely with other methods such as the MAPs and TAPs. The algorithms were 
automatic and a robust to increased noise levels as shown in Table 1. The 
resolution of the system is higher than others [52] and the images generated was 
in TIFF format making them easy to distribute and analyse. Other imaging 
systems are limited by their proprietary formats.   
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 Optical imaging of the Pitx2c deficient mouse 
left atrium  
5.1. Introduction and overview 
Atrial fibrillation (AF) is the most common sustained arrhythmia in human and a 
common cause of stroke and cardiac deaths. Although much progress has been 
made in the characterisation of factors that cause AF [29], [46], [129], the 
mechanisms involved remain elusive [130], [131]. Genome-wide association 
studies have found that common gene variants or single nucleotide 
polymorphisms (SNP) on chromosomes 4q25, close to the PITX2 gene are 
strongly associated with AF [48], [49]. These variants are associated with altered 
mRNA expression of the transcription factor Pitx2 [132] and show an increased 
risk of AF by up to 1.72 times [49].  
Pitx2 is a homeobox transcription factor which is responsible for the body’s left-
right asymmetry [133], [134]. Four isoforms of Pitx2 are found (a-d), isoform-c 
mRNA levels are expressed in the adult left atrium (LA) in mice and humans [55], 
[135]. Pitx2c expression levels can be found up to 100 fold higher in the LA 
compared to the other three chambers of the heart [54], [55]. Furthermore, 
evidence is found that Pitx2c regulates ion channel expression within the atria 
[53]. A complete lack of Pitx2 in the atrium is thought to downregulate sodium (INa) 
and potassium (IK1) channels expressions which can lead to electrophysiological 
remodelling and atrial arrhythmias [53]. It has been shown from previous studies 
using Pitx2c+/- mouse models that there is a shortening of the action potential 
duration (APD) at the fast paced stimulations [55].  
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One therapy for controlling arrhythmias is by use of antiarrhythmic drugs (AAD). 
AADs have only been shown to be moderately effective [45], [136] but we lack the 
understanding of the mechanisms affecting their efficacy [47], [136]. Therefore it is 
advantageous to limit therapies to patients that will show an increased benefit. 
Understanding the reasons behind altered individual responses to AADs allow for 
a personalised approach to prescribing antiarrhythmic therapies. A study has 
shown that approximately every third to fourth AF patient who receives AADs 
caries the SNP closest to the 4q25 chromosome. The 4q25 chromosome lies 
close to the PITX2 gene and is strongly associated with AF. Some SNP variants 
respond well to sodium channel inhibitors such as flecainide [137].  
It was hypothesised that Pitx2c+/- littermates show electrophysiological changes 
such as shortened APD compared to wild-type (WT) and that flecainide shows a 
preferential affect to Pitx2c+/-. In addition to this, regular activation patterns were 
expected in both genotypes at baseline as no overt structural changes have been 
witnessed in previous studies [55]. However, it was expected that the use of 
flecainide reduces the conduction velocity (CV) in both genotypes. It was 
postulated that flecainide has a functional role in reducing the presence of AF in 
those with the Pitx2 downregulated mRNA by increasing the APD and by its 
differential ion channel expression. This can lead to a modification of the efficacy 
of AADs to maintain sinus rhythm in Pitx2 downregulation. 
Here the high resolution optical mapping system was used to measure the APD 
values from WT and Pitx2c+/- littermates along with comparing baseline values 
before and after the addition of flecainide acetate. The conduction properties were 
to study the structural variations between the genotypes with flecainide. 
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5.2. Methods 
The study was performed on WT and Pitx2c+/- heterozygous mouse littermates 
bred on an MF1 background. Mice were of adult age of 12-20 weeks old. Pitx2c+/- 
mice were generated by removal of the isoform-c specific exon as seen in Figure 
5.1. Mice were first generated and previously described by Lui et al. 2002 [115], 
not by the author of this thesis.  
Experimental protocols for animal dissection and optical mapping are described in 
the materials and methods chapter 3 on page 46. 
 
Figure 5.1. Gene targeting strategy for Pitx2.  
A) Summarises the exons in the Pitx2 isoforms. Exon 4 is present in Pitx2c only. B) 
Illustrates the Pitx2 genomic structure. Boxes represent the exons and lines represent 
introns. The box indicated by neo represents the neomycin gene cassette which is 
specific to Pitx2c. C) Illustrates the genomic structure with exon 4 now replaced with 
neomycin, thus removing the expression of Pitx2c. This strategy was first described by Lui 
et al. 2002 [115].  
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5.3. Results 
5.3.1. Atrial electrophysiological properties in Pitx2c 
deficiency 
To investigate whether a downregulation of Pitx2c leads to functional changes in 
the mouse LA, WT and Pitx2c+/- littermates were tested. In this study the APD) 
and CV values were recorded during pacing.  
The activation patterns for each genotype were not shown to be different or 
irregular as shown in Figure 5.2. However, outlying pixels were observed which 
can be seen above in dark red which did not follow the colour gradient from blue 
to red. These points were likely to be caused by pins which were used to hold the 
tissue to the imaging chamber. The pins can block the view from the camera but 
also can cause localise damage to the tissue. The CVs calculated from the 
isochronal maps showed that there were no changes between genotypes (WT: n = 
8, Pitx2c+/-: n = 12) at all cycle lengths (CL) which can be seen in Figure 5.3.  
Figure 5.4 show atrial APD values were significantly shorter in Pitx2c+/- (n=12) 
atria compared to WT littermates (n=12). Figure 5.4A shows that at 100ms CL 
mean values at AP30 were 6.39 ± 0.75ms for WT and 4.63 ± 0.37ms for Pitx2c+/- 
showing a reduction by almost 2ms. Figure 5.4B shows the mean values at 100ms 
CL at APD50 were 8.88 ± 1.08ms for WT and 6.61 ± 0.37ms again a reduction of 
approximately 2ms. Figure 5.4C shows the mean values for APD70 at 100ms 
were found to be 12.48 ± 1.55ms for WT and 9.40 ± 0.58ms for Pitx2c+/-, a 
reduction of almost 3ms. Significance was measured across the board between 
genotypes. Performing Bonferroni post hoc analysis revealed that the significance 
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arose from the shorter CLs (APD30: 100ms, 80ms; APD50: 120ms, 100ms, 80ms; 
APD70: 100ms). This suggests that the genotype differences were more 
pronounced when the LA were stimulated faster.  
Taken together, this data shows that the rate of conduction is no different between 
the genotypes. However, there is a reduced APD in the Pitx2c+/- LA compared to 
the WT LA. With this information, it can be tested to see whether the effects of 
flecainide have a greater effect on the Pitx2c+/- model compared to the WT LA.  
 
 
Figure 5.2. Activation patterns for WT and Pitx2c+/- left atrial samples.  
LA samples between WT (n=8) and Pitx2c+/- (n=12) were compared. This shows 
representative examples of the LA stimulated at 100ms CL. The blue regions indicate the 
start of activation with it propagating upwards. No irregular activation patterns were found 
between the genotypes. The CV for the samples shown above were 29.3cm/sec and 
22.8cm/sec for the WT and Pitx2c+/-, respectively. From the 8 WT and 12 Pitx2c+/- 
samples, the mean CV values showed no significant difference between the genotypes. 
Outlying pixels were observed which can be seen above in dark red which did not follow 
the colour gradient from blue to red. These points were likely to be caused by pins which 
were used to hold the tissue to the imaging chamber. The pins may incur some damage 
to the local area of the tissue affecting the activation time of the sample.  
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Figure 5.3. Cycle length dependent conduction velocity measurements between WT 
Pitx2c+/- littermates. 
The CV of the WT and Pitx2c+/- LA were measured. The decrease in CL stimulations 
showed a reduction in CV in both genotypes. No differences in CV were found between 
genotypes for all CLs. This suggests that Pitx2c deficient LA samples do not show a 
change in CV compared to WT samples. Points indicate mean values with error bars 
representing SEM. Statistical analysis was performed using two way repeated measures 
ANOVA.   
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Figure 5.4. Pitx2c+/- deficient mice indicate a lower APD value in the left atrium.  
WT and Pitx2c+/- littermates were stimulated at multiple CLs and action potentials 
recorded and analysed. Samples from Pitx2c deficient mice showed a significantly lower 
APD value when compared to WT littermates. Significance across the board is denoted 
by * P<0.05. Bonferonni post hoc analysis revealed that significance arose from the 
shorter CLs (APD30: 100ms, 80ms; APD50: 120ms, 100ms, 80ms; APD70: 100ms). 
Statistical analysis was performed using two way repeated measures ANOVA. Error bars 
represent SEM.  
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5.3.2. Flecainide reduces conduction velocity in the left 
atrium 
Figure 5.5 shows isochronal maps of WT and Pitx2c+/- LA samples before and 
after the infusion of flecainide. The atrial samples in the Figure 5.5 were stimulated 
at 100ms CL. Following the infusion of flecainide the activation times increase 
substantially, as indicated by the large areas of red in the lower row of Figure 5.5. 
Figure 5.6 shows the CV values from 5 WT and Pitx2x+/- samples both showing a 
slowed conduction as a result of the flecainide. Mean CV at baseline for WT mice 
24.92 ± 3.05cm/sec compared to 17.54 ± 1.06cm/sec after 15 minutes of 
flecainide infusion and stimulated at 100ms CL. Mean CV values for Pitx2c+/- 
before and after flecainide were 25.76 ± 2.17cm/sec and 20.36 ± 1.29cm/sec, 
respectively at 100ms stimulation CL. Significance was measured across the 
board for the WT and Pitx2c+/- LA. Performing Bonferroni post tests revealed that 
the significance in the WT were at 300ms, 100ms and 80ms. For the Pitx2c+/-, the 
post test showed that the significance was due to 120ms, 100ms and 80ms. 
Figure 5.6C compares the difference in conduction between the genotypes after 
flecainide infusion showing no significant changes between the WT and Pitx2c+/- 
littermates. This data suggests that the flecainide does not have a preferential 
effect on CV between the genotypes.  
 112 
 
 
Figure 5.5. Activation maps at baseline and 1µM flecainide for WT and Pitx2c+/-.  
This shows LA samples from both WT (n=5) and Pitx2c+/- (n=5) stimulated at 100ms CL at 
baseline (top row) and flecainide infusion (bottom row). The flecainide was infused for 15 
minutes at a concentration of 1µM. CV values for the WT atrium in this sample were 
calculated to be 22.1cm/sec at baseline and 17.3cm/sec with flecainide. CV values for the 
Pitx2c+/- sample was 27.8cm/sec at baseline and 17.0cm/sec with flecainide. The slow in 
CV due to flecainide can be seen with the large number of red pixels indicating later 
activation times compared to baseline levels.  
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Figure 5.6. Conduction velocity reduction in left atrial WT and Pitx2c+/- littermates in 
response to 1µM flecainide.  
The CV of the WT and Pitx2c+/- LA were measured at baseline and after 1µM flecainide 
infusion. A) Shows a significant reduction in CV with flecainide compared to baseline 
levels for WT LA samples. B) Indicates a reduction in CV after flecainide for Pitx2c+/- 
littermates. C) Shows the comparison between genotypes with flecainide indicating no 
difference between the CV. This suggests that the flecainide does not have a preferential 
effect on CV between the genotypes. Significance across the board is denoted by * 
P<0.05. Bonferroni post tests revealed that the significance in the WT were at 300ms, 
100ms and 80ms. Pitx2c+/- post test showed that the significance was due to 120ms, 
100ms and 80ms. Error bars represent SEM. Statistical analysis was performed using two 
way repeated measures ANOVA. 
 114 
 
5.3.3. Flecainide prolongs the APD in Pitx2c+/- 
The addition of flecainide following baseline measurements showed a 
prolongation in APD. Figure 5.7 shows effect of the addition of 1µM flecainide 
compared to baseline measurements for both genotypes. Figure 5.7A to Figure 
5.7C shows that there was a trend in prolongation at all APD and stimulation 
pacing cycles for WT (n=5) littermates but was not statistically significant. Baseline 
values were calculated as 10.95 ± 0.85ms compared to 13.70 ± 1.81ms with 
flecainide at APD70 and 100ms CL. Figure 5.7D to Figure 5.7F showed a 
significant prolongation in APD after the infusion of flecainide in Pitx2c+/- (n=5). At 
APD70 and 100ms baseline values were 8.58 ± 0.61ms compared to 14.46 ± 
1.95ms after flecainide. The greatest difference was seen in the shorter CL 
stimulations. Performing Bonferroni post hoc tests revealed that the significance 
was due to 100ms and 80ms in AP50 and APD70. This coincides with the nature 
of flecainide’s use dependence; the effect is increased with as heart rate 
increases.  
The differences in APD values previously witnessed between WT and Pitx2c+/- in 
Figure 5.4 appear to be abolished with 1µM flecainide as seen in Figure 5.8. The 
values at baseline showed a decreasing APD with shorter stimulation CLs which 
were also abolished with flecainide.  
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Figure 5.7. Action potential duration prolongation in response to 1µM flecainide 
infusion in WT and Pitx2c+/- littermates.  
APD measurements were made on the LA at baseline and with 1M flecainide. A) to C) 
Shows the change in APD for WT littermates from baseline to flecainide had no significant 
differences. However, the data suggests that there is a trend in increased APD value with 
flecainide. D) to F) Shows a significant increase for all APD measurements in Pitx2c+/- 
samples with flecainide. Significance is denoted by across the board is denoted by * 
P<0.05. Bonferroni post hoc tests revealed that the significance was due to 100ms and 
80ms in AP50 and APD70. Points indicate mean values with error bars representing 
SEM. Statistical analysis was performed using two way repeated measures ANOVA. 
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Figure 5.8. Action potential duration differences between WT and Pitx2c+/- 
littermates after 1µM flecainide infusion.  
This shows the APD measurements at 30%, 50% and 70% repolarisation for both 
genotypes after the addition of flecainide. The comparisons show no change in APD 
between genotypes, which suggests that the differences previously seen at baseline were 
absolved. Points indicate mean values with error bars representing SEM. Statistical 
analysis was performed using two way repeated measures ANOVA. 
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5.4. Discussion 
In this study, no changes affecting the activation spread and CV of the LA 
samples between WT and Pitx2c+/- were witnessed. This data supports previous 
findings by Kirchhof et al (2011) whereby the isochronal maps showed no irregular 
activation patterns and activation times as measured by contact and optical 
mapping but with cruder spatial resolution of the optical signal. Activation times 
give an indication of CV by measuring the duration between a stimulus artefact 
and the fastest upstroke [138], [32]. As this method only measures in theory two 
points, the conduction pathway may be non-linear and complex [123] as 
discussed in the method development chapter. The CV measurements made by 
the optical mapping system gives a more reliable result as this can measure 
complex activation patterns.  
These findings also showed that there was a significant reduction in APD value for 
the atrial samples which were Pitx2c+/- deficient compared to WT littermates 
(Figure 5.4). Kirchhof et al also showed reduced APD at short paced CL 
stimulations in Pitx2c+/- compared to WT littermates. Figure 5.4 shows that the 
difference between the genotypes is seen at the shorter stimulation CLs, whereas 
the previous study [55] showed a reduction at the short CLs only (80ms CL for 
APD50 and APD70).  
The CV and activation patterns were not different between genotypes which 
suggest that shortening of the APD is responsible for the wavelength reduction in 
Pitx2c+/- mice.  
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5.4.1. Flecainide and Pitx2c deficiency 
It has been shown that a lack of Pitx2c in the atrium impairs the sodium channel 
expression [53]. Flecainide is a sodium channel blocker which may enhance its 
effects with the lower sodium channel expression in Pitx2c+/- mice. The results 
shown corroborate with this enhanced effect as hypothesised. Figure 5.7 showed 
that the APD had increased significantly only for the Pitx2c+/- mice and not for the 
WT littermates. In addition to this, flecainide abolished the difference in APD in the 
LA between the genotypes. One explanation for the APD values reaching similar 
levels between the genotypes after flecainide may be that flecainide non-
selectively binds to potassium channels [139], [140]. The potassium current plays 
a major role in repolarising the cardiac AP and it would be interesting to see 
whether the expression of potassium channels is affected by Pitx2c+/- which could 
explain the APD shortening compared to WT. Flecainide was also shown to 
significantly reduce the CV in both genotypes of the LA. The CV slowing was 
apparent from the isochronal maps shown in Figure 5.5, whereby both genotypes 
were affected to the same degree. As discussed earlier, a reduced repolarisation 
in Pitx2c+/- with a static CV value may increase inducible AF.  
A limitation of the optical mapping system was that the changes in fluorescent 
intensities which give rise to optical action potentials were not absolute voltage 
values. Hence other techniques as such microelectrode and patch clamp aid in 
supporting our findings. Current unpublished data from the group have shown a 
significant difference between resting membrane potential between the WT and 
Pitx2c+/- littermates. Using microelectrode measurements atrial cardiomyocytes 
with reduced Pitx2 mRNA expression showed a higher positive resting membrane 
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potential in different experimental conditions. Patch clamp studies showed a small 
difference in holding potential and have reproduced the observed differences in 
sodium channel blockade by flecainide found in Pitx2-deficient cardiomyocytes. 
Controlling the holding potential abolished any difference in Pitx2 deficient and WT 
isolated atrial cardiomyocytes. Our unpublished data suggest that such a 
difference could explain the effectiveness of sodium channel blockers in patients 
with a common gene variants on chromosome 4q25 (see Syeda et al. Appendix 5 
- PITX2 modulates atrial membrane potential and reduced PITX2 potentiates the 
antiarrhythmic effects of sodium-channel blockers.).  
The key finding here was that flecainide shows an enhanced antiarrhythmic effect 
in Pitx2c+/- LA. From a clinical perspective, sodium channel blockers may be an 
attractive therapy for AF patients with reduced Pitx2c expression.  
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 Optical imaging of the plakoglobin deficient 
mouse left atrium  
6.1. Introduction and overview 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart 
disease which is a significant cause of sudden death in young athletes. ARVC is 
caused by genetic defects in genes coding proteins in the “area composita” i.e. of 
the desmosomal region of the myocardium. Mutations in the proteins which 
encode the cell-cell junction play a central role in ARVC [114], [141].  
Previous studies have shown that the chromosomes near the 17q21 locus 
encodes the gene for plakoglobin [69]–[71]. Plakoglobin is a protein which is a key 
constituent for the adherent junctions and is responsible for the tight adhesion 
between cardiomyocytes [69], [71]. It is involved in the area composita of adhering 
junctions, which consists of adherent fascia molecules in the intercalated disk of 
vertebrates [67], [68] and anchorage of cytoskeleton filaments to specific 
cadherins [72].  
Genetically altered murine models have verified the roles of junctional protein 
dysfunction in ARVC. Homozygous deletion of plakoglobin (plako-/-) is lethal during 
gestation [72]. However, heterozygous deletion (plako+/-) in murine models is 
sufficient to provoke the ARVC phenotype which consists of enlarged right 
ventricle (RV) and inducible ventricular tachycardia [64]. Kirchhof et al have also 
shown that the RV enlargement and ventricular tachycardia was inducible without 
fibro-fatty infiltration of the cardiac muscle. Other studies have characterised 
ARVC by the fibro-fatty replacement of cardiomyocytes primarily in the RV [58], 
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[142], but also show biventricular infiltration and abnormalities in conduction and 
repolarisation  [143]. This cardiac remodelling due to the fibrosis and enlargement 
of the RV can act as a substrate for arrhythmias.  
It has been shown that patients with ARVC have not only a greater prevalence of 
ventricular arrhythmias, mostly generating from the RV, but also more atrial 
arrhythmias [65], [144], [145]. Studies of atrial pathology in ARVC are still only 
recent. Other studies have shown a reduction in sodium channel availability in 
some cases of human ARVC [146], [147]. As the cardiac sodium channel (Nav1.5) 
is responsible for the upstroke phase of the action potential, a reduction in 
availability can lead to reduced sodium current and conduction velocity (CV) which 
in turn increases arrhythmia susceptibility. Other desmosomal proteins such as 
Plakophillin-2 have been shown to decrease sodium current and CV [148], [149]. 
Therefore, optical mapping was used to investigate potential changes in CV 
across the whole left atrium (LA). Functional changes were also investigated using 
the optical mapping system to study action potential variations between wild-type 
(WT) and plako+/- littermates. It was hypothesised that there may be changes 
between the plako+/- atrial CVs and APDs due to potential functional and structural 
differences compared to WT samples.  
6.1.1. Flecainide and plakoglobin deficiency 
Flecainide is antiarrhythmic drug (AAD) which is a sodium channel blocker. In the 
desmosomal macromolecular complex, Nav1.5 channels are preferentially 
expressed at the intercalated disc [150]. As discussed previously, the ARVC 
model may lead to sodium channel dysfunction [146], [147] and increased 
arrhythmia susceptibility. One of flecainide’s effects is prolonging the inactivated 
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state of the sodium channel [151] increasing the time between the next possible 
action potential, known as the effective refractory period (ERP). As sodium is 
responsible for the depolarisation of an action potential, a blockade in the channel 
reduces the sodium current density causing a decrease in CV. Subtle sodium 
channel effects may be enhanced by flecainide as it causes sodium channel 
blockade. This may give insight into the differences between effects of the sodium 
channel block on the atrial plakoglobin deficient model.  
It was hypothesised that as some patients with ARVC are predisposed to sodium 
channel irregularities, the effect of flecainide on atrial CV might be enhanced in 
plakoglobin deficiency.  
6.1.2. Effect of endurance training 
There is an increasing body of evidence for those who are predisposed to ARVC, 
which suggests to avoid excessive exercise [152], [153]. An estimated 22% of 
young athletes who suffer from sudden cardiac death do so as a result of ARVC 
[152]. Previous studies have shown that older age groups of endurance trained 
plako+/- mice developed ventricular arrhythmias and conduction slowing in the RV 
[64]. Another study performed in rat models showed significant increase in cardiac 
fibrosis due to intensive training for 16 weeks which were reversed after 8 weeks 
post training [154]. Human studies have found that intense exercise may cause 
acute dysfunction in the RV along with structural remodelling [155]. Rigorous 
physical activity has also shown to increase the incidence of AF in older adults 
(>=65 years) [156] and younger men [157]. Early stage dysfunction can be 
reversed by halting training and evidence shows that preload reducing therapy, 
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protecting the RV from stress during exercise, can prevent ARVC in mouse 
models [158].  
Structural and functional changes which may give rise to atrial arrhythmias in 
ARVC models have not been well described. Here, findings where the atrial APD 
and CV were measured along with the addition of flecainide which may 
exacerbate small changes in sodium activity are presented.  
6.1.3. Effect of dihydrotestosterone  
Androgenic anabolic steroids (AAS) are synthetic derivatives of the male sex 
hormone testosterone and can enhance an athlete’s performance. In animal 
studies, observations have shown AAS to produce hazardous effects on heart 
structure and function [159]. Dihydrotestosterone (DHT) is a metabolite of 
testosterone which has often been abused as an AAS and can be detected in the 
plasma by mass spectrometry. One study showed hypertrophic effects in that the 
weight of the right ventricular wall and atria to body weight ratio increased 
significantly in rats given elevated doses of DHT [160]. In general, there exists a 
higher prevalence of cardiovascular disease in males [161], [162].  
These cardiovascular effects of AAS on atria of mice genetically predisposed to 
vulnerable cell-cell connections could exacerbate small changes in cardiac 
function. Hypertrophic effects have been shown in the ventricles [160] but little 
work has been published on the effects of ARVC on the mouse atria. It was 
suspected that there may be small changes in atrial morphology causing 
conduction differences between plako+/- and WT littermates that may increase with 
DHT. DHT treatment may result in APD changes. With the development of the 
high resolution optical mapping system these hypotheses were investigated. 
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6.2. Methods 
This study was performed on atria of WT and Plakoglobin deficient littermates 
(plako+/-) [64], [114]. Mice were of adult age of 12-20 weeks old. Plako+/- mice 
were generated by removal of the plakoglobin specific exon as seen in Figure 6.1. 
Mice were first generated and previously described by Ruiz et al. 1996 [72], not by 
the author of this thesis.  
Experimental protocols and procedures are described in the material and methods 
on page 46. Other procedures specific to this study are as follows.  
 
Figure 6.1. Gene targeting strategy for plakoglobin.  
A) Shows the genomic structure of plakoglobin. Boxes represent the exons and lines 
represent introns. The neomycin gene cassette is represented by the box labelled neo. 
The cassette targets a part portion of exon 3, the following intron sequence, and a portion 
of exon 4. B) Illustrates the genomic structure with the inserted neomycin cassette with 
portions of exon 3 and exon 4 removed. The result of the exon removal stops the 
expression of plakoglobin. This strategy was described by Ruiz et al. 1996 [72].  
 
 
 125 
 
6.2.1. Controlled exercise intervention 
To test the effects of exercise as a mode of exacerbating ARVC like phenotype, 
plako+/- mice were endurance trained by swimming. Cohorts of mice were placed 
in 30x50x30cm containers (Home Bargains, UK) with lukewarm tap water for 
training. To ensure a suitable temperature, floating bath thermometers (Philips, 
NL) were used to maintain the water at 28ºC. Swimming sessions were performed 
over 6 weeks, 6 days a week at 2 sessions per day. Each session was performed 
in the morning and late afternoon. The mice were originally trained for 2 minutes 
per session to acclimatise them to the water. The duration was increased by 1 
minute per day until they reached 24 minutes and then 2 minutes per day until 45 
minutes was reached. For cages with fewer than 3 mice, multiple cages were 
combined but no more than 7 were placed into each container. To distinguish the 
mice, white marks were drawn on their tail. Only mice of the same sex were 
allowed to share a single container. To ensure the mice were swimming 
adequately, an activity score was used for each mouse: 
 0 = floating  
 1 = moderate intensity 
 2 = actively swimming 
After the end of each swimming session, mice were dried and returned to their 
respective cages. Any signs of distress during the training session, the mice were 
quickly removed from the container and dried.  
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The swim training was carried out at the Biomedical Services Unit (BMSU) at the 
University of Birmingham by the author and at least another licensed individual or 
a qualified staff member of the BMSU for every session.  
6.2.2. Effective refractory period measurements 
Programmed stimulation was used to determine the ERP of the LA and recorded 
using optical mapping. The electrodes were attached to a constant voltage 
isolation unit (Grass Technologies, USA) which was connected to a Grass s88x 
stimulator (Grass Technologies, USA). The voltage used was twice the diastolic 
threshold that was determined using the same method as described in section 3.6. 
The recording time was increased to 100 seconds as this allowed ample time to 
determine the ERP. A train of eight stimuli (S1) was produced at a rate of 120ms 
CL with an early ninth stimulus (S2). This procedure was repeated with the S2 
stimulus reducing in 1ms decrements until a response was not produced. The 
ERP was determined by the time between the last S1 beat and when the S2 failed 
to produce an action potential as seen in Figure 6.2. 
 
Figure 6.2. Effective refractory period determination using S2 stimulus at 120ms.  
The ERP was determined using optical mapping by providing a train of eight stimuli (S1) 
at 120ms CL and a ninth premature stimulus (S2). From above, the middle train’s S2 beat 
comes 1ms earlier than the previous train shown on the left. The S1-S2 train is repeated 
with 1ms decrements until the ninth stimulus fails to illicit a response as seen from the 
train on the right.  
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6.2.3. Dihydrotestosterone pump implantation 
To test the effects of doping, mice were surgically implanted with osmotic pumps 
(Alzet, USA) which released 5ɑ-Dihydrotestosterone (DHT) (Sigma-Aldrich, USA) 
over a period of 42 days at a rate of 0.15µl per hour. The osmotic pumps were 
prepared by Dr Genna Riley from the University of Birmingham and surgical 
implantation by Ian Ricketts (Named Animal Care and Welfare Officer, Biomedical 
Services Unit, University of Birmingham, UK) not by the author of this thesis. A 
200µl solution of 62.5mg/ml of DHT-ethanol solution was filled into each pump. 
The pumps each contained a flow moderator which was initially removed, so that a 
filling tube could be inserted. The pumps were held upright and the DHT-ethanol 
solution was injected through the aperture. The pumps were filled when a small 
volume of solution would begin to overflow. The flow moderator was replaced and 
the pumps were stored in centrifuge tubes for a minimum of 48 hours before 
implantation. The 48 hour period was necessary as the DHT-ethanol solution 
required time to diffuse out of the pump.  
Mice were anaesthetised by inhalation with isoflurane, (Abbott Laboratories, USA). 
A small incision was made on the back skin of the mouse, approximately 2cm 
above the base of the tail. A blunt dissection was performed using surgical 
scissors until a space was suitable for the pump. Forceps held the incision open 
whilst the pump was slowly inserted. The wounds were then closed with surgical 
clips. 
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6.3. Results 
6.3.1. Atrial electrophysiological properties in 
plakoglobin deficiency 
In order to investigate if plakoglobin heterozygous deficiency leads to changes in 
atrial CV and atrial action potential, the LA from plako+/- mice and their WT 
littermates were examined using optical mapping. Example activation maps are 
shown in Figure 6.3 depicting a typical activation spread starting from the bottom 
to the top in atria from young sedentary mice. There were no signs of irregular 
activation patterns in either young sedentary plako+/- or WT mice. In Figure 6.3 CV 
values were calculated to be 29.3cm/sec and 25.7cm/sec for WT and plako+/-, 
respectively. 
 
Figure 6.3. Sedentary WT and plako+/- littermate activation maps.  
Sednetary LA samples from WT (n=13) and plako+/-(n=11) littermates were compared. 
Representative examples of the LA stimulated at 100ms CL are shown above. CV values 
were calculated to be 29.3cm/sec and 25.7cm/sec for WT and plako+/-, respectively. The 
mean values from both genotypes suggested that plako+/- LA had no significant CV 
slowing compared to WT. No irregular activation patterns were found between the 
samples. The blue regions indicate the start of activation propagating upwards to the red 
and orange regions. The LA samples were pinned to the imaging chamber which may 
have caused irregularities in certain pixels which can be seen on the edges of the 
activation maps.  
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Furthermore, CV changes at various cycle lengths (CLs) were investigated. Figure 
6.4 shows the comparison of CV plako+/- vs WT all CLs from 300-80ms. The mean 
CV values from 300ms to 80ms CL were calculated to be 31.35 ± 1.27cm/sec, 
27.93 ± 1.24cm/sec, 26.29 ± 1.44cm/sec and 25.05 ± 1.11cm/sec, respectively for 
the WT littermates (n = 13). For the plako+/- samples (n=12) the CV calculations 
were 30.89 ± 1.04cm/sec, 28.90 ± 1.41cm/sec, 27.68 ± 1.11cm/sec and 25.38 ± 
1.12cm/sec for 300ms to 80ms, respectively. CV decreased with decreasing CL as 
expected in both genotypes.  
 
Figure 6.4. Conduction velocity measurements from sedentary WT and plako+/- LA 
samples.  
The CV of the WT and plako+/- LA were measured. The decrease in CL stimulations 
showed a reduction in CV in both genotypes. No differences in CV were found between 
genotypes for all CLs. This suggests that plako deficient LA samples do not show a 
change in CV compared to WT samples. Points indicate mean values with error bars 
representing SEM. Statistical analysis was performed using two way repeated measures 
ANOVA.  
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Figure 6.5. Atrial action potential duration measurements from WT and plako+/- 
sedentary mice.  
APD measurements were taken from the LA of 13 WT and 12 plako+/- mice at decreasing 
CLs. A), B), C) represent APD measurements at 30%, 50% and 70% repolarisation, 
respectively. No significant changes were observed between genotypes. Points indicate 
mean values with error bars representing SEM. Statistical analysis was performed using 
two way repeated measures ANOVA.  
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Both genotypes exhibit decreases in APD70 with decreasing stimulation CLs 
(Figure 6.5). There was however, no significant difference in APD70 in plako+/- and 
WT littermates seen. Measurements were also performed at APD50 and 30 
showing no statistical difference between the genotypes.  
6.3.1.1. Flecainide prolongs APDs in WT and plako+/-
atria 
In order to investigate alterations in physiological parameters with the addition of a 
sodium channel blocker known to slow CV, 1µM of flecainide acetate was added 
to the tissue samples. A significant prolongation in APDs was found in WT mice at 
all APD30, APD50 and APD70 with flecainide, this is shown on the left column of 
Figure 6.6. Significance was seen across the board and performing Bonferroni 
post hoc test revealed that at all CLs significance was found. A prolongation was 
also found in the plako+/- mice at APD30 and APD70 (Figure 6.6) APD50 showed a 
strong trend that durations were increased with flecainide. (p=0.054), a reason for 
the lack of significance was due to outliers in the dataset. Performing Bonferroni 
post hoc test revealed that only 300ms CL was significant at APD30 and APD70. 
The APD values at 120ms and 100ms CL for the plako+/- show a large deviation in 
the standard errors. Looking at the individual APD values, the variation is caused 
by strong outliers. The data presented here were from a mean of 9 APDs from 5 
WT and 4 plako+/-.  
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Figure 6.6. Flecainide prolongation of action potential duration in the WT and 
plako+/- left atrium.  
APD measurements were recorded at baseline and then repeated with 1µM flecainide 
with decreasing stimulation CL for both WT and plako+/- littermates. A) to C) Shows WT 
data from 5 samples at APD30, APD50 and APD70. The WT APD measurements show a 
significant increase in mean values with flecainide. Bonferroni post hoc test revealed that 
at all CLs significance was found. D) to F) Shows plako+/- data from 4 LA samples at 
baseline and with flecainide. A significant increase in APD value was seen at APD30 and 
APD70. From D) to F) large SEM values can be seen at 120ms and 100ms CL, this was 
due to outlying measurements. Bonferroni post hoc test revealed that only 300ms CL was 
significant at APD30 and APD70. Significance across the board is denoted by * P<0.05 
between control and flecainide. Points indicate mean values with error bars representing 
SEM. Statistical analysis was performed using two way repeated measures ANOVA. 
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6.3.1.2. Flecainide slows conduction in WT and 
plako+/- murine atria 
The CV measurements were recorded from sedentary WT and plako+/- LA 
samples. Recordings were made at baseline and repeated with 1um flecainide 
infused after 15 minutes. Flecainide reduced CV in both WT and plako+/- 
littermates as shown in Figure 6.7. Significance was witnessed across the board 
with flecainide. Performing Bonferroni post test showed that the results were 
significant at 120ms and 80ms WT and at 100ms for the plako+/- LA.  
Of the original cohort of 13 WT and 12 plako+/- LA, 5 WT and 4 plako+/-pairs were 
used for the flecainide experiments. The remainder of the atrial preparations 
suffered from lack of stimulus capture with the flecainide infusion. Flecainide 
increases the threshold potential required to invoke a depolarisation [163]. As a 
result of the increased potential, stimuli were often not evoked by the stimulator in 
some of the experiments. CV slowing was consistent at all CLs of the stimulation 
protocol. Figure 6.8 (bottom row) illustrates the activation spread of WT and 
plako+/- littermates with flecainide paced at 100ms CL. These maps indicate the 
activation time has prolonged compared to those in Figure 6.8 (top row), as the 
samples with flecainide have a high proportion of red pixels indicating 30ms 
activation time. These maps show the irregularity of activation spread across the 
atrium on samples of both genotypes with flecainide. The irregularity of the 
activation is due to the CV slowing to an extent that the activation travels via an 
alternate route, hence the discontinuity from blue to red regions.  
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Figure 6.7. Conduction velocity reduction with flecainide infusion. 
The CV measurements were recorded from sedentary WT and plako+/- LA samples. 
Recordings were made at baseline and repeated with 1um flecainide infused after 15 
minutes. A) Shows a significant decrease in CV with flecainide compared to baseline 
levels in WT LA. B) Shows CV measurements for plako+/- samples significantly decreased 
after flecainide. Significance across the board is denoted by * P<0.05 when compared to 
control and flecainide samples. Performing Bonferroni post test showed that the results 
were significant at 120ms and 80ms WT and at 100ms for the plako+/- LA. Points indicate 
mean values with error bars representing SEM. Statistical analysis was performed using 
two way repeated measures ANOVA.  
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Figure 6.8. Activation maps of left atrial preparations from WT and young sedentary 
plakoglobin deficient mice with 1µm flecainide stimulated at 100ms CL.  
The maps shown above are activation patterns of WT and plako+/- LA samples stimulated 
at 100ms CL. The measurements were taken at baseline and after 15 minutes of 1µM 
flecainide infusion. The top row indicates control samples from WT and plako+/- with their 
activation spreading upwards from the blue to the red regions. The bottom row illustrates 
activation patterns after flecainide infusion for both genotypes. After the addition of 
flecainide, the activation times increased which can be seen from the large red regions in 
the maps. The irregularity of the activation is due to the CV slowing to an extent that the 
activation travels via an alternate route, hence the discontinuity from blue to red regions. 
The CV values for WT LA shown above were calculated to be 29.3cm/sec at control and 
11.7cm/sec with flecainide. The Plako+/- CV values were measured at 25.7cm/sec at 
control and 17.32cm/sec with flecainide. 
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6.3.1.3. Cardiac refractoriness 
In order to investigate the LA refractoriness in atria from sedentary WT and the 
plako+/- LA (n=3), the ERP was measured by an extra early stimulus (S2) as 
described in section 6.2.2. Measurements were performed before and after the 
infusion of 1µm flecainide at 120ms CL. Figure 6.9 shows that the atrial ERP was 
significantly prolonged with the addition of flecainide for plako+/- from 29.3 ± 0.9ms 
to 43.0 ± 3.0ms after infusion. Statistical significance was calculated by paired 
Student’s t-test at P<0.05. In the WT mice the mean ERP values increased from 
43.6 ± 4.7ms to 51.6 ± 6.6ms with flecainide but were not statistically significant. It 
should be noted that the WT LA had a significantly longer ERP that the plako+/- 
samples at baseline. A longer ERP indicates that it may be protective against atrial 
arrhythmias as it limits the time that the cardiomyocytes can re-excite. However, 
greater sample sizes are required for more conclusive results.  
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Figure 6.9. Effective refractory measurements in sedentary WT and plako+/- 
littermates before and after flecainide. 
The ERP of sedentary WT and plako+/- littermates (n=3) were measured from the LA at 
120ms CL. Measurements were taken at baseline and repeated after 1µM flecainide 
infusion. In the WT mice, mean ERP values increased from 43.6 ± 4.7ms to 51.6 ± 6.6ms 
with flecainide. In the plako+/- samples, the mean values significantly increased from 29.3 
± 0.9ms to 43.0 ± 3.0ms. The plako+/- LA had a significantly shorter ERP than the WT 
samples. Significance is denoted by * (P<0.05). Statistical significance was calculated by 
paired Student’s t-test. Error bars indicate SEM.  
 
6.3.2. Effect of endurance training on left atrial 
electrophysiological parameters function  
6.3.2.1. Effects on left atrial conduction velocity 
Initial experiments investigated the potential of moderate swim training induced 
cardiac remodelling. The majority of samples showed normal activation patterns 
as seen in Figure 6.10. A sample of 14 WT and 10 plako+/- mice were used in the 
training cohort. No changes in CV were observed between WT and plako+/- LA 
preparations from sedentary or trained young mice from activation maps. The CV 
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from the activation maps are presented in Figure 6.10C. The mean values for WT 
trained LA were 29.78 ± 1.34cm/sec, 24.44 ± 1.36cm/sec, 24.48 ± 1.36 cm/sec, 
and 22.87 ± 1.61cm/sec for stimulation CLs from 300ms to 80ms, respectively. 
The mean values for plako+/- trained samples were 29.50 ± 1.37cm/sec, 25.37 ± 
1.62cm/sec, 24.28 ± 1.69cm/sec, and 23.34±1.70cm/sec for 300ms to 80ms, 
respectively. In addition to this, no atrial changes in CV were detected from the 
swim training itself when compared to atria from sedentary mice. From Figure 6.11 
no significant changes in CV were determined from either the WT or plako+/- 
littermates post training. At certain CLs such as 120ms in both WT and plako+/- 
appear to have lower CV values, however, there was no statistical significance in 
this cohort.  
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Figure 6.10. Sedentary and swim trained activation maps. WT and plako+/- littermate 
left atrial maps stimulated at 100ms CL.  
Activation maps were generated from the LA of WT and plako+/- mice from both sedentary 
and swim trained cohorts. The top row shows samples which were sedentary for both 
genotypes and measured at 100ms CL. The sedentary CV values for WT and plako+/- 
were 23.68cm/sec and 26.44cm/sec, respectively. The bottom row shows samples which 
were swim trained for both genotypes measured at 100ms CL. The CV values for trained 
mice were 25.13cm/sec and 20.99cm/sec for WT and plako+/-, respectively. However, the 
measurements from the cohort of 13 WT sedentary, 14 WT trained, 11 plako+/- sedentary 
and 10 plako+/- trained LA showed that the training showed no significant effect on CV in 
both genotypes. The activation pattern of the LA showed no effects from the swim training 
in this cohort  
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Figure 6.11. Conduction velocity values in response to swim training in WT and 
plako+/- littermates.  
The data presented here compares the CV of the LA in a sedentary cohort to a trained 
group in both WT and plako+/-. A) Shows the mean CV values for the WT LA for sedentary 
and trained mice. B) Shows the mean CV values plako+/- LA for sedentary and trained 
mice. C) Compares the genotype differences as a result of swim training. The effect of 
training has shown no change in CV for LA measurements for both genotypes. Points 
indicate mean values with error bars representing SEM. Statistical analysis was 
performed using two way repeated measures ANOVA. 
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6.3.3. Effects on APD 
To test the effect of swim training further atrial AP changes in the LA were 
investigated. Comparisons between sedentary cohorts and trained cohorts were 
made as seen in Figure 6.12. The mean value for APD70 in WT sedentary mice at 
100ms CL was 12.04 ± 0.96ms compared to the trained value of 12.63 ± 0.61ms. 
For the plako+/- samples the values for APD70 were 12.04 ± 0.77ms for sedentary 
versus 13.06 ± 1.40ms trained at 100ms CL. All results showed a pattern of 
decreasing APD value with decreasing CL. 
Figure 6.12 shows the APD values for the sedentary and trained cohorts did not 
detect statistically significant changes for neither WT nor plako+/- at APD50 and 70 
in the LA. However, there was a significant increase in APD30 in WT mice due to 
training but not in plako+/-. Performing a Bonferroni post hoc analysis revealed that 
there were no statistical changes at specific CLs. Results show a slight trend in 
increased APD value due to training, but this showed no statistical significance.  
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Figure 6.12. Action potential duration differences in response to swim training in 
WT and plako+/- littermates.  
Data presented here compares the APD of the LA in a sedentary cohort of mice to a 
trained group. A) to C) Compares the effect of swim trained and sedentary mice at 
APD30, APD50 and APD70 in WT mice. D) to F) Compares the plako+/- genotype. The 
effect of training has shown no significant changes in APD for both genotypes with the 
exception of WT LA at APD30. Performing a Bonferroni post hoc test revealed that at 
there were no significant changes at individual CLs measurements for the WT mice at 
APD30. Significance is denoted by * P<0.05 comparing the sedentary samples to the 
swim trained. Points indicate mean values with error bars representing SEM. Statistical 
analysis was performed using two way repeated measures ANOVA. 
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Figure 6.13. Action potential duration differences between WT and plako+/- 
littermates after swim training.  
The effect of training was compared between WT and plako+/- samples. The APDs were 
measured at APD30, APD50 and APD70. Any changes across APD due to the effect of 
swim training were not witnessed. Points indicate mean values with error bars 
representing SEM. Statistical analysis was performed using two way repeated measures 
ANOVA.  
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6.3.4. Flecainide prolongs APD left atria after endurance 
training 
To determine the effects of reducing sodium channel activity in the LA. 1µM 
flecainide was added to WT and plako+/- littermates as described in the methods. 
The effect of flecainide has shown to prolong the APD significantly for WT pairs 
(n=7) as shown in Figure 6.14. Significance was calculated by performing 
repeated measures two way ANOVA. Bonferroni post test revealed that 
significance was found at all values bar APD30 at 300ms in the WT LA, 
suggesting the flecainide had a strong affect. The average increase after 
flecainide in WT at APD70 was 36%, 41%, 47% and 60% for CLs of 300ms, 
120ms, 100ms and 80ms, respectively. A trend in APD prolongation in the trained 
plako+/- was seen which did not reach significance in this cohort of 6 samples. The 
average increase in duration for the plako+/- atrial samples was 17%, 17%, 18%, 
and 16% for stimulation CLs of 300ms to 80ms, respectively. This percentage 
increase was much lower in the plako+/- than compared to WT. The smaller 
percentage change in plako+/- suggests that there may be less of a compounded 
effect from the flecainide and the swim training compared to WT samples. This 
raises further questions regarding sodium channels in the plakoglobin deficient 
model but investigations into this is beyond the scope of this study.  
6.3.5. Reduction in conduction velocity in the left atrium 
due to flecainide 
To investigate the effect of flecainide on the LA further, CV values were measured 
from WT and plako+/- pairs. The results show that there is a significant CV slowing 
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in the trained WT mice but not present in the plako+/- group. Significance was 
measured by repeated measures two way ANOVA, Bonferroni post hoc tests were 
also performed. The post hoc test revealed that the significance in the WT LA was 
at 100ms. On average the CV values dropped from 18 to 26% in the WT mice 
(n=6) and 13 to 22% in the plako+/- (n=7). The CV slowing due to flecainide can be 
seen in Figure 6.15.  
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Figure 6.14. Action potential duration increases in response to flecainide in swim 
trained mice.  
Paired data from WT and plako+/- sedentary and swim trained littermates were stimulated 
at decreasing CLs at baseline values and repeated with 1µM flecainide. A) to C) Shows a 
significant increase in APD in response to flecainide for WT trained LA samples. 
Bonferroni post test revealed that significance was found at all values bar APD30 at 
300ms in the WT LA. D) to F) Show a trend in increased APD with flecainide compared to 
control values. The effects of flecainide appeared to have a greater effect on the WT swim 
trained than the plako+/- mice. Significance is denoted by ** P<0.01 compared with the 
baseline and flecainide mean values.  
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Figure 6.15. Flecainide reduces conduction velocity measurements from left atrial 
swim trained mice. 
CV values were measured at baseline stimulation CLs and repeated with 1µM flecainide 
infusion. A) Shows a significant decrease in CV in WT trained mice after the addition of 
flecainide compared to at baseline. B) Shows a trend in decreased CV but this not 
statistically significant in plako+/-. Significance is denoted by * P<0.05. Performing 
Bonferroni post hoc test revealed that the significance in the WT LA was at 100ms. Points 
indicate mean values with error bars representing SEM. Statistical analysis was 
performed using two way repeated measures ANOVA. 
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6.3.6. Flecainide and refractoriness after endurance 
training  
To investigate the refractoriness effect of flecainide on the LA after swim training, 
WT and plako+/- littermates were stimulated with an extra early beat after a train of 
8 stimulations as described in the methods. The S2 protocol was performed at 
120ms CL at baseline and repeated after 15 minutes of 1µM flecainide infusion. 
Figure 6.16 shows that both the WT and plako+/- atria ERP were prolonged due to 
flecainide. WT (n=7) measurements were found to be 36.14 ± 3.60ms at baseline 
versus 48.71 ± 4.45ms flecainide. Plako+/- (n=5) ERP values were 43.20 ± 6.76ms 
at baseline compared to 54.00 ± 5.10ms with flecainide. Statistical analysis was 
performed using non parametric paired t-test (Wilcoxon matched pairs test) and 
significance was deemed at P<0.05. The plako+/- post training showed a longer 
ERP compared to LA plako+/- non trained (29.3 ± 0.9ms). The shorter ERP values 
in the sedentary plako+/- LA suggests that they may be more susceptible to atrial 
arrhythmias as there is a shorter time before the cardiomyocytes can be re-
excited. However, from unpublished data from the lab show that swim training 
increases its arrhythmia inducibility. This is an interesting find and warrants further 
investigation.  
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Figure 6.16. Effective refractory measurements in swim trained WT and plako+/- 
littermates before and after flecainide.  
The ERP of swim trained WT (n=7) and plako+/- (n=5) littermates were measured from the 
LA at 120ms CL. Measurements were taken at baseline and repeated after 1µM flecainide 
infusion. In the WT mice, mean ERP values increased from 36.14 ± 3.60ms to 48.71 ± 
4.45ms with flecainide. In the plako+/- samples, the mean values significantly increased 
from 43.20 ± 6.76ms to 54.00 ± 5.10ms. Significance is denoted by * (P<0.05). Statistical 
significance was calculated by paired Student’s t-test. Error bars indicate SEM. 
 
6.3.7. The effect of dihydrotestosterone on left atrium in 
sedentary models  
An application for the optical mapping was to investigate the effects of DHT in WT 
and plako+/- littermates. The use of DHT as a doping agent may cause structural 
remodelling such as fibrosis and atria of the plako+/- model may be more 
susceptible to adverse effects. The mice were implanted with osmotic pumps as 
described in the method chapter. Optical mapping experiments were performed on 
isolated LA littermate pairs to measure CV and APD values. Figure 6.17 illustrates 
the isochronal maps for both WT and plako+/- LA samples with DHT.  
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Figure 6.17. Sedentary DHT left atrial activation maps.  
LA activation maps were generated from samples stimulated at 100ms CL from WT and 
plako+/- littermates. Osmotic pumps were filled with DHT and implanted in the mice over a 
period of 42 days. The atrial CV from both genotypes showed no significant differences 
between genotypes. Samples were measured from 5 WT and 3 plako+/- mice LA with 
DHT. However, due to the low sample size, the results presented here were not 
conclusive and warrant more experimentation. 
 
6.3.8. Conduction velocity differences in murine models 
exposed to DHT  
The atrial CV values as assessed with optical mapping were unchanged when 
comparing samples with DHT exposure to sedentary samples. The data presented 
is from 5 WT DHT treated mice and 3 plako+/- DHT samples. Figure 6.18 illustrate 
the CV values and show no significant change in mean values between DHT and 
sedentary and genotype differences with the DHT pumps implanted. The mean 
values for the CV values for the WT DHT littermates were 32.65 ± 0.99cm/sec, 
28.05 ± 1.98cm/sec and 25.14 ± 1.84cm/sec and 23.08 ± 2.3cm/sec. For the 
plako+/- DHT mean values: 29.72 ± 2.94cm/sec, 27.19 ± 2.11cm/sec, 24.48 ± 
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2.3cm/sec and 22.88 ± 1.92cm/sec for CLs of 300ms, 120ms, 100ms and 80ms, 
respectively.  
6.3.9. APD prolongation in the left atrium with DHT  
Figure 6.19 shows a comparison between the sedentary cohorts of mice with and 
without DHT pumps implanted. The mean values for APD values for the plako+/- 
LA samples showed a prolongation. At 70% repolarisation mean values for plako+/- 
sedentary mice without DHT (n=11) stimulated at 100ms CL was 15.85 ± 1.94ms 
compared to 12.04 ± 0.77ms with DHT (n=3). Significance was calculated by two 
way repeated measures ANOVA. Performing Bonferroni post hoc test revealed 
that the main contributor of significance between the DHT and control were due to 
the 300ms CL at all APD values in plako+/- and at 120ms at APD30. The post hoc 
test suggests that the DHT mainly affect the LA during slower stimulations. 
However, more experiments should be repeated for higher statistical power due to 
the small sample size (n=3) and variability in experiments.  
A change was seen at APD30 in the WT cohorts (n=13) from 6.28 ± 0.45ms to 
8.97 ± 0.86ms with DHT (n=5), but no statistical differences were found at other 
APD values. Post hoc analysis revealed that the point of greatest significance was 
measured at 100ms in APD30 in the WT. Figure 6.20 show the changes in APD 
values seen with the addition of DHT were not significantly different between the 
WT and plako+/- genotypes.  
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Figure 6.18. Atrial conduction velocity values remain unchanged in response to 
DHT.  
The data here compares WT and plako+/- littermates with DHT osmotic pumps implanted 
to sedentary WT and plako+/- littermates. A) Shows the effect on CV in WT mice. B) The 
effect of DHT implanted plako+/- mice is compared to plako+/- sedentary LA samples. C) 
Comparisons between the WT and plako+/- LA CV show no difference between genotypes 
with DHT. Due to the low sample size with DHT, the results were not conclusive and 
warrant more experimentation. Points indicate mean values with error bars representing 
SEM. Statistical analysis was performed using two way repeated measures ANOVA. 
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Figure 6.19. Atrial action potential duration changes compared between sedentary 
control and sedentary DHT mice.  
The data presented here show sedentary WT and plako+/- littermate cohorts compared to 
littermates with DHT osmotic pumps implanted. A) to C) shows comparisons between WT 
mice with a trend in APD at APD50 and APD70. APD30 shows a significant increase in 
duration. Post hoc analysis revealed that the point of greatest significance was measured 
at 100ms in APD30 in the WT. D) to F) Presents the comparison between control groups 
and DHT samples. Significant increases was seen for all APD values. Performing 
Bonferroni post hoc test revealed that the main contributor of significance between the 
DHT and control were due to the 300ms CL at all APD values in plako+/- and at 120ms at 
APD30. Significance across the board is denoted by * P<0.05 when comparing mean 
values of sedentary and DHT littermates. Points indicate mean values with error bars 
representing SEM. Statistical analysis was performed using two way repeated measures 
ANOVA.  
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Figure 6.20. Action potential duration in the left atrium of WT and plako+/- littermates 
in mice with DHT osmotic pumps implanted. 
The data presented here compares the APD of the LA from both WT and plako+/- that 
have been implanted with osmotic mini pumps. The pumps were filled with DHT for the 
duration of 42 days. A) to C) Compares the APD values at APD30, APD50 and APD70, 
respectively. The effect of DHT showed no significant changes on APD value. Due to the 
low sample size with DHT, the results were not conclusive and warrant more 
experimentation. Points indicate mean values with error bars representing SEM. 
Statistical analysis was performed using two way repeated measures ANOVA.  
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6.4. Discussion and conclusion 
The aim of this chapter was to apply the high resolution optical mapping system 
and the analysis algorithms to characterise LA electrophysiology of a genetically 
altered mouse model. Optical mapping was used to investigate the functional and 
structural differences between WT and plako+/- LA physiology. The effects of 
endurance training on the LA and the use of acute flecainide and chronic DHT 
were also tested.  
6.4.1. Effects of plakoglobin deficiency 
Optical mapping of the LA of the WT and plako+/- sedentary littermates did not 
reveal any measurable changes in activation pattern, CV and APD. ARVC mainly 
affects the RV giving rise to its name, but it has been shown that the left ventricle 
can also be affected [143]. As such it was suspected that there may be atrial fibro-
fatty replacement or atrial dilation due to the heterozygous deficiency of the 
plakoglobin protein which could cause conduction defects. A study has shown that 
the electrophysiological abnormalities precede structural changes in ARVC in 
desmoplakin deficient mouse models [164]. This was also shown to be true in 
human ARVC [165]. The sodium current is responsible for the upstroke phase of 
the action potential. The maximum upstroke velocity is used here to calculate the 
start of the action potential (starting time point for the APD measurements). A 
small change may be undetectable using the current optical mapping system. 
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6.4.1.1. Effect of flecainide 
Flecainide was used to establish whether CV and APD were altered preferentially 
in atria isolated from plako+/- mice. Some ARVC phenotypes have been shown to 
have lower Nav1.5 channel expression [146]. It was expected that flecainide 
would show an enhanced selectivity in plako+/- atrium compared to WT. Figure 6.6 
shows that the APD is prolonged in both genotypes. The use of 1µM flecainide 
caused some difficulty in obtaining analysable images from the optical mapping 
system as it also caused the atrial myocardium to occasionally ignore stimulus 
events. As a result, the number of analysable experiments was reduced and 
hence more experiments are required in the future. Figure 6.7 shows that the CV 
is reduced for the LA of both genotypes during flecainide with no selectivity to 
plakoglobin. It was hypothesised that with the possible dysfunction in the sodium 
channels in ARVC hearts and possible desmosomal damage, the effect of 
flecainide could be greater in the plako+/- atrium. The activation maps in Figure 6.8 
show a large change in pattern with flecainide compared to control samples. There 
were many areas of late activation due to the slow CV but no indications that 
specific patterns arise from genotype related incidences.  
The ERP was measured at one CL of 120ms for a sample size of 3 from each 
genotype (Figure 6.9). It revealed that flecainide did not significantly increase the 
ERP in WT mice. This result was surprising as flecainide prolongs the time for 
sodium channels to re-open after the blockade [151] and thus increases the ERP. 
There was a significant increase in ERP in the plako+/- mice compared to the WT 
mice with the presence of flecainide. As genetic alterations in the desmosomal 
macromolecular complex were shown to cause dysfunction in the sodium 
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channels, it is possible that the addition of flecainide significantly increases the 
threshold voltage leading to an increase in ERP [163]. The increase in ERP is 
likely to be protective against any atrial arrhythmias as this limits the opportunity 
for cardiomyocytes to be re-excited. However, concrete conclusions from the low 
sample size cannot be drawn. Performing power calculations will be warranted to 
determine the necessary sample size required for statistical significance for future 
experiments. 
6.4.2. Effects of controlled endurance training 
Assessment of the effect of training in WT and plako+/- littermates was made using 
optical mapping. There were no changes between the activation patterns (Figure 
6.10) or any obvious irregularities in the LA. CV measurements showed no change 
as a result of swim training in the LA of either genotype (Figure 6.11). A previous 
study [64], [114] showed plako+/- trained mice developed arrhythmias and CV 
slowing in the RV. It was hypothesised that these effects may have been 
witnessed in the LA as a recent study showed an increase in protein expression of 
fibrotic markers in the ventricles and atrium in trained rats [154].  
The atrial APD vales were not significantly different as a result of training. 
Arrhythmias have been shown to be increased in trained humans [156] and 
mouse models [64]. It appears that the swim training had little effect on atrial 
electrophysiology as described by optical mapping in this study. One limitation of 
this study was possibly the only mild to moderate intensity of the swim training. 
However, the activity scores were reviewed to ensure that the mice were 
swimming sufficiently and mice that were floating were encouraged to swim. The 
study performed by Benito et al had rats trained using treadmills for up to 5 days a 
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week for 16 weeks. In the study by Benito et al, treadmills provided an electric 
stimulus on a grid which was placed at the end of the lane to ensure the rats were 
running at speeds up to 60cm/sec for 60 minutes. This speed and duration is a 
considerable amount for a rodent. In our study, it could be argued that intensity of 
training was milder compared to the training performed by Benito et al. The 
swimming sessions also ran for a shorter period of time (6 weeks) which may not 
have been long enough for any hypertrophic or cardiac dysfunctions to be 
observed. It is therefore possible that a longer and more intense swim training 
protocol may reveal underlying differences in electrophysiological properties. 
Swim training was the preferred method in this study as equipment was easily 
obtainable but running may be more intense and likely to reveal cardiac 
dysfunctions. It should be noted that the severity of endurance training is limited 
by regulations of the biomedical services unit and that the welfare of the mice 
were not caused excessive stress during the swim training. Histological 
techniques are the gold standard for measuring fibrosis and hypertrophy but it has 
been shown that electrophysiological changes can occur before any histological 
ones [164], [165]. Therefore the use of techniques such as optical mapping may 
provide earlier insight into disease characteristics before they are measurable in 
histology.  
6.4.2.1. Effects of flecainide 
As no changes in baseline electrophysiology were shown in the LA of trained mice 
compared to sedentary mice, it was hypothesised that flecainide coupled with the 
swim training could highlight any subtle electrophysiological changes between the 
two genotypes. Indeed, some ARVC patients have been shown to have a reduced 
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sodium channel expression [146]. Figure 6.14 shows that with the addition of 
flecainide, the APD was significantly prolonged (p<0.01) in the WT trained atria 
and displayed a trend in APD prolongation in the plako+/- samples. It was expected 
that flecainide may show a more pronounced effect in the plako+/- atria especially 
compounded with any effects of swim training. The addition of flecainide should 
cause a sodium channel block, prolonging the depolarisation, increasing the 
refractory period and reducing CV [151]. Whilst these results were unexpected, 
there were biological variations within the samples and the training as discussed 
earlier. However, using these results for preliminary data allows for planning of 
future experiments such as statistical power to determine the number of samples 
required.  
Our experiments also found that using a total of 24 LA samples (14 WT and 10 
plako+/-), only 13 flecainide experiments were successful (6 WT and 7 plako+/-) in 
the trained mice. In the sedentary cohort, there was a total of 25 samples (13 WT 
and 12 plako+/-), where 9 experiments with flecainide were successful (5 WT and 4 
plako+/-). Flecainide increases the threshold potential required to invoke a 
depolarisation [163]. As a result of the increased potential, stimuli were often not 
evoked by the stimulator in some of the experiments. The effect of flecainide on 
the sodium channels increases with the heart rate, known as use-dependence 
[44], [166]. As a result of the use-dependence, action potentials at the shorter CL 
(100ms and 80ms) were difficult to stimulate. If no action potentials were evoked, 
the protocol was repeated but failure to do so after several attempts lead to 
experimental loss. Different concentrations of flecainide may be investigated in 
future to find the optimal dosage.  
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ERP measurements (Figure 6.16) were collected and showed an increase in both 
genotypes after training at 120ms CL. These results were expected as flecainide 
causes a reduction in sodium channel activity, thus lengthening refractoriness of 
the atrial tissue. As the CV was not significantly lengthened, it appeared that 
flecainide may prove to be protective against arrhythmias by increasing the 
wavelength [167]. As wavelength is the product of CV and ERP, an increase in 
either of these values increases the wavelength value. Re-entry is favoured by 
shorter wavelengths as a travelling impulse has a greater window of opportunity to 
re-excite another cell which can cause an arrhythmia [32]. The ERP results 
showed no significant change in the WT LA after flecainide, however, there was 
an increase in ERP with the plako+/- with flecainide. A greater change in the 
plako+/- atrium was expected as it was thought to have fewer sodium channels 
[146] which may cause flecainide to saturate the number of available channels. 
Atrial ERP in plako+/- samples for the sedentary LA were shown to be lower 
compared to the trained samples. A longer ERP is believed to be protective 
against arrhythmias as it limits the time a cardiomyocyte can re-excite. The longer 
ERP in the trained plako+/- compared to WT suggests that the swim training had a 
protective effect, however, there exists variability within the plako+/- LA samples 
post training and the sample size of the plako+/- LA sedentary was only 3.  
6.4.3. The effect of DHT and plakoglobin deficiency 
APD and CV values were measured from sedentary mice with DHT osmotic 
pumps implanted from both WT and plako+/-. These mice were compared against 
sedentary mice without DHT. CV values showed no change in the presence of 
DHT. This is surprising as previous studies have shown that DHT administration 
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induces hypertrophy [160], [168], [169]. As a result, the propagation of an action 
potential can be reduced. 
 When comparing the APD values, the plako+/- LA shows a slight but significant 
prolongation in with DHT treated atria. Bearing in mind the experimental number 
was low (n=3), this cannot be considered confirming evidence. A prolongation was 
also seen in the WT at APD30, but neither at APD50 nor APD70 which may be 
due to statistical chance. The dosage of 62.5mg/ml of DHT and ethanol was used 
as it was deemed sufficient to yield a supraphysiological dose used in literature 
[170]. It should be noted that mice will have a baseline value of testosterone and 
any addition of DHT may act as a surplus. Nevertheless, no alterations in cardiac 
electrophysiological parameters were observed in our studies. However, bearing 
in mind the low experimental numbers (n=3), further experiments are required in 
order to reach statistically meaningful conclusions. The low sample size was due 
to time and resource limitations. 
 The future work for investigating DHT in plako+/- LA will include: repeating the 
experiments with larger sample groups, administering placebo pumps with no DHT 
and finally, a cohort of littermates which have been endurance trained. The 
endurance training and DHT may prove relevant to athletes doping.  
6.4.4. Overall conclusions on plako+/- mouse studies 
 APD and CV measurements in the LA showed no significant change 
between WT and plako+/- mice without training.  
o It was hypothesised a reduced CV in the plako+/- but 
electrophysiological changes may have been too small to detect. 
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 Untrained mice showed an increase in APD and a reduced CV in the LA 
after treatment with flecainide for both genotypes. 
o Flecainide had not shown a preferential treatment in either genotype, 
however, the plako+/- LA data shows greater variability within the 
APD values. If differences between the genotypes are small, the 
biological variation between samples may greater and hence not 
detectable.  
 Flecainide prolongs the ERP in plako+/- sedentary LA samples.  
o The prolongation of the ERP indicates a protective effect against 
arrhythmia inducibility after flecainide.  
 APD and CV measurements show no significant change in the LA of swim 
trained mice.  
o It was hypothesised that the effect of training would exacerbate the 
ARVC like phenotype but previous studies have shown strong 
effects of endurance training in the form of running. It is likely that 
the swim training involved required increased intensity to witness 
these effects.  
 Flecainide prolongs APD in WT LA samples after training 
o The prolongation was expected to be seen in the plako+/- LA also, 
but biological variations exist between each mouse and the efficacy 
of training severity may have contributed to this finding.  
 Flecainide prolongs the ERP in WT and plako+/- LA samples after training. 
o A short ERP is seen to be favourable to arrhythmic activity hence 
flecainide may protect against this.  
 ERP in plako+/- trained (n=5) LA is greater than untrained (n=3).  
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o This was unexpected as training was assumed to enhance 
arrhythmia inducibility. However, variations in training and low 
sample sizes warrant further study. These results may be used to 
determine the sample sizes necessary for power calculation 
statistics.  
 Untrained mice treated with DHT show a slight increase in APD for plako+/- 
LA but no changes in CV were observed in either genotype.  
o Low sample sizes (n=5 and 3 for WT and plako+/-, respectively) limit 
conclusive results. Further studies should include placebo vehicle 
pumps but also cohorts after training to mimic athletic steroid doping.  
Overall, the effect of training did not yield significant changes as expected which 
has led to question the efficacy of the training regime compared to other studies. 
The effect of flecainide on the plakoglobin deficient model yielded some 
unexpected results. This raises further questions regarding sodium channels in the 
plakoglobin deficiency model but investigations into this is beyond the scope of 
this study.   
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 Discussion 
7.1. General Outcomes  
The main aim of this thesis was to develop an optical mapping system which could 
be used to investigate the electrophysiological properties of mouse models. These 
investigations were performed using an off the shelf camera with a high spatial 
resolution to study isolated left atrial (LA) samples from genetically altered murine 
models of heart disease. The outcomes of this thesis were: 
 The high spatial property of the camera has led to further studies on the 
electrophysiological heterogeneity of the LA (see Appendix 1) along with 
regional differences in ion channel expression which has led to a 
publication – see Appendix 2.  
 Development and automated analysis of optical mapping data. The 
algorithms implemented allowed for analysis without user bias. Action 
potential duration (APD) values were automatically determined from 
fluorescence data from pre-selected regions. Conduction velocity (CV) 
values were calculated automatically from isochronal maps derived from 
time series images. This has led to publications in Appendix 3 and 
Appendix 4.  
 Pitx2c+/- mice showed a shorter APD value than their wild-type (WT) 
littermates. This data confirms previous findings of a shorter APD in the 
Pitx2c+/- LA with respect to WT [55]. 
 165 
 
 The use of flecainide indicated a more pronounced effect to Pitx2c+/- mice 
LA, showing a possible reason for its efficacy for certain patients. This work 
contributed to a publication which is currently under review – Appendix 5.  
 Optical mapping was applied to a Plakoglobin+/- deficient model to 
characterise CV and APD after chronic and with acute interventions. 
o No significant changes were witnessed in LA of untrained cohorts at 
baseline and with flecainide treatment.  
o The effect of swim training showed limited changes between 
genotypes in APD and CV but a prolongation in atrial ERP after 
flecainide treatment.  
o Plako+/- untrained mice treated with DHT showed a prolongation in 
atrial APD. These findings were preliminary as larger sample sizes 
were required and cohorts of trained and placebo pumps need to be 
studied.  
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7.2. Optical mapping applications on cardiac 
electrophysiology 
The system makes use of new imaging technology, namely a high-resolution 2nd 
generation CMOS camera, to achieve high temporal and spatial resolution of 
electrical activation and repolarisation in the murine atrium. It was demonstrated 
that recording was feasible using the system and shown that the measurements 
yield comparable action potential waveforms and action potential durations when 
compared to monophasic and transmembrane atrial action potentials. 
Furthermore, it was shown that the system was capable of detecting changes in 
conduction velocity and functional conduction block. In our hands, the 
oversampling of recordings allowed us to maximise the information collected in 
each experiment, as a higher spatial resolution is conducive to the detection of 
small activation changes. Larger sampling areas needed for the assessment of 
atrial repolarisation, as a higher signal to noise ratio may be needed to accurately 
determine the APD. In addition to this, the algorithms used were useful in reducing 
the time needed for a user to analyse APD measurements and produce activation 
maps. For example, to correct for baseline shifts, it is common to fit a linear or 
polynomial equation to the signal [124]. In the experiments, these baseline shifts 
were extremely variable. Therefore, a different approach to existing correction 
methods was used. Here a common top hat filter which was normally applied to 
2D images but was used on a 1D signal on our action potentials. Another example 
was the detection of t=0 on the isochronal maps. It proved to be a useful tool for 
speeding up analysis and for limiting user bias. 
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Assessment of murine atrial electrophysiology is an essential tool to understand 
the functional consequences of defined genetic modifications, including complex 
gene expression changes e.g. secondary to altered function of transcription 
factors [55], [74], [135] or the effects of inhibitory or regulatory RNA molecules. 
Environmental factors such as the effect of training, interventions and chronic or 
acute drug treatment [114], [171] can be assessed with the increased number of 
pixels in this system in the future, including larger and irregular specimens. The 
increased spatial resolution in this system also allowed for the identification of 
heterogeneities within the tissue. Imaging of murine embryos should also be 
possible with this system [172].  
By building an optical mapping system around a novel 2nd generation 
oversampling high-resolution CMOS camera with high light sensitivity, the system 
was able to record electrical activation and repolarisation with high accuracy and 
reliability, yielding information that reflects murine atrial biology. The ORCA 
camera has recently been used and shown to capture action potentials in 
spontaneously spiking human embryonic kidney (HEK) cells [173]. Signals from 
HEK cells occur at approximately 3 APs per second. The pacing rate applied in 
our experiments in live intact organ tissue was much higher and represented a 
higher challenge to the camera resolution. The validation data suggested that the 
system reliably recorded atrial repolarisation, making it attractive for the study of 
arrhythmia mechanisms in genetically altered murine models that mimic inherited 
arrhythmogenic diseases and/or replicate common gene expression changes 
associated with common cardiac diseases.  
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7.3. Technical aspects of optical mapping 
Optical mapping of mouse hearts has been used to characterise arrhythmia 
mechanisms since the beginning of this century. Initially, systems were developed 
to measure ventricular activation and repolarisation [174], [175], and more recently 
expanded to atrial preparations [55], [176], [177]. One of the most commonly used 
systems is the custom-made SCIMEDIA system that provides a 100x100 pixel 
field at high temporal resolution (Bezzina et al., 2013; Kirchhof et al., 2011). 
Especially at high sampling rates, the relatively low signal strength generated by 
the thin murine atrial tissue proved to be challenging. The system developed and 
validated here used an emerging technology, namely the 2nd generation CMOS 
detector. The camera was capable of detecting low amplitude light signals at 
superior spatial resolution (128x2048 pixels) and good temporal resolution (1-2 
kHz). A higher temporal resolution was needed when capturing quick cellular 
changes, such as AP depolarisation. A higher spatial resolution was desirable 
when trying to precisely locate phenomena changing at a lower rate. With this 
resolution span, each individual pixel provided a signal with a relatively low SNR, 
due to the limited number of light emitting events of the recorded tissue. The 
spatial oversampling of the signals during data acquisition allowed for the post-
processing of signals to optimise the information per pixel. Specifically, a high 
spatial resolution was used to assess atrial activation with optimal accuracy and 
an acceptable SNR. The employed algorithm for correcting the baseline fluctuation 
was robust to all types of – sometimes random – changes in baseline 
fluorescence, thus increased the reliability of the measurements and the yield of 
analysable experiments. Reliable assessment of repolarisation, in contrast, was 
possible using combination of individual signals in the analysis phase, thereby 
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sacrificing some of the spatial resolution, and by signal averaging during steady 
state pacing. Thus, the proposed new, versatile system allowed for the adjustment 
of image parameters after the end of the experiment to suit specific analysis 
needs, therefore increasing the information yield from each experiment.  
This system was capable of recording valid action potential waveforms over a 
wide range of paced cycle lengths (CLs), and with simultaneous recording of 
APDs from all regions of the LA. Using the post-processing methods described 
above, this system will provide detailed insights into the regional differences in 
atrial action potential duration, and their change in genetically modified models. 
The preparation used here was stable over experimental protocols of 1 to 1.5 
hours duration, demonstrating that superfusion of the murine atrium is adequate to 
maintain the integrity of the superfused atrium during acute interventions such as 
antiarrhythmic drugs at bradycardic and physiological CLs. Automated analysis of 
APD and activation patterns was another important feature of the present system. 
The stage where user input was required for cropping of the images could have 
been automated as the LA was the only object within the field of view, but was left 
as manual cropping as it allowed for flexibility in future applications. The camera 
acquisition rate was not dependent on the larger horizontal pixel size, so multiple 
samples or filters can be simultaneously imaged, hence cropping different regions 
may prove advantageous for these types of experiments.   
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7.4. Limitations and future developments 
7.4.1. Experimental limitations 
The optical mapping system makes use of voltage sensitive dyes. These dyes 
have many advantages over other electrophysiology techniques and are an 
important tool, but little is known about their effects on cardiac tissue. In order for 
dyes to function, there is always an interaction on the cellular level. Di-4-ANEPPS 
is one of the most used dyes, but there have been studies to show 
electrophysiological changes associated with the dye such as decreased APD 
value and slowed conduction velocity [102], [179]. Di-4-ANEPPS show some level 
of internalisation [100] which at increased illuminations showed an increase in 
temperature and phototoxicity [89], [179]. The effect of heat has been shown to 
significantly affect the characteristics of atrial myocytes [180]. These should be 
considered when attempting optical mapping experiments. The use of electro-
mechanical uncouplers such as blebbistatin may have an effect on the outcome of 
results. A recent study showed that blebbistatin has the ability to precipitate and 
accumulate in the vasculature [181], although this may have proved to be less 
significant in a superfusion system and proves to be an important tool in optical 
imaging [117].  
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7.4.2. Future Work 
Due to the multidisciplinary aspects of this project, it can be lead into multiple 
avenues which include: 
 Combined calcium imaging – The optical mapping system has already been 
modified for it to be used for calcium imaging using Rhod-2 acetoxymethyl 
ester derivative including software changes. As the Hamamatsu Flash4.0 
camera has the ability of imaging with a 2048 pixel width, the system can 
be modified to image both voltage and calcium simultaneously including the 
software generation for analysing both types of images (see appendix for 
submission by Holmes et al).  
 Improved experimental numbers for DHT investigation – the sample size for 
the plako+/- models was low which limited statistical reliability. Repeating 
these experiments with a larger cohort and placebo control groups will be 
necessary for both sedentary and swim trained.  
 Increased number flecainide samples – for both Pitx2c+/- and plako+/- 
cohorts the sample size with flecainide decreased. Techniques to avoid 
experimental loss need to be investigated such as varying dosage of 
flecainide. Another aspect may be to develop a method of stimulation to 
increase voltage at short CLs as the rates at 100ms and 80ms often missed 
stimulations.  
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Appendices 
Appendix 1 - Ectopic activity and arrhythmias due 
to left atrial APD heterogeneity.  
Introduction  
This chapter discusses an additional application of the optical mapping system 
applied to investigate the heterogeneity of action potentials across the whole left 
atrium (LA). The investigations of this chapter have led onto further developments 
of the optical mapping system to analyse calcium transient heterogeneity. In 
addition to this, channel expressions were measured from multiple sections of the 
LA. Calcium imaging and ion channel expression measurements were performed 
by other research lab members and not the author of this thesis. The main 
advantage of the optical mapping system presented here is its high spatial 
resolution. Other advantages over contact methods such as microelectrode and 
MAP electrodes include the ability to measure multiple regions of interest from a 
single image acquisition hence it is an ideal method for investigation of action 
potential duration (APD) variation. The optical mapping system was used to 
calculate APDs for each pixel and to generate a map, representing the distribution 
of APD value.  
The heterogeneity of the LA is of interest as the pulmonary vein region has been 
proposed as a key anchorage point for re-entrant activity in atrial fibrillation (AF) 
[182], [183]. Other studies have shown that a gradient or heterogeneity and high 
frequency activity in the atria contribute or help maintain AF [184], [185]. Mapping 
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studies have shown that the complicated 3D nature of the atrium is a key 
component of the activation patterns during AF [186]. It is also hypothesised that 
the activation and repolarisation of characteristics of the left atrial pulmonary vein 
(LA-PV) region differs from the rest of the LA [187], which indicates a susceptibility 
to conduction slowing.  
The development of the pulmonary vein area in the LA is subtly different to the left 
atrial appendage (LAA). The LAA forms an outfacing pouch of the primary heart 
field and the LA-PV develops from the left posterior second heart field [188], [189]. 
Structurally, the two regions are also distinct with the LAA exhibiting clear 
pectinations compared with the relatively smooth walled LA-PV, relating 
functionally to differences in contraction [190]. It is becoming apparent that a 
heterogeneous electrical arrangement may act a substrate for arrhythmic activity. 
Regional cellular electrical differences in the right atrium have been characterised 
in both animals [191], [192] and humans [193], including detailed analysis of the 
sinoatrial node, the atrioventricular node region and the conduction system [194], 
[195] but few studies have been performed on small tissues such as murine LA. 
Here we investigate the APD heterogeneity of the LA to identify 
electrophysiological variations within tissues.  
We have used optical mapping to contribute to a larger study whereby 
microelectrodes were also used to measure APD variations across the different 
regions of the LA. In addition to this, ion channel expressions were measured to 
study the profile in multiple regions of the LA. The results and findings for these 
were compiled in a research paper titled “A Regional Reduction in Ito and IKACh in 
the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential 
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Prolongation and Increased Ectopic Activity” (see Appendix - 2) but only the 
optical mapping techniques and results are discussed in this chapter.  
Methods 
Mouse LA samples were collected as described in the materials and methods 
chapter. The samples were then stimulated as described in material and methods: 
Stimulation protocol along with the optical mapping technique. 18 mice from an 
MF-1 background were used in this cohort. Images were analysed using MATLAB 
algorithms as described in Optical mapping design and development: Action 
potential duration maps. 
Results  
Using the high-spatial resolution optical mapping system we were then able to 
characterise the regional changes in AP repolarisation across the whole LA in 
greater detail. For these experiments, images were recorded from LAs isolated 
from male MF-1 mice (n=18 LA). An example raw fluorescent image is shown in 
Figure 1A and the corresponding isochronal APD70 and APD50 distribution maps 
for this LA, paced at 10Hz, were presented in Figure 1B. Characteristic example 
OAPs recorded from each of the 9 regions within a single LA are shown in Figure 
1C. The most obvious finding was that OAPs in the LA-PV (regions 1-3) were 
significantly longer than other LA regions (Figure 1D). In addition, APD70 times 
were significantly different between segments 1 and 3 (Figure 1D), suggestive of 
considerable APD heterogeneity within the LA-PV region that was not apparent in 
the mid or lateral LAA. A summary of the mean 9 region APD70 spatial distribution 
is presented in Figure 1E. 
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Figure 1. High spatial resolution action potential duration distribution patterns in 
the murine left atrium 
A) Raw fluorescence image of a LA loaded with di-4-ANEPPS, along with the 9 region 
grid used for regional analysis. B) Corresponding high spatial resolution isochronal action 
potential duration (APD70) distribution map. C) Example action potentials recorded from 
the 9 different LA regions during 10Hz pacing. Green dotted line indicates APD70. D) Box 
and whisker plot of APD70 values measured in each LA region. +, † and * denote P<0.05 
vs region 1,2 and 3, respectively, one way repeated measures ANOVA with Bonferroni 
post hoc analysis. (N=18 LA). (E) 9 region map depicting mean APD70 values, ± SEM, in 
the 9 regions of the LA.  
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Discussion 
Here we demonstrate an important application of the high resolution mapping 
system which other techniques fall short. We show that the regions 1-3, the PV 
area may be an important source of ectopic activity in the mouse LA. The PV 
region shows unique characteristics of a prolonged APD. Additional data gathered 
from the research group also shows increased action potential amplitude and 
upstroke velocity. Using the optical mapping system, we display APD distribution 
maps of the murine LA in high detail and identify that in addition to APs being 
longer, the LA-PV also exhibits increased intra-regional APD heterogeneity. As a 
result of these findings, this led onto further research investigating calcium 
handling and ion channel expression. The expression profile for the ion channels 
proved to be significantly different between the LA-PV and lateral wall of the LAA 
regions. Calcium relaxation time distribution maps were also analysed in an intact 
murine LA and identified that calcium clearance is protracted in the LA-PV. In 
addition, the LA-PV has a slower rate of calcium release. These findings may 
provide some insight into the possible causes of the heightened susceptibility to 
ectopy and the altered electrical properties and calcium handling. 
Our findings were consistent with the idea that the atrial LA-PV myocardium is a 
source of focal ectopic activity in the LA, given that all measured ectopic activity 
was abolished after LA-PV resection. In our experiments, the pulmonary vein, a 
common source of ectopic activity [196] was removed before experimentation, in 
order to evaluate specifically the electrical properties of the atrial myocardium. 
Nevertheless, it is possible that some elements of LA-PV myocardium were 
derived from the dorsal mesocardium and developing pulmonary vein sleeve, as it 
 194 
 
infiltrates to fuse and form the posterior LA wall [197]. Thus, some spontaneous 
activity that we observed may be a consequence of localised regions of pulmonary 
vein-like myocardium that has been incorporated into the LA-PV atrial 
myocardium. Importantly, since most, but not all atrial fibrillation is terminated in 
patients following pulmonary vein isolation [198], [199], it is conceivable that this 
region gives rise to the ectopic activity accounting for some cases of atrial 
fibrillation recurrence.  
Despite a number of important studies reporting APD variation in the right atrium 
in animals [191], [192] and humans [193], little is known about APD variation in the 
LA. Recordings of TAPs and OAPs were used in this study to observe regional 
differences in LA APD. The high resolution optical mapping system allowed us to 
develop and observe APD distribution maps of the murine LA in detail. The APD70 
distribution maps show that APs in the LA-PV region were prolonged in 
comparison to the rest of the LA. The prolonged APD in the LA-PV could promote 
the development of focal ectopic activity in this area of atrial myocardium most 
likely by increasing the probability of calcium channel recovery and reactivation 
thereby provoking calcium mediated early-after depolarisations [46]. OAP analysis 
also revealed significant APD heterogeneity within the LA-PV. This possibly 
correlates with a previous investigation where changes in effective refractory 
periods in response to vagal stimulation were most variable in the LA-PV region 
[187]. The increase in APD heterogeneity in this region could contribute to the 
heightened susceptibility of the LA-PV to develop and establish re-entrant circuits 
following the emergence of triggered activity [46], [55].  
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Appendix 2 - A Regional Reduction in Ito and IKACh 
in the Murine Posterior Left Atrial Myocardium Is 
Associated with Action Potential Prolongation and 
Increased Ectopic Activity.  
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Appendix 3 - Optical mapping design for murine 
atrial electrophysiology.                     
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Appendix 4 - An automated system using spatial 
oversampling for optical mapping in murine atria. 
Development and validation with monophasic and 
transmembrane action potentials.  
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Abstract 
Background Antiarrhythmic drugs are widely used to treat patients with atrial fibrillation, 
but the mechanisms conveying their variable effectiveness are not known. Recent data 
suggest that PITX2 may have an important role in regulating gene expression and 
electrical function of the adult left atrium. 
Objectives We determined left atrial PITX2 expression in AF patients requiring rhythm 
control therapy. We furthermore assessed the effects of PITX2 on left atrial 
electrophysiology and the effect of antiarrhythmic drugs. 
Methods Left atrial PITX2 mRNA levels were measured in 95 patients undergoing 
thoracoscopic AF ablation. The effects of flecainide, a sodium channel blocker, and d,l-
sotalol, a potassium channel blocker, were studied in littermate mice with normal and 
reduced PITX2 by electrophysiological study, optical mapping, and patch clamp studies. 
PITX2-dependent mechanisms of antiarrhythmic drug action were studied in HEK cells 
expressing human Na channels and by modelling human action potentials. 
Results Flecainide (1µmol/L) was more effective in suppressing atrial arrhythmias in atria 
with reduced PITX2 mRNA levels (Pitx2c+/-). Resting membrane potential was more 
depolarized in Pitx2c+/- atria, and TASK-2 gene and protein expression were decreased. 
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This resulted in enhanced post-repolarization refractoriness (refractoriness beyond 90% 
repolarisation) and a more effective sodium channel inhibition. Defined holding 
potentials eliminated differences in flecainide’s effects between wildtype and Pitx2c+/- 
atrial cardiomyocytes. More positive holding potentials replicated the increased 
effectiveness of flecainide in blocking human Nav1.5 channels in HEK293 cells. Computer 
modelling reproduced an enhanced effectiveness of sodium channel block when resting 
membrane potential was slightly depolarized. 
Conclusions PITX2 modulates atrial resting membrane potential and thereby alters the 
effectiveness of Na channel blockers such as flecainide. PITX2 and ion channels regulating 
the resting membrane potential may provide novel targets for antiarrhythmic drug 
development and companion therapeutics in AF. 
 
Abbreviations 
AAD- Antiarrhythmic drug 
Key words 
Pitx2, atrial fibrillation, antiarrhythmic drugs, sodium channel, electrophysiology, drug 
targets, personalized medicine 
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Introduction 
Atrial fibrillation (AF) causes cardiovascular deaths, frequent hospitalizations and 
cognitive decline even in anticoagulated and rate controlled patients (1,2). 
Antiarrhythmic drug (AAD) therapy remains the most commonly used treatment to 
maintain sinus rhythm in AF patients, but the effectiveness of AADs is limited (3). 
Unfortunately, we lack a basic understanding of why antiarrhythmic drugs prevent AF 
over long periods in some patients, but not others (4,5).  Identifying factors that modify 
the effects of AADs would allow the selection of responsive patients and could help to 
guide development of novel AADs (6). 
 
PITX2 is a transcription factor that regulates the development of the left atrium and other 
parts of the chest. Its c isoform is expressed in the adult left atrium and regulates the 
expression of left atrial ion channels (7-9). Low atrial Pitx2 expression renders mice 
susceptible to AF and shortens the left atrial action potential (8,10,11). Here, we studied 
how variations in atrial PITX2 expression modify the effects of AADs.  
 
We detected variable left atrial PITX2 mRNA expression in AF patients requiring rhythm 
control therapy. We found that low PITX2 enhances the effect of flecainide, mediated by 
a more positive resting membrane potential (RMP). We identified reduced TASK-2 
expression as a possible driver of this effect and replicated these effects in cells 
expressing human Na channels and in a human atrial AP model. 
 
Methods 
Study approval. All experiments were conducted under the Animals (Scientific 
Procedures) Act, 1986, approved by the Home Office (PPL number 30/2967) and by the 
institutional review board at the University of Birmingham. Analyses of human atrial 
tissue were approved by the Institutional Review Board of the Academic Medical Center, 
Amsterdam, Netherlands. All patients provided written informed consent. 
 
Human DNA extraction and SNP analysis. Left atrial appendage (LAA) was excised in 95 
patients undergoing bilateral thoracoscopic AF ablation using an endoscopic stapling 
device (Endo Gia stapler, Tyco Healthcare Group, North Haven, CT), snap frozen in liquid 
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nitrogen and stored at -80°C (12). DNA was extracted from using DNAeasy and PITX2 
mRNA content was quantified by rtPCR.  
Murine studies. Adult mice (12-16 weeks) on an MF1 background with normal or reduced 
(Pitx2c+/− (8)) atrial PITX2c expression were studied. 
Arrhythmia inducibility, action potential duration, and activation times. Left atrial 
epicardial monophasic action potentials (MAP) were recorded from Langendorff-perfused 
(4ml.min-1, 37°C) beating murine hearts as described (8,13). Programmed stimulation was 
performed at baseline and with flecainide (Sigma, 1µmol/L) or d,l-sotalol (Sigma, 
10µmol/L) Arrhythmia inducibility and ERP were measured by using single RA extrastimuli 
after steady state pacing in 1ms decrements (8,13).  
Transmembrane action potentials were recorded using borosilicate glass microelectrodes 
from isolated murine left atria as published (14). Resting membrane potential, action 
potential duration, upstroke velocity, and activation times were analysed and compared 
between groups (13,15,16). 
 
Modelling of the electrophysiological consequences of different resting membrane 
potentials. We used the human atrial cell model of Courtemanche, Ramirez and Nattel 
(17). Simulations were run in model atrial cell strands of 100 cells (cell length 100μm). To 
reach steady state, the 5 leftmost cells of the strand were paced (S1) for 2 minutes at 
1000 and 500 ms basic cycle length.  A premature stimulation (S2) was applied to 
determine the ERP and CV was measured from cells 25-75. RMP was measured as the 
minimum diastolic potential during pacing at basic cycle length. Values for all other 
parameters were measured from the 50th cell. Post-repolarization refractoriness was 
calculated as the difference between APD at -60mV repolarization and ERP. 
 
Na+ current recordings in murine left atrial cardiomyocytes and HEK293 cells expressing 
the human Nav1.5 channel. Murine hearts were removed under terminal anaesthesia 
and cell isolation was performed as published (18)For INa recordings, murine left atrial 
cardiomyocytes or HEK293 cells stably expressing the human Nav1.5 channel (SB ion 
channels, UK) were superfused at 5ml.min-1, 22±0.5 °C with a solution containing in mM: 
NaCl 130, CsCl 5, HEPES 10, CaCl2 1.8, MgCl 1.2 and glucose 10, pH 7.4 (CsOH). 
100μM CdCl2 was added to block L-type Ca2+ currents. Whole cell patch clamp recordings 
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were obtained in voltage clamp mode using borosilicate glass pipettes (tip resistance 1–3 
MΩ, pipette solution CsCl 115, NaCl 5, HEPES 10, EGTA 10, MgATP 5, MgCl2 0.5 and 
TEA 10, pH 7.2). Na+ currents were elicited at 100ms steps to -10mV from holding 
potentials of -100 to -65mV using an Axopatch 1D amplifier (Molecular Devices, USA) and 
a CED micro1401 driven by Signal v6 (CED, UK).  
 
Standard IK1 currents were isolated using 50μM BaCl2 and applying 10mV step 
depolarisations (500ms) from -120mV to +50mV (18). For background K+ current 
measurements, the external solution contained in mM: NaCl 130, KCl 5.4, CaCl2 1, MgCl2 
1, HEPES 10, TEA 10, 4-AP 5, glibenclamide (2μM), BaCl2 (100μM), NiCl2 2 and glucose 
5.5 (pH 7.4 with NaOH), to block voltage-gated K+ and Ca2+ channels and IK1 and IKATP. 
Currents were measured in response to a 5s voltage ramp from -80 to 0mV. Background 
TASK-like K+ current was isolated with 10mM BaCl2. Full details are presented in the 
supplementary methods 
 
mRNA and protein concentration of atrial ion channels. Murine right and left atria were 
harvested and immediately snap frozen. We extracted RNA and produced cDNA  from 
snap frozen murine left and right atria, (SuperScript® VILO™, Life Technologies, UK). We 
quantified the expression of 20 major atrial ion channels and genes with suspected PITX2-
dependent regulation (9) using custom-designed 96-well TLDA plates (Life Technologies). 
Western immunoblotting was performed by incubation of left atrial tissue lysates with 
antibodies detecting TASK-2 , Kv1.6, Na/K ATPase alpha-1 , Na/K ATPase alpha-2, Na/Ca 
exchanger 1 , Serca2a, Nav1.5, or calnexin), and developed using enhanced 
chemiluminescence (Amersham, UK). For details of antibodies, see Supplementary 
Methods 
 
Optical action potential and calcium transient recordings left atria. Mouse hearts were 
rapidly excised under terminal anaesthesia, mounted on a Langendorff apparatus, and 
perfused with either Di-4-Anepps (50 µmol/L; Biotium, California, USA) or Rhod-2 
acetoxymethyl ester (5µmol/L) at 36-37°C for 10 minutes. The LA was isolated and signals 
recorded as described previously (14).. Ca2+ transients were obtained independently of 
voltage measurements. Optical action potentials and Ca2+ transients were analyzed for 
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APD, activation spread, longitudinal conduction velocity, and calcium transients using 
custom-made MATLAB algorithms (The MathWorks, USA, (14)).     
 
Statistics. All experiments were performed and analysed blinded to genotype in 
littermate pairs of mice. Categorical data were compared using Fisher’s exact test. 
Numerical data were compared by two-sided paired t tests (e.g. measurements before 
and after perfusion of flecainide or sotalol) and Wilcoxon signed-rank tests. Multiple 
measurements were assessed by repeated measures analysis of variance followed by 
multiple comparison (Bonferroni t-test) if the overall test was significant. Two-sided p 
values <0.05 were considered significant. Boxplots depict individual measurements 
(points), mean and SEM. Statistics and figures were created using GraphPad Prism 5.  
 
Results 
PITX2 / PITX2c mRNA levels in human left atrial tissue by SNP status. PITX2 mRNA varied 
markedly in human left atrial tissue harvested from patients undergoing combined 
endocardial and thoracoscopic AF ablation (n=95, Figure 1, Table 1 (12)), suggesting that 
a 50% lowered PITX2 expression defines a large, potentially clinically relevant group of AF 
patients. This did not correlate with AF risk based on SNP haplotype (Table 2), although 
we found reduced PITX2 levels in patients with 5 risk alleles. 
Flecainide suppresses atrial arrhythmias in Pitx2c+/- hearts. Flecainide completely 
suppressed induced atrial arrhythmias in hearts with reduced PITX2 expression (Pitx2c+/-, 
0/17 hearts with atrial arrhythmias), but less in hearts with normal PITX2 expression 
(3/12 hearts with atrial arrhythmias, Figure 2A-C). Flecainide prolonged effective 
refractory periods (ERP) and post-repolarization refractoriness (PRR; calculated as the 
difference between the ERP and APD90) more in hearts with reduced PITX2 expression 
(Figure 2D and E, Table 3). Pitx2c+/- hearts had shorter atrial action potentials as expected 
(8). Flecainide abolished APD differences between Pitx2c+/- and wildtype left atria by 
prolonging early repolarization (APD30, APD50 and APD70, Table 3). Atrial PITX2 
expression did not modulate the effects of sotalol on atrial APD or ERP (Table 4).  
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Atria with low Pitx2c expression show a more depolarized resting membrane potential. 
Resting membrane potentials (RMP) were slightly depolarized in left atrial cells with 
reduced Pitx2c expression (Figures 3A and B, mean depolarization 1.2– 2.4mV, all 
p<0.05). DV/dtmax was not significantly affected by atrial PITX2 levels (100ms paced CL 
wild type: 104.4± 4.3 V/s; Pitx2c+/-:: 93.7 ± 4.5 V/s). Flecainide altered atrial RMP (Figure 
3B) and reduced action potential amplitude (100ms CL: wildtype baseline  77.5± 1.2 mV, 
n=30, wildtype flecainide 71.3 ± 1.2 mV, n=31; Pitx2c+/- baseline  73.4 ±1.3 mV, n=22, 
Pitx2c+/- flecainide 65.1 ± 1.45 mV, n=24), consistent with its sodium channel blocking 
effect.  
Resting membrane potential differences explain the differential effect of flecainide in 
atria with reduced Pitx2c expression. Atrial PITX2 expression did not modify Na+ currents 
(INa) recorded from isolated cardiomyocytes at holding potentials ranging from -100 to -
65mV (Figure 4A-C). Peak sodium current (INa) was reduced at more depolarized holding 
potentials (P<0.001; WT: -100mV: 96 ± 4; -80mV: 72 ± 5; -75mV: 59± 5 ; -70mV: 43 ± 4; -
65mV 30± 3 pA/pF,  n = 40, N = 7 . Pitx2c+/- : -100mV: 91 ± 4; -80mV: 60 ± 4; -75mV: 48± 4 
; -70mV: 35 ± 4 ; -65mV 24± 3 pA/pF, n = 41, N = 10).  Flecainide inhibited INa better at 
more positive holding potentials (-100mV: 49± 3 %; -80mV: 58 ± 4 %; -75mV: 63 ± 4 %; -
70mV: 68 ± 5 % n=; -65mV 75± 5 % n = 86, N = 17) in cells from atria with normal or 
reduced PITX2 expression, suggesting that the greater efficiency of flecainide in atria with 
reduced Pitx2c expression is secondary to RMP depolarization (Figure 4C). Consistent 
with this, flecainide inhibited human Nav1.5 channels more potently in more depolarized 
HEK cells channels (-65 – -75 mV, Figure 4D-E). 
PITX2 regulates expression of KCNK5 channels and modifies background leak currents. 
Kcna6 and Kcnk5 mRNA expression were reduced in Pitx2c+/-  murine left atria (Figure 5A, 
Supplementary table 1) while mRNA concentrations of 20 ion channels or related genes 
were not altered. Kv1.6 protein expression was unaltered and expression of TASK-2 was 
reduced in murine atria with reduced PITX2 expression (Figure 5B). Nav1.5 mRNA and 
protein expression were not changed (Figures 5A and B).  Background leak currents, 
which include TASK-related currents were reduced in Pitx2c+/- murine atria, while IK1 did 
not differ between genotypes (Figure 7). 
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Depolarizing the RMP in a human atrial model mimics the effects of flecainide in atria 
with reduced Pitx2c expression. We simulated a depolarized RMP in the Courtemanche  
AP model by a 25% reduction in IK1. This reduced the RMP at 500ms paced cycle length by 
2mV from–79.9 mV (“normal PITX2”) to -77.9 mV (“low PITX2”). Sodium channels 
recovered from inactivation more slowly upon partial INa block (50 or 60%, Figure 6A). 
Furthermore, PRR was enhanced in the “low PITX2” model (Figure 4B and Table 5). INa 
inhibition reduced upstroke velocity (dV/dtmax) and conduction velocity in both models. 
Action potential simulations reproduced the prolongation of post-repolarization 
refractoriness (Figure 4B). 
 
Pitx2 does not modify the effects of flecainide on left atrial electrical conduction and 
calcium handling. Reduced Pitx2 expression did not alter atrial conduction velocities or 
activation patterns (Supplementary Figure 1A-C, Table 6), consistent with published data 
(8). As expected, 1µmol/L flecainide decreased atrial conduction velocities without 
differences between atria with normal or reduced Pitx2c expression (Supplementary 
Figures 1B and C). Ca2+ relaxation times at 50% relaxation were not different in atria with 
reduced or normal PITX2 expression (Supplementary Figures 1D and E). Flecainide 
(1µmol/L) shortened 50% Ca2+ relaxation times by approximately 10% and decreased the 
Ca2+ transient amplitude by approximately 50% in atria with normal and reduced Pitx2c 
expression (Supplementary Figure 1E and F). Also, we did not find changes in expression 
of Na/Ca exchanger, Serca2a or Na/K ATPase alpha-1 and alpha-2 subunit protein in atria 
with normal and reduced Pitx2c expression (Supplementary Figure 2). 
 
Discussion 
Main findings. We demonstrate that left atrial Pitx2 mRNA concentrations vary in 
patients with AF requiring rhythm control therapy. Furthermore, flecainide increases 
post-repolarization refractoriness and suppresses arrhythmias more effectively in atria 
with halved Pitx2 expression, mediated by a more depolarized resting membrane 
potential. Drug-induced PRR is thought to prevent premature excitation as reactivation 
can then only occur after complete repolarisation, after the vulnerable period of 
excitability (19,20). We found similar effects in cells expressing human sodium channels 
and in the Courtemanche Nattel model of human atrial action potentials.  
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Thus, our study highlights modulation of the atrial resting membrane potential by PITX2, 
possibly mediated by background currents such as TASK-2, as a target for AAD therapy, 
including atrial-selective therapy. Furthermore, our results suggest that markers for atrial 
PITX2 expression can be used to stratify sodium channel blocker therapy.  
 
Small changes in the atrial resting membrane potential cause marked post-
repolarization refractoriness induced by flecainide. We identified low atrial PITX2 
expression as an important determinant of the antiarrhythmic effects of Na channel 
blockers: Low left atrial Pitx2 mRNA depolarized the atrial RMP (Figure 3), consistent with 
another, earlier report (11). A depolarized RMP increased flecainide-induced post-
repolarization refractoriness (Figure 2)(21-25). The conduction-slowing effect of 
flecainide was not modulated by reduced atrial PITX2 (Supplementary Figure 1), an 
important surrogate for drug safety. Both the modelling experiments (Figure 6) and the 
experiments in HEK cells expressing human sodium channels (Figure 4, Table 4) confirm 
that small changes in resting membrane potential can markedly modulate sodium 
channel inhibition.  
 
The resting membrane potential: A potential target for antiarrhythmic drug or 
companion drug development. Open-state sodium channel blockers such as flecainide or 
propafenone bind preferentially to sodium channels integrated in membranes with 
slightly depolarized resting potentials, where more channels are in the open or 
inactivated state (26,27). Our data suggest that AAD combinations that combine a sodium 
channel blocker with a membrane potential modifying substance, such as amiodarone 
(28) or the combination of dronedarone and ranolazine (24,29,30), may have synergistic 
antiarrhythmic effects because they modulate the atrial resting membrane potential and 
thereby enhance the effect of sodium channel blockade. Further studies of such drug 
combinations are warranted. Our data also suggest that such combined effects may be of 
special relevance in patients who have a depolarized resting membrane potential, e.g. 
secondary to low left atrial PITX2. As PITX2 expression is confined to the left atrium in the 
heart, AAD therapy that leverages modifications in RMP may achieve “atrial specific” 
antiarrhythmic drug therapy. 
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Molecular mechanism of depolarized resting membrane potential in atria with reduced 
Pitx2c. RMP is maintained by an intricate balance of different transmembrane currents 
and closely related to the potassium equilibrium potential. We identified that PITX2 
modifies expression of the genes encoding Kv1.6 and TASK-2 (Figure 5). Complete deletion 
of Pitx2 regulates other potassium and sodium channels such as Kcnj2 (8,31), which alter 
the RMP, but these were not responsible for the depolarized RMP observed in our study. 
Two-pore domain potassium channels, such as TASK-2, contribute to the RMP in a variety 
of cells including skeletal and cardiac muscle (32,33). So far, an altered function of the 
TASK-1 channel and of IK1 has been implicated in atrial remodelling and atrial fibrillation 
(34,35). Here we demonstrate that TASK-2 is expressed in atrial myocardium (Figure 5B), 
suggesting that a reduced function of TASK-2 could depolarize the RMP (Figures 2&6, 
(8,11)), in analogy to the effect of TASK-2 in neuronal and cartilage tissue (36,37).  
 
Developing clinical markers for patients with a depolarized RMP. While it will be 
challenging to directly assess left atrial RMP in AF patients, our data suggest that 
differences in atrial RMP could explain the effectiveness of sodium channel blockers in 
carriers of common gene variants on chromosome 4q25 (38), although left atrial PITX2c 
levels are modulated by factors other than SNP status (Table 1). It seems desirable to 
develop and validate drivers that modify the RMP and clinical markers for patients prone 
to a depolarized atrial RMP to select appropriate AADs for individual patients in the 
future, thus paving the way to a stratified or personalized antiarrhythmic drug therapy 
selection (6,39). 
 
Limitations. We provide robust evidence that left atrial Pitx2 expression varies in AF 
patients, and that reduced Pitx2c expression enhances the antiarrhythmic effects of 
sodium channel blockers by modulating the atrial resting membrane potential. Our study 
was partly motivated by the assumption that gene variants on chromosome 4q25 modify 
Pitx2 expression, an assumption that has not been definitively proven (9,11,40,41). Our 
analysis here and that of others indicate that SNP status does not always correlate with 
Pitx2 levels(42,43). Our findings are relevant to AAD therapy even if the presumed link 
 241 
 
between PITX2 expression and genetic variants on chromosome 4q25 proves elusive. 
Validating our findings in patients is desirable but will be challenging as access to fresh 
left atrial cardiomyocytes is limited.  
 
Further studies exploring the relevance of TASK channels for the atrial resting membrane 
potential are warranted. 
 
Perspectives 
Competency in Medical Knowledge. Antiarrhythmic drugs are commonly used to prevent 
symptomatic AF recurrences, but their effectiveness varies. This study identifies the atrial 
resting membrane potential as an important modulator determining the effects of 
sodium channel blockers. PITX2, a transcription factor linked to left-right asymmetry in 
the chest during development, modulates the expression of left atrial ion channels 
maintaining the resting potential.  
 
Translational Implications.  
What’s known? AADs only prevent recurrent AF in approximately half of AF patients, 
while putting all patients at risk of side effects. The reasons why AADs are variably 
effective are unknown.  
 
What’s new? We identified PITX2 as a modulator of the atrial resting membrane 
potential, probably via TASK2. A slight depolarization of the atrial resting membrane 
potential markedly enhances the antiarrhythmic effects of sodium channel blockers. 
Within the limitations of an experimental study, our data suggest that sodium channel 
blockers are an attractive AAD therapy in AF patients with reduced PITX2 expression, as 
the enhanced post-repolarization refractoriness counters the PITX2-induced shortening 
of the atrial action potential. Our data also underpin the use of modifiers of the atrial 
resting membrane potential as companion therapeutics for sodium channel blockers.  
 
What’s next? Markers for a depolarized atrial resting membrane potential may in the 
future help to select AAD therapy. Our study calls for investigations of the use of sodium 
channel blockers as antiarrhythmic agents of first choice in AF patients with low atrial 
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PITX2 levels. Ion channels regulating resting membrane potential may provide novel 
targets for the development ofAADs and/or for the development of companion 
therapeutics to existing compounds, e.g. targeting TASK-2 channels.  
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Figure Legends 
Figure 1  
Pitx2 mRNA expression as a fraction of actin in human left atrial appendages taken from 
atrial fibrillation patients undergoing thoracoscopic AF ablation therapy 
Figure 2  
A Image and schematic representation of the Langendorff perfused heart.  
B Atrial arrhythmia inducibility in isolated, beating wildtype and Pitx2c+/- hearts.  
Flecainide abolished atrial arrhythmia inducibility in Pitx2c+/- hearts only *p<0.05 
flecainide vs baseline (Fisher’s exact test). Baseline: WT n= 16, Pitx2c+/- n= 21. Flecainide: 
WT n= 12, Pitx2c+/- n= 17 
C Representative trace of AF induced during programmed stimulation at baseline, 
showing reduced severity of arrhythmias with 1µmol/L flecainide in Pitx2c+/- atria. S2= 
single extrastimulus  
D Effects of flecainide on atrial effective refractory period (ERP), in wildtype and Pitx2c+/- 
isolated, beating hearts. Shown is the difference (ms) in ERP between baseline and 
1µmol/L flecainide at 80-120ms paced cycle length (CL) following a single extra stimulus 
(S2).  Horizontal lines represent mean ± SEM. Wildtype (open circles) n=10-11, Pitx2c+/- 
(closed circles) n= 11-13, individual values are displayed, *p<0.05 between genotypes 
across all CL, 2-way ANOVA. Data points for each genotype have been offset at each cycle 
length for clarity. 
E Schematic representation of the overall effects of 1µmol/L flecainide on ERP. Flecainide 
prolongs ERP in both genotypes, this effect is more pronounced in Pitx2c+/- atria than in 
wildtype. Flecainide causes post-repolarization refractoriness (PRR), the difference 
between ERP (black and red lines) and APD90 (blue lines), in wildtype and Pitx2c+/- atria. 
Flecainide-induced PRR in Pitx2c+/- is almost 3 times that of wildtype atria. *p<0.05 
wildtype vs Pitx2c+/-  # p<0.05 Baseline vs 1µmol/L flecainide. 
Figure 3 
 A Schematic representation of sharp microelectrode electrode recordings from the 
superfused whole left atrium (LA).  
B Resting membrane potential (RMP) in wildtype and Pitx2c+/- left atria (LA) at baseline 
(black; n wildtype =30, Pitx2c+/-=31) and with 1µmol/L flecainide (red; n wildtype=22, 
 247 
 
Pitx2c+/-=23). Pitx2c+/- LA have depolarized RMP; the difference between wildtype and 
Pitx2c+/- is exaggerated with flecainide. Horizontal lines represent mean ± SEM. 2-way 
repeated measures ANOVA *p<0.05, ***p<0.001 across all cycle lengths. Individual 
values are also shown. Data points for each genotype have been offset at each cycle 
length for clarity. 
C Maximum upstroke velocity (dV/dtmax) in wildtype and Pitx2c+/- left atria at baseline 
(black; n widltype=30, Pitx2c+/-=31) and with 1µmol/L flecainide (red; n wildtype=22, 
Pitx2c+/-=24). Flecainide brings about a difference in dV/dtmax between wildtype and 
Pitx2c+/- LA. Horizontal lines represent mean ± SEM. 2-way repeated measures ANOVA. 
**p<0.01 Individual values are also shown. Data points for each genotype have been 
offset at each cycle length for clarity. 
Figure 4 
A Schematic representation of patch clamp experiments carried out in isolated atrial 
cardiomyocytes. Human embryonic kidney (HEK) cells were patch clamped using the 
same setup. 
B Representative traces showing sodium current (INa) measured by patch clamping, in 
isolated atrial cardiomyocytes at baseline (black) and with 1µmol/L flecainide (red), at 
increasing holding potentials (-100 to -65 mV). Horizontal line = 1 ms, vertical line = 
40pA/pF 
C Percentage reduction in peak INa caused by 1µmol/L flecainide in atrial CM from 
wildtype and Pitx2c+/- LA. Reduction in peak INa is enhanced with increased holding 
potentials, irrespective of the origin of the cardiomyocytes. Wildtype n= 10; Pitx2c+/- n = 9 
D Representative traces showing sodium currents (INa) in Nav1.5-transfected HEK cells at 
baseline (black) and with 1µmol/L flecainide (red) at increasing holding potentials (-100 to 
-65 mV). 
E Percentage reduction in peak INa caused by 1µmol/L flecainide in Nav1.5-transfected 
HEK cells. Reduction in peak INa was enhanced with increased holding potentials. The 
greatest difference in % reduction was between -70mV and -65mV. 
Figure 5 
A Relative quantity (RQ) of mRNA of selected ion channels in left atria from Pitx2c+/- and 
wild-type mice. Expression levels were measured relative to wildtype sample 1. Kcnk5 
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encodes TASK-2, Kcna6 encodes Kv1.6 and Scn5a encodes Nav1.5. WT = 6, Pitx2c+/- = 6. 
*p<0.05 Student’s t-test. See Supplementary Table 1 for all ion channels measured.  
B Quantity of TASK-2, KV1.6 and Nav1.5 proteins relative to calnexin (arbitrary units). 
Representative immunoblots are displayed below the corresponding dot plot. WT = 7, 
Pitx2c+/- = 8. *p<0.05 Student’s t-test. Molecular weights: TASK-2 55 kDa; Kv1.6 58 kDa; 
Nav1.5 248 kDa. 
Figure 6 
A Propagated action potentials (top) simulated with the Courtemanche-Ramirez-Nattel 
model modified to reflect the action potential characteristics of murine Pitx2c+/- atria and 
the effect of 60% INa block at pacing cycle lengths of 500 and 1000 ms, with 2 minutes 
prepacing, and corresponding time courses of the product of the two inactivation gates h 
and j of INa (bottom), reflecting INa availability. 
B Effects of reduced sodium conductance (gNa) on post-repolarization refractoriness in 
the simulations. Reduction in gNa caused PRR in the reference model and Pitx2c deficiency 
model. After reducing gNa, PRR was greater in the Pitx2c deficiency model than in the 
reference model (red lines). 
Figure 7 
A Representative traces showing IK1 currents (50µmol/L Ba2+) measured by patch 
clamping, in isolated wildtype and Pitx2c+/- atrial cardiomyocytes at test potentials 
ranging from -120 to 50mV. 
B Ik1 currents  in atrial cardiomyocytes from wildtype and Pitx2c+/- LA at test potentials 
ranging from -120 to 50mV. There is no significant difference between genotypes. 
C Representative traces showing background leak currents (10mmol/L Ba2+) in isolated 
wildtype and Pitx2c+/- atrial cardiomyocytes. 
D Background leak currents  in atrial cardiomyocytes from wildtype and Pitx2c+/- LA at test 
potentials ranging from -120 to 50mV. Pitx2c+/- cardiomyocytes had significantly reduced 
background currents 
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Table 1. Baseline characteristics of atrial fibrillation patients. Left atrial appendages were 
collected from these patients. 
Baseline Characteristics  
Patients, n  101 
Age (years) 59.7±8.4 (40-76) 
Male, n (%) 79 (78) 
CHA2DS2VASc-score (mean). 1.3 (0-6) 
Congestive heart failure, n (%) 6 (6) 
Hypertension, n (%) 34 (34) 
Age ≥ 75, n (%) 1 (1) 
Diabetes, n (%) 9 (9) 
Stroke/TIA/Embolus, n (%) 10 (10) 
Vascular disease, n (%) 10 (10) 
Female gender, n (%) 22 (22) 
Age ≥ 65, n (%) 31 (31) 
CHA2DS2VASc-score = 0, n (%) 60 (59) 
CHA2DS2VASc-score = 1, n (%) 
CHA2DS2VASc-score ≥ 2, n (%) 
24 (24) 
17 (17) 
Previous catheter PVI, n (%) 20 (20) 
Type AF  
Paroxysmal, n (%) 44 (44) 
Persistent, n (%) 56 (55) 
Longstanding Persistent, n (%) 1 (1) 
AF duration (years) 6.0 (1-35) 
Anti-arrhythmic drugs,  
 Class IA, n (%) 4 (4) 
 Class IC, n (%) 33 (33) 
 Class II, n (%) 53 (52) 
 Class III, n (%) 41 (41) 
 Class IV, n (%) 17 (17) 
 Digoxin, n (%) 15 (15) 
Anticoagulants (before PVI procedure),  
Coumarins, n (%) 89 (88) 
Antiplatelets, n (%) 6 (6) 
  
AF: atrial fibrillation, PVI: pulmonary vein isolation, TIA: transient ischemic attack 
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Table 2: Effects of flecainide on refractoriness and repolarization in PITX2-deficient (Pitx2c+/-) 
and wildtype mouse hearts.  
All values are given as mean±SEM. # indicate significant compared to baseline, * indicate significant 
differences compared to wildtype. Number of atria are in brackets. CL= cycle length 
 
Wildtype Pitx2c+/- 
Paced CL 
(ms) 
120 100 80  120 100 80 
Left atrial effective refractory period (ms) 
 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecainid
e 
 
23.5±2.
3(11) 
29.8±3.
0(11) 
22.2±2.
1(11) 
29.6±3.
3(11) 
21.9±2.
4(10) 
28.7±3.5
(10)* 
30.5±2.
4(11) 
38.5±3.
3(11)# 
28.0±2.
3(13) 
40.2±2.
8(13)# 
27.5±2.
5(13) 
41.2±3.0
(13)*# 
Left atrial monophasic action potential duration (ms) 
 Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baseline Flecaini
de 
APD5
0  
10.2±1.
3(8) 
14.5±1.
7(8) 
10.8±1(
8) 
11.9±1.
6(8) 
10.4±0.
7(7) 
12.0±1.1
(7) 
12.4±1.
1(15) 
14.4±1.
3(15) 
11.5±1.
0(15) 
12.4±1.
1(15) 
10.6±0.9
(11) 
10.3±1.
0(11) 
APD7
0 
17.8±2.
2(9) 
23±2.1(
9) 
18.4±1.
6(9) 
18.7±2.
2(9) 
18.1±1.
2(8) 
18.1±1.9
(8) 
18.0±1.
6(15) 
19.2±1.
8(15) 
16.0±1.
4(13) 
16.2±1.
4(13) 
14.9±1.0
(10)* 
13.1±0.
7(10) 
APD9
0 
31.3±3.
0(8) 
37.4±2.
8(8) 
31.5±2.
5(9) 
29.9±2.
9(9) 
31.0±1.
4(8) 
28.4±2.7
(8) 
28.3±2.
2(13) 
29.9±2.
2(13) 
27.4±2.
2(13) 
26.6±1.
5(13) 
26.8±1.7
(10) 
23.1±1.
4(10) 
 
Left atrial transmembrane action potential duration (ms) 
 Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baseline Flecaini
de 
APD3
0 
4.5±0.1
(30) 
5.5±0.3
(22) 
4.5±0.1
(30) 
5.4±0.3
(22) 
4.4±0.1
(30) 
5.2±0.3(
22) 
4.0±0.1
(31) 
4.7±0.2
(24) 
3.9±0.1
(31) 
4.6±0.2
(24) 
3.8±0.1(
31)* 
4.4±0.2
(24) 
APD5
0 
6.7±0.2
(30) 
8.2±0.5
(22) 
6.6±0.2
(30) 
8.0±0.4
(22) 
6.4±0.2
(30) 
7.8±0.5(
22) 
5.9±0.2
(31) 
7.1±0.4
(24) 
5.7±0.2
(31) 
7.0±0.4
(24) 
5.6±0.2(
31)* 
6.7±0.3
(24) 
APD7
0 
10.5±0.
4(30) 
12.7±0.
8(22) 
10.1±0.
4(30) 
12.1±0.
7(22) 
9.6±0.4
(30) 
11.8±0.7
(22) 
8.9±0.4
(31) 
10.7±0.
6(24) 
8.6±0.4
(31) 
10.3±0.
6(24) 
8.3±0.3(
31)* 
9.8 ± 
0.5(24) 
APD9
0 
20.9±1.
0(30) 
23.4±1.
5(22) 
19.9±0.
9(30) 
22.2±1.
4(22) 
18.4±0.
8(30) 
21.6±1.3
(22) 
17.6±0.
9(31) 
20.3±1.
1(24) 
16.5±0.
8(31) 
19.2±1.
0(24) 
15.7±0.8
(31)* 
17.9±0.
9(24) 
Left atrial optical action potential duration (ms) 
 Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecaini
de 
Baselin
e 
Flecainid
e 
APD3
0 
6.1±0.3
(10) 
7.3±0.6
(6) 
6.4±0.8
(10) 
5.9±1.0
(6) 
6.1±0.4
(10) 
6.9±1.3(
6) 
4.9±0.4
(10) 
7.7±0.9
(8) 
4.6±0.3
(10) 
5.4±0.7
(8) 
4.3±0.4
(10)* 
5.7±0.7(
8) 
APD5
0 
8.5±0.6
(10) 
10.7±1.
2(6) 
8.9±1.1
(10) 
8.5±1.2
(6) 
8.3±0.7
(10) 
10.3±1.8
(6) 
6.9±0.4
(10) 
10.0±1.
0(8) 
6.6±0.4
(10) 
8.1±0.9
(8) 
6.1±0.4
(10)* 
8.0±0.9(
8) 
APD7
0 
11.7±1.
2(10) 
15.0±2.
1(6) 
12.5±1.
5(10) 
12.8±1.
7(6) 
11.5±1.
1(10) 
14.4±2.5
(6) 
9.4±0.0
(10) 
13.3±1.
2(8) 
9.4±0.6
(10) 
11.6±1.
5(8) 
9.1±0.5
(10)* 
11.2 ± 
1.2(8) 
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Table 3: Electrophysiological effects of sotalol (10µmol/L) in Pitx2c+/- and 
wildtype left atria.  
All values are given as mean±SEM; number of atria are in brackets 
Wildtype Pitx2c+/- 
120 100 120 100 
 
Left atrial effective refractory period 
Baseline Sotalol Baseline Sotalol Baseline Sotalol Baseline Sotalol 
38.7±7.
8(7) 
33.9±6.
3(7) 
32.2±6.1
(6) 
29.2±5.
3(6) 
39.3±4.0
(4) 
26.8±3.
5(4) 
37.0±5.7
(4) 
24.0±3.
7(4) 
 
Left atrial action potential duration 
Baseline Sotalol Baseline Sotalol Baseline Sotalol Baseline Sotalol 
11.5±1.
2(9) 
13.4±1.
2(9) 
10.9±2.0
(7) 
12.2±1.
3(7) 
10.8±1.1
(7) 
11.2±1.
0(7) 
8.3±0.9(
4) 
11.1±1.
7(4) 
17.6±2.
2(9) 
20.0±1.
9(9) 
16.0±1.3
(7) 
18.2±2.
3(7) 
16.5±1.6
(7) 
17.3±1.
2(7) 
13.0±1.5
(4) 
17.0±1.
9(4) 
30.7±3.
2(9) 
33.5±2.
7(9) 
29.0±1.9
(7) 
30.9±3.
2(7) 
29.7±2.7
(7) 
31.2±2.
0(7) 
23.8±2.8
(4) 
29.6±2.
9(4) 
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Table 4: Electrophysiological effects of reduced sodium conductance in a human atrial 
model of PITX2 deficiency 
 Wildtype model Pitx2c-deficiency model 
Paced cycle length (ms) 500 1000 500 1000 
gNa Resting membrane potential (mV) 
100% -79.92 -81.28 -77.90 -79.61 
50% -79.6 -81.12 -77.33 -79.37 
40% -79.43 -81.01 -76.99 -79.23 
gNa Action potential duration at repolarization to -60 mV (ms) 
100% 217 253 206 226 
50% 239 266 233 239 
40% 248 273 245 245 
gNa Effective refractory period (ms) 
100% 266 301 261 280 
50% 308 335 316 320 
40% 327 352 342 339 
gNa Post-repolarization refractoriness (ms) 
100% 49 48 55 54 
50% 69 69 83 81 
40% 79 79 97 94 
gNa Conduction velocity (cm/s) 
100% 49.5 50.0 50.3 50.5 
50% 36.9 37.0 37.5 37.5 
40% 32.9 32.7 33.0 33.1 
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Table 5. Electrical activation time and conduction velocity in Pitx2c+/- and wildtype left 
atria. All values are given as mean±SEM; number of atria are in brackets. 
 
Table 6: PITX2c expression in LA tissue obtained from AF ablation patients. This dataset was grouped 
according to the number of high-risk SNP alleles of SNP1 rs2200733, SNP2 rs6838973 and SNP3 rs1448818. 
These three SNPs are located close to the PITX2 gene. Data were divided into 0-6 high-risk alleles. The data 
demonstrated that there were no trends in mRNA expression associated with increasing number of risk 
alleles.  
 
        
Risk 
Alleles 
Min. 
  
25% 
IQR 
Median 75% 
IQR 
Max.  Mean SEM N 
0 3.22 3.22 3.69 5.22 5.22 4.04 0.6 3 
1 1.83 2.96 4.25 6.25 7.16 4.54 0.5 13 
2 2.05 2.65 3.78 4.75 7.11 3.94 0.3 22 
3 1.12 2.74 3.72 4.92 7.42 3.83 0.4 17 
4 2.13 3.00 4.29 5.41 7.73 4.39 0.5 10 
5 1.94 1.96 2.66 4.66 5.12 3.10 0.7 4 
6 4.95 4.95 4.95 4.95 4.95 4.95 0 1 
 
  
 Wildtype Pitx2c+/- 
Paced 
cycle 
length 
(ms) 
1000 300 120 100 80 1000 300 120 100 80 
Activation 
time (ms) 
6±0.3(
22) 
6±0.3(
22) 
9±0.5(
22) 
12±1.0
(22) 
16±1.4
(22) 
6±0.
2 
7±0.3 12±0.9 
13±0.
9 
18±1.
2 
Conductio
n Velocity 
(cm/s) 
---- 
30±1.
8(8) 
25±2.
4(8) 
25±1.9
(8) 
23±1.9
(8) 
--- 
29±1.
5(8) 
26±1.6
(8) 
25±1.
6(8) 
23±1.
6(8) 
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Appendix 6 - Can preload-reducing therapy 
prevent disease progression in arrhythmogenic 
right ventricular cardiomyopathy? Experimental 
evidence and concept for a clinical trial. 
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